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Abstract 
 
As nucleic acid lesions are involved in most of the diseases, deoxyribonucleic acid 
(DNA) and ribonucleic acid are attractive targets for drug design. Due to the high 
homogeneity of B-DNA, the main drawback of DNA binding drugs is their random 
distribution thereby affecting genome functions in an uncontrolled manner.  
To overcome this situation, secondary structures such as G-quadruplexes (G4), which 
can be found in genome regions involved in cell proliferation and genome stability, can 
be target. This thesis opened new perspectives and reinforced previously existing 
perceptions over the structural feactures that G4 ligand should have. With regards to 
non-fused aromatic ligands, this work confirmed that the presence of more than one 
aromatic core (such as benzene or naphtalene) seems to be essential to: (a) have an 
aromatic surface big enough to selectively interact with the G-quartet; (b) give some 
rigidity to the structure. Respecting the polyaromatic fused compounds, a new scaffold 
(benzo[h][1,6]naphthyridin-2(1H)-one) was tested as G4 ligand aromatic core and the 
FRET melting data give information that can be used in the design of new derivatives. 
Besides that, it is also essential to highlight the very good antiproliferative results 
obtained with some of the compounds synthesised. Alternativelly, peptide nucleic acids 
(PNAs) also have nucleic acids as drug target. Attempts to understand the structure-
activity relationship and improve solubility, cell permeability, bioavailability, and binding 
orientation with nucleic acids of PNA have resulted in several structural modifications, 
such as α-PNA. α-PNA has a backbone consisting of α-amino acids, some of them 
carrying a nucleobase in their side chain. This thesis also described their synthesis of 
new α-PNA monomers containing sulfur. From a chemical point of view, this work is also 
interesting for the variety of reactions that were employed where the click thiol-ene 
reactions stood out. 
 
KEYWORDS: G-quadruplexes ligands; Naphthalene; Benzo[h][1,6]naphthyridin-2(1H)-
one ; α-Peptide Nucleic Acids; Chimeric cysteine.  
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Resumo 
 
Tendo em conta que as lesões ou mutações nas moléculas de ácidos nucleicos 
contribuem para a etiopatogenia da maioria das doenças (como por exemplo as 
neoplasias malignas) os ácidos desoxirribonucleico e ribonucleico têm sido encarados 
como importantes alvos terapêuticos. No entanto, a sua elevada homogeneidade 
estrutural torna difícil a acção dos fármacos em regiões específicas do genoma. Esta 
ligação não específica às moléculas de ácidos nucleicos resulta, muitas vezes, em 
reacções adversas. Para evitar estas reacções adversas é importante desenvolver 
fármacos que actuem em regiões específicas do genoma. Ao longo dos tempos, 
diferentes abordagens têm sido adoptadas com esse objectivo entre elas a síntese de 
moléculas que tenham como alvo estruturas secundárias específicas, como os G-
quadruplexes (G4), ou mesmo sequências de nucleótidos específicas. 
Os G4 são estruturas secundárias de sequências de ácidos nucleicos ricos em guanina 
que são capazes de se organizar num arranjo em quadrado de guaninas (tétradas) 
estabilizado por ligações de hidrogénio e pela existência de catiões monovalentes no 
centro das tétradas. Os G4 podem ser intramoleculares, bimoleculares ou 
tetramoleculares e dependendo da direcção das cadeias ou partes da cadeia que 
formam as tétradas, as estruturas podem ser descritas como paralelas ou antiparalelas. 
Deste modo, os G4 têm algumas características estruturais que os permitem diferenciar 
da dupla hélice de ácido desoxirribonucleico como (a) uma maior superfície aromática 
das tétradas de guanina disponível para interacções com os fármacos, (b) os quatro 
sulcos que se diferenciam dos sulcos da dupla hélice de ácido desoxirribonucleico no 
que diz respeito à profundidade, largura, potencial electrostático e distribuição dos 
átomos que participam nas ligações de hidrogénio e (c) a presença do ião metálico. Estas 
sequências ricas em guaninas são um interessante alvo terapêutico não só pelas suas 
características estruturais mas sobretudo por se localizarem geralmente em regiões do 
genoma envolvidas na divisão celular (como por exemplo nos promotores dos 
oncogenes) ou nas extremidades dos cromossomas (telómeros). O objectivo dos 
ligandos de G4 é estabilizar estas estruturas secundárias dos ácidos nucleicos de modo 
a evitar a divisão e proliferação celular (no caso dos G4 presentes nos promotores dos 
oncogenes) ou evitar a conservação do tamanho dos telómeros (associada à 
imortalidade das células característica das células neoplásicas). Apesar das diferenças 
estruturais supracitadas, um dos maiores desafios para o desenvolvimento de moléculas 
que estabilizem os G4 é a sua pouca selectividade relativamente à dupla hélice de ácido 
desoxirribonucleico. Com o objectivo de aumentar esta selectividade, os ligandos de G4 
apresentam geralmente as seguintes características estruturais: (a) uma extensa 
superfície aromática com tamanho e forma similar à das tétradas de guanina de modo 
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a estabelecerem interacções de empilhamento π-π, (b) cadeias laterais com grupos 
carregados positivamente capazes de interagir com os grupos fosfato presentes nos 
sulcos e assegurar a solubilidade das moléculas e (c) um centro catiónico no núcleo 
aromático que geralmente interage com o centro electrostático negativo do G4. Os 
ligandos de G4 descritos na literatura dividem-se em 3 grupos: compostos macrocíclicos, 
poliaromáticos fundidos e aromáticos não fundidos. Esta tese apresenta a síntese de 
duas novas famílias de moléculas (desenhadas com base nas características previamente 
referidas para os ligandos de G4) e que foram testadas como potenciais ligandos de G4 
recorrendo à transferência ressonante de energia por fluorescência (FRET). No Capítulo 
II são descritos compostos simétricos cujo núcleo aromático é o benzeno, o naftaleno 
ou o 2,7-bifenilnaftaleno e que contêm heteroatomos (enxofre na maioria dos 
compostos) nas suas cadeias laterais. Estes compostos pertencentes à família dos 
compostos aromáticos não fundidos, revelaram não aumentar significativamente a 
estabilidade das sequências oligonucleotídicas testadas. Estes resultados realçam a 
importância de existir mais de um anel aromático na estrutura dos ligandos aromáticos 
não fundidos de modo a que: (a) a superfície aromática dos compostos seja 
suficientemente grande para estabelecer interacções de empilhamento π-π com as 
tétradas de guanina; e (b) para conferirem rigidez à estrutura. Alguns destes compostos 
apresentaram actividade antiproliferativa interessante em três linhas tumorais e 
aumentaram significativamente os níveis de apoptose quando as células foram expostas 
à concentração da molécula que induziu metade do efeito máximo. Com base nestes 
resultados, a indução da apoptose parece ser importante para o mecanismo de acção 
destes compostos ao passo que a estabilização dos G4 não parece ter um papel 
relevante. Com o objectivo de melhorar a capacidade de estabilização de G4, um grupo 
de compostos pertencentes à família de compostos poliaromáticos fundidos foi 
sintetizado, conforme descrito no Capítulo III. Estes compostos derivados de 
benzo[h][1,6]naftiridin-2(1H)-ona não são simétrico (contrariamente aos compostos 
descritos no Capítulo II) e possuem uma maior superfície aromática. Estas moléculas 
apresentaram uma melhor capacidade de estabilização do G4 quando comparados com 
os compostos descritos no Capítulo II. Além disso, os resultados obtidos com os ensaios 
de FRET forneceram informações que poderão ser úteis futuramente na síntese de 
compostos derivados deste núcleo aromático.  
Alternativamente aos compostos que têm como objectivo a estabilização de G4, 
foram sintetizadas moléculas cujo alvo são sequências nucleotídicas específicas. Os 
oligonucleótidos naturais possuem limitações importantes à sua acção como o facto de 
(a) poderem ser degradados por nucleases, tanto in vivo como in vitro, e por isso serem 
clivados antes de atingirem o alvo, (b) terem dificuldade em penetrar na célula 
atravessando a membrana, e (c) a sua síntese ser pouco rentável. Por este motivo, foram 
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desenvolvidos análogos dos oligonucleótidos com capacidade de estabelecer interações 
específicas com bases azotadas dos ácidos nucleicos, mas com uma maior estabilidade 
em meio biológico, maior capacidade de atravessar membranas e mais facilmente 
sintetizáveis. Dentro dos vários análogos de oligonucleótidos sintetizados encontram-se 
os ácidos nucleicos peptídicos. Nestes análogos o esqueleto ribose-fosfato foi 
substituído por um pseudopéptido com bases azotadas nas cadeias laterais. Os ácidos 
nucleicos peptídicos apresentam algumas vantagens quando comparados com os ácidos 
nucleicos naturais nomeadamente o facto de (a) não serem degradados nem por 
nucleases nem por proteases; (b) terem pouca afinidade para as proteínas plasmáticas; 
(c) terem uma maior afinidade e especificidade para cadeias de ácidos nucleicos que as 
duas cadeias de ácido desoxirribonucleico que constituem a dupla hélice, e (d) a sua 
síntese ser menos complexa uma vez que se baseia na formação de ligações peptídicas 
entre os diferentes monómeros. Os ácidos nucleicos peptídicos podem ter várias 
aplicações nomeadamente na terapêutica, no diagnóstico e como sondas. Com o 
objectivo de melhorar algumas das características dos ácidos nucleicos peptídicos como 
a sua solubilidade, permeabilidade celular ou biodisponibilidade foram feitas algumas 
alterações estruturais. Um dos exemplos desta modificação são os α-ácidos nucleicos 
peptídicos em que o esqueleto do análogo é composto por α-aminoácidos, alguns dos 
quais com uma base azotada na cadeia lateral. Para a síntese deste análogo de 
oligonucleótidos são necessários aminoácidos quiméricos. Na literatura, já foram 
descritos, por exemplo, derivados da alanina, homoalanina, serina tirosina, lisina e 
prolina. O Capítulo IV desta tese foca-se na síntese de aminoácidos quiméricos derivados 
da cisteína que poderão vir a ser utilizados como monómeros na síntese de α-ácidos 
nucleicos peptídicos. A escolha da cisteína teve como objectivo aumentar a variabilidade 
estrutural dos α-ácidos nucleicos peptídicos. Futuramente, poder-se-á verificar qual o 
impacto da presença destes aminoácidos quiméricos com um átomo de enxofre na 
afinidade dos α-ácidos nucleicos peptídicos que os incorporem para as sequências-alvo 
de oligonucleótidos. De um ponto de vista sintético também é importante realçar a 
grande diversidade de reações que foram utilizadas durante a elaboração deste 
trabalho. A reações tiol-eno merece ser destacada não só por ter sido essencial na 
síntese dos monómeros α-ácidos nucleicos peptídicos mas também por ter sido usada 
na síntese dos ligandos descritos no Capítulo II. 
 
PALAVRAS-CHAVE: Ligandos de G-quadruplexes; Naftaleno; benzo[h][1,6]naftiridin-
2(1H)-ona; α-Ácidos Nucleicos Peptídicos; Cisteína quimérica. 
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1 Chapter I 
I. STATE OF THE ART 
 
1. Nucleic acids 
 
Nucleic acids (NA) – deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) – are 
biological macromolecules that exist in every living cells. DNA is the storage of genetic 
information to encode other components of cells, such as proteins and RNA molecules.1 
RNA may: (a) act as a messenger between DNA and ribosomes – the protein synthesis 
machinery (messenger RNA, mRNA); (b) form vital portions of ribosomes (ribosomal 
RNA, rRNA); (c) serve as the carrier of amino acids used in protein synthesis (transfer 
RNA, tRNA); (d) play critical roles in biological reactions as catalyst.2  
Structurally, DNA and RNA differ in their nucleotide composition, namely in the 
nitrogenous bases (also referred as nucleobase) and in the five-carbon sugar.3 These 
polynucleotide chains can twist and fold into three-dimensional conformations 
stabilized by hydrogen bonding between specific pairs of nitrogenous bases. Besides the 
differences in nucleotide composition, DNA and RNA conformations are also quite 
different. 
DNA conformation. In 1953 Watson and Crick first described the DNA as a right-
handed double helix (double strand, dsDNA) based on X-ray crystallography obtained by 
Rosalind Franklin.4 Their description refers to B-DNA (Figure I.1), the most common 
conformation in living cells, but there are two other dsDNA conformations: A-DNA and 
Z-DNA. The former is a shorter and wider form that has been found in dehydrated 
samples of DNA and rarely under normal physiological circumstances. Z-DNA, a left-
handed conformation, is a transient form of dsDNA which exists only in response to 
certain types of biological activity and seems to be important in the protection against 
viral disease.1 Besides that, it has been found that under certain conditions, DNA has the 
potential to fold into various other secondary structures. As exemplified in Figure I.1, 
these unusual secondary structures can involve one to four strands of NAs including 
triplexes, tetraplexes (G-quadruplexes, G4, and complementar i-motifs), and other non-
B forms. Common features in these peculiar NA architectures include sequence 
dependency, base stacking and base pairing through H-bond interactions, although a 
wide variety of pairing motifs are found. Interestingly, these DNA secondary structures 
can be formed by sequences that are widely distributed throughout the human genome, 
typically in regions associated with critical biological processes. Moreover, all these 
structures are hypothesized, or even known, to play crucial roles in a range of biological 
functions in vivo, including replication, gene expression regulation, and DNA 
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recombination. There is also increasing evidence that non-canonical DNA structures 
might be involved in a number of human diseases.5  
RNA conformation. Unlike DNA, RNA is usually a single-stranded molecule which can 
form secondary structures, such as hairpin loops, stabilized by intramolecular hydrogen 
bonds between complementary bases. Such base-pairing of RNA is critical for many RNA 
functions, for example the ability of tRNA to bind to the correct sequence of mRNA 
during translation. Furthermore, it can also form double-stranded structures (RNA/RNA, 
DNA/RNA).6 
 
 
Figure I.1. Different NA conformations (adapted from [7]). 
 
As NA play a significant role in gene mutation, defects in repair mechanism and 
uncontrolled proliferation of cells, they are very interesting molecular targets. Actually, 
there are several small molecules which act on proliferating cells by causing DNA 
damages that lead to inhibition of critical processes like replication and transcription 
and ultimately to blockage of cell proliferation.  Due to the high homogeneity of B-DNA, 
the main drawback of DNA binding drugs is their random interaction on the polymeric 
DNA scaffold thereby affecting genome functions in an unspecific manner. To overcome 
this situation, an approach currently explored is the targeting of secondary structures, 
such as G4. Alternatively, oligonucleotide analogues (OAs), such peptide nucleic acids 
(PNAs), have been synthesised. 
 
2. G-quadruplexes (G4s) 
 
Guanine-rich sequences of NAs have a high propensity to self-associate into planar 
guanine quartets – G-quartets or G-tetrads (Figure I.2). These G-quartets, which were 
first reported by Gellert and co-workers8 over 50 years ago, arise from the association 
of four guanines into a cyclic Hoogsteen hydrogen bonding motif in which each guanine 
is both the donor and acceptor of two hydrogen bonds with its neighbours (from N1–O6 
and N2–N7). As G-quartet contains eight hydrogen bonds in comparison to the two or 
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three present in Watson–Crick base pairs, they are often more stable than dsDNA.9 Due 
to their large π-surfaces, the G-quartets tend to stack on each other adopting a 
secondary NA structure, G-quadruplexes. G4s are then further stabilized by association 
of metal ions that coordinate to carbonyl O6 atoms (with strong negative electrostatic 
potential).10 The metal ion stabilizing influence is linked to the increasing radii (Li+ < Na+< 
K+) with K+ being optimal, and dramatically increasing G4 stability.11 
 
  
Figure I.2. Structural features of G4s (M: metal ion; adapted from [12]). 
 
2.1. G-Quadruplex strutural polymorphism 
 
From the earliest days of studying G4s in vitro, extensive structural polymorphism was 
noted contrasting with the highly predictable B-form dsDNA. G4s are formed for one 
(monomer), two (dimer) or four (tetramer) NA strands which may be oriented in anti-
parallel, parallel, or mixed configuration (Figure I.3).  
The structural diversity also depends on the number of G-quartets comprising a 
quadruplex, variations in size and composition of linkers connecting G-strands (loop), 
conformation of glycosidic bonds of guanine bases in quartets and sometimes on the 
nature of the metal ion.13 
Loop length plays a major role in defining the final topology and stability of G4s and 
is more important in therapeutic selectivity to target a G4 than its topology. In addition, 
 
4 Chapter I 
loop residues can themselves form stacking and hydrogen bonding interactions, further 
stabilizing (or destabilizing) the G4.11 
Conformational state of the glycosidic bond (C4-N9-C1) refers to the angle between the 
guanine base (N9) and the sugar in the G-tetrad and can be either syn (0 to 90o) or anti 
(-120 to 180o) and is dependent on the backbone strand orientation. The relationship 
between backbone strand orientation, glycosidic torsion angles and groove width is 
based on simple geometric relationships and structural constraints imposed by the 
guanines held in stacked G-quartets. The combinations of syn and anti base orientations 
around the tetrads changes significantly the access to hydrogen bond donors and 
acceptors within the grooves, altering hydration networks, accessibility and a variety of 
surfaces for protein, DNA and ligand interaction.14  
Although some general trends are apparent, it is difficult to predict the propensity of 
a sequence to fold into a particular structure. In addition to that, as many G4-forming 
sequences (QFS) adopt multiple folding topologies in solution, depending on the 
presence of metal ions, ligands, or molecular crowding conditions, it is possible that 
different conformations are present in vivo in different conditions. The in vivo 
equilibrium may be affected by temperature, ionic conditions, and the binding of 
particular proteins.13 Therefore, each sequence needs to be structurally characterized 
empirically under different folding conditions and checked for conformational 
heterogeneity between two or more topologies in solution. There has been some 
developing computational methods for predicting G4s stabilities,15-17 which will likely 
improve further as in increasing amounts of empirical data are incorporated. 
 
 
Figure I.3.  Some of the G4s topologies (reproduced from [18]) 
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2.2. Important G-quadruplexes in human genome 
 
The unique structural characteristics of G4s and their polymorphism may contribute 
to their varied biological roles. Bioinformatic analysis has identified approximately 376 
000 QFS within the human genome.19 These sequences are found, for instance, in the 
promoter regions of proto-oncogenes (c-MYC, BCL-2, c-KIT, k-RAS) and other important 
genes (HIF-1α, VEGF, PDGF-A, PDGFR-β, hTERT, RB1) and telomeric 3’-overhang.20 Unlike 
telomeric regions that contain a well-defined repetitive sequence (TTAGGG in 
vertebrates) and where G4 can be formed from the single-stranded DNA (ssDNA) 
template at the 3′ end of human telomeres, QFS within promoter regions of genomic 
DNA are diverse in G-run length, loop sequences and the G4s formation is constrained 
by the duplex nature of genomic DNA. The formation of G4 within promoters may occur 
during cellular mechanisms that involve unwinding of the dsDNA. The driving forces for 
the duplex to the G4 DNA transition are the transcription induced negative superhelicity, 
molecular crowding conditions, and stabilization of the resultant G4s by proteins and 
ligands.20 The major role of the DNA G4s may be its ability to “turn-on” or “turn-off” 
some physiological events by the transcriptional regulation of genes or telomere 
length.11 
While much attention in the G4s field has been focused on DNA, in the 1990s, there 
were early reports of G4s formation from biologically relevant RNA molecules.21 An 
example of the potential importance of G4s RNA emerged from the discovery of G-rich 
telomeric repeat-containing RNA, a non-coding RNA molecule which arise from RNA 
polymerase II transcription of the C-rich strand human DNA telomeres.22 Another 
example is the presence of quadruplex forming sequences in the 3’- and 5’-untranslated 
regions of mRNAs, which has been shown to play important roles in the post-
transcriptional regulation of gene expression.23 
Moreover, G4s have been found to play roles in epigenetics and evolution process. 
Observation has indicated close relations between G4 motif and CpG methylation in the 
genome of cancer samples. Also, G4s DNA were found to relate to DNA damages, such 
as genomic instability and chromosomal rearrangements.24 
 
2.3. G-quadruplex as drug target 
 
The recent demonstration of the presence of G4s DNA and RNA in human cells25-27 
has added support to the concept that these structures can be targets for therapeutic 
intervention, at the single gene or polygene levels.  
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The concept of targeting G4s as a therapeutic strategy was first developed for 
telomeric DNA. The G4 formation and stabilization in the telomeric 3’-overhang by the 
binding of small molecules can: (a) inhibit the end-capping28 and catalytic functions29 of 
the telomerase enzyme (the reverse transcriptase  which is responsible for maintaining 
the telomere length, Figure I.4a) and (b) binding of other telomere-binding proteins 
(hPOT1).30 These telomerase inhibitors can be a very specific cancer therapeutic tools 
because (a) this enzyme is upregulated in most cancer cells, and (b) there is a marked 
difference in telomere length between telomerase-positive adult stem cells or germ cells 
(average telomere length ~15 kb) and cancer cells (~5 kb).31  
More recently this strategy has been extended to the stabilization of other G4s DNA 
structures which can lead to a range of biological effects: (a) G4 formation and 
stabilization in promoters can result in inhibition of the transcription of a targeted gene 
(Figure I.4b);32 and (b) binding to G4 ribossomal DNA selectively disrupt interaction of 
with the nucleolin protein thereby inhibiting RNA Polymerase I complex activity.33 
The G4s RNA structures can also be a target for small molecules resulting in the 
modulation the mRNA translation. It can happen either by stabilization of G4s RNA 
structures (and thus impairing the assembly and/or the scanning process of the 43S 
ribosomal complex) or by destabilizing the G4s RNA structures (and thus stimulating 
translation).21 
 
 
Figure I.4. Inhibition of (a) telomerase (yellow) activity or (b) gene transcription by ligands 
(blue) (adapted from [34]). 
 
2.4. G-quadruplex ligands 
 
There are some structural features that differentiate dsDNA and G4s: (a) a guanine 
quartet has a greater surface available for stacking contacts; (b) the four G4 grooves are 
diverse and differ from the duplex grooves in width, depth, electrostatic potential and 
distribution of hydrogen bond donor/acceptor atoms; (c) loops present in G4 are 
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variously arranged around the quartets and grooves; and (d) there are metal ions in the 
central channel.30 Despite these differences, one of the main challenges for the 
development of G4-interacting molecules is the selectivity. In fact, excepting few cases, 
the selectivity for G4 over dsDNA of most ligands is in the range of 10-100 folds.24 
Besides that, with the increasing number of G4 reported in genomic studies, drug design 
must be directed not only to differentiating between secondary DNA species but also to 
recognizing different G4s. 
Ligands may bind to G4 through different binding modes: (a) inner intercalation 
between G-quartets, (b) stacking from top or bottom surface of G4, (c) loops or grooves 
binding, or (d) a combination of more than one of these binding modes. As inner 
intercalation between G-quartet planes is disadvantageous in terms of energy (because 
it alters the π-π quartet stacking and weakens the coordination bonds between the 
guanines and metal ions), stacking with the terminal G-quartets is thereby the main 
mode of interactions with G4s.30 In order to bind to G4, ligands usually present some of 
the following features: (a) an extended planar aromatic system (fused or flexible) similar 
to G-quartet in size and shape to establish interactions through π-π stacking; (b) side 
chains that are able to interact with the loops and grooves (positively charged 
substituents usually enhance the binding affinities with the anionic phosphate backbone 
and ensure sufficient solubility of a molecule with a large hydrophobic aromatic core); 
(c) a cationic center of the aromatic core which usually interacts with the negative 
electrostatic center of the G4 by electrostatic interaction; and (d) hydrogen bonding 
patterns generated by specific molecular shape that offer recognition to the groove 
regions of G4. This bonding network can be built on either aromatic or nonaromatic 
core.24 Other important requirements are that a ligand should be stable in physiological 
conditions (without degradation or aggregation), be simple to synthesize, and have 
acceptable pharmacological parameters.30  
A database known as G4LDB (http://www.g4ldb.org), which has a collection of G4-
interactive ligands, provide a platform for the study of these ligand and their discovery.35 
Usually, they are divided in three G4 ligand families: the macrocyclic family, the 
polyaromatic fused family and a family of aromatic non-fused system.  
 
2.4.1. Macrocyclic compounds 
 
The macrocyclic systems (Figure I.5) described up to now as G4 ligands can be divided 
in three different categories: (a) telomestatin like (i.e., neutral and rigid macrocycles), 
(b) porphyrin (TMPyP4) like (i.e., cationic and rigid macrocycles), and the less studied (c) 
family of flexible cyclophane-macrocycles (i.e., cationic and non planar). 
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Telomestatin like. Telomestatin (I.1), a secondary metabolite isolated from 
Streptomyces anulatus,36 is one of the most active known G4 ligands. It has a 
characteristic planar macrocyclic structure consisting of seven oxazoles and a thiazoline 
moiety and presents high affinity for G4 and no affinity for dsDNA.37 Its exceptional 
effectiveness in binding G4 can be probably explained by the hydrophobic character of 
the molecule, which contributes to stacking interactions, and the similarity between the 
macrocycle and the G-quartet size. In addition, it exhibited an antiproliferative activity 
against a wide variety of cancer cell lines with half maximal inhibitory concentration 
(IC50) values between 0.1 and 5 μM and with no effect observed at 5 μM on fibroblast 
MRC-5 cells. This observation has been substantiated by the finding that telomestatin 
does not interfere with telomere replication in normal cells. In contrast, one major 
disadvantages of telomestatin is its synthesis.38 Various modifications were performed 
on this molecular structure by changing the number and/or type of heterocycles used39-
57 or by dimerization of the macrocyclic scaffolds.58,59 But a real breakthrough was 
achieved with the aminoquinoline-based cyclic oligoamide (I.2)60,61 which retained a 
high selectivity for G4 DNA and it is also able to discriminate different G4 DNA (human 
telomeric vs. oncogenic c-KIT). The very attractive in vitro biophysical results were also 
complemented by the low general cytotoxicity of the cyclic oligopeptides. Despite the 
real viability of the neutral macrocyclic scaffold for G4 recognition, the equilibrium 
between hydrosolubility and activity is difficult to achieve. One improvement has been 
the introduction of amino side chains that increase water-solubility and electrostatic 
attraction with the DNA target without altering the G4 selectivity of the ligand, which 
relies on the shape and rigidity of the polyhetroaryl cyclic scaffold itself.38  
Porphyrins like. TMPyP4 (I.3) is the pivotal example of this family of ligands. This 
tetracationic porphyrin has been widely used, essentially due to its great affinity for 
several G4 targets, as well as its commercial availability.38 However, the interest in 
employing TMPyP4 is somewhat counterbalanced by its lack of G4 selectivity.37,62,63 The 
porphyrin core has been extensively explored as a macrocyclic scaffold not only by 
changing the nature and number of the surrounding side arms64-70 but also employing 
ring-size analogues of the 16-membered porphyrins for the construction of G4 
ligands.18,71-78 However, worth noting that the equilibrium between affinity and 
selectivity is difficult to achieve maybe due to the highly cationic nature of this scaffold.38 
N-methyl mesoporphyrin IX (I.4) is interesting as the unique representative of the 
negatively charged macrocyclic G4 ligands, since the two carboxylic groups 
deprotonated at physiological pH.63,79 Whilst this molecule became rapidly known as 
highly G4 selective, it is regarded as a weak G4 binder because its negative charge 
prevents favorable electrostatic interactions with DNA.80 With an inner cavity 
particularly suited to coordination of a metal, porphyrins and their analogues have been 
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also widely exploited to form metal complexes.74,81-95 Among them, a Mn(III) complex 
(I.5) deserves particular attention since it was able to interact with G4 10,000 times 
faster than with dsDNA.96 More recently, metal-porphyrin conjugates with  Re(I)70 and 
Pt(II)97 in periphery were found to effectively stabilize various kinds of G4s. 
 
Figure I.5. Examples of macrocyclic G4 ligands. 
 
Cyclophane-Type Macrocycles. Mainly two types of cyclophane-like macrocycles 
have been studied for their interaction with G4s: (a) the cyclo-bis-intercalator and cyclo-
tris-intercalator family and (b) the neomycin-capped aromatic platforms. The cyclo-bis-
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intercalator and cyclo-tris-intercalator macrocycles contain two or three flat aromatic 
units, respectively, usually derived from simple intercalators linked together by different 
chains.98-100 Bis-ortho-quinacridine (I.6)101 and bis-acridine,102 two well-known examples 
of this family, formed non-planar cage like structures and showed a better binding 
affinity than their monomeric analogues. Some molecules containing only one flat 
aromatic unit and a macrocyclic framework were also synthesised as G4 ligands.99,103,104 
The second category of cyclophane-type macrocycles combine an aromatic platforms 
able to stack on a G-quartet with a well-known loop-binding motif, that is, the 
aminoglycoside neomycin.105,106 The most active prototype of this series is the 
quinacridine derivative105 that is a potent binder of the telomeric G4 DNA whereas it 
elicits a poor affinity for dsDNA. 
 
2.4.2. Polyaromatic fused compounds 
 
The overwhelming majority of ligands belongs to this group. Here, only some of the 
more important families will be mentioned. 
Acridine and acridone derivatives. Some acridine derivatives (e.g., the 3,6-
disubstituted acridine,107-109 3,6,9-trisubstituted acridine)110,111 are among the most 
important ligands while others (such as 3,9- and 4,9-disubstituted acridine derivatives) 
present more modest results.112 BRACO-19 (I.7, Figure I.6) stands out among the 
members of this family. This ligand showed strong binding affinity for G4s structures, 
high telomerase inhibitory activity which resulted in telomere uncapping and removal 
of telomere-binding protein from telomere, resulting in telomere aberration, DNA 
damage response and cell growth cessation in cancer cell lines. Moreover, this molecule 
can cause translocation of telomerase from nuclear to cytoplasm. Additionally, I.7 did 
not induce the growth inhibition of normal human primary astrocytes, as well as the 
DNA damage response, telomere abnormality and T-loop disassembly.113 I.7 also 
showed significant in vivo anticancer activity in tumor xenografts, with tumor shrinking 
up to 96% and curative responses in some animals.114 A series of BRACO-19 dimer 
ligands showed to bind to human telomeric G4 DNA and exhibited potent inhibition of 
human telomerase with IC50 values similar to or lower than those of BRACO-19. 
Furthermore, these ligands displayed greater potency in the inhibition of hPOT1 and 
increased selectivity for G4 DNA when compared to BRACO-19.115 
The tricyclic system of acridines was subsequently modified to tetracyclic116,117 and 
pentacyclic system,116,118-121  to enlarge the plane size for π-π stacking. One example of 
the pentacyclic system, RHPS4 (I.8, Figure I.6) have shown a potent telomerase 
inhibition at submicromolar concentrations, causing irreversible proliferation arrest and 
exhibiting antitumoral activity in vivo and ex-vivo.122 
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Several series of disubstituted acridone compounds have also been studied as G4 
ligands.123 Particularly, a series of 4,5-disubstituted acridone derivatives (I.9, Figure I.6) 
were found to have high affinity for human telomeric G4 DNA, with improved selectivity 
compared with trisubstituted acridine compounds.124 Most of the compounds have 
distinguishing cytotoxicity between cancer cells and normal cell lines. Interestingly, the 
properties of these 4,5-acridones are in striking contrast with a series of 4,5-
disubstituted acridines that show low G4 stabilizing ability.125 
In xanthene and xanthone derivatives, the nitrogen of the acridine and acridone 
scaffold is replaced by an oxygen.  Two and three-side chain xanthone and xanthene 
derivatives, as well as a dimeric “bridged” were synthesised. A trisubstuted compound 
(I.10, Figure I.6) showed the highest binding affinity to the human telomeric G4 DNA.126 
Based on the dimeric xanthone derivative (I.11, Figure I.6), the new 7-ring compound 
HELIXA4C (I.12, Figure I.6) was tested and the experimental results clearly indicated that 
the drug induces a certain amount of telomere-localized damage.127 
Anthraquinones and derivatives. Anthraquinones are well-known pharmacophores 
with DNA-interacting properties. Doxorubicin is example of an anthraquinone derivative 
widely used as antitumor drug in clinical practice which bind to the human telomeric 
sequence without selectivity over dsDNA.128 Mitoxantrone is another anthraquinone 
used clinically that stabilized G4 very efficiently.129  
Several types of disubstituted amido anthraquinones with amine terminal side chains 
were evaluated as G4s ligands.130,131 They represent an example of how the pattern of 
disubstitution modulates dsDNA vs. G4s selectivity. In fact, the presence of 1,4-
substituents shifts the binding preference to the dsDNA structure, whereas 2,6- or 2,7-
congeners incremented G4 recognition.132 Nevertheless, the modification of side-chain 
terminal groups from amine to amino acid can enhance the interactions between the 
ligand and the G4s groove regions, therefore improving selectivity toward G4s 
structures.132,133 More recently, researchers found that peptidyl-anthraquinones were 
excellent selective ligands for G4s. In this molecules, shifting side chains from position 
2,6- or 2,7- to 1,5- or, to a lesser extent, to 1,8- helps increasing G4 stabilization but it 
also promotes effective binding to dsDNA.134 Alternatively, conjugation of the 
anthraquinone core with neomycin resulted in ligand I.13 (Figure I.6) which exhibits a 
nanomolar affinity for human telomeric G4 DNA, 1000-fold higher when compared to 
its constituent units.135 This higher affinity is ascribed to the dual binding mode of the 
conjugate which can interact with the guanines of the G4 (anthraquinone) via π-stacking 
interactions and with the grooves (since neomicyn is a loop-binding agent as previously 
stated). Ethynyl-anthraquinones derivatives were also synthesised as G4 bi-modal 
ligands, acting on a selective reversible recognition and subsequent alkylation upon  
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Figure I.6. Examples of acridine, anthraquinone and anthracene derivatives G4 ligands. 
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reductive activation. The best compound of this series (I.14, Figure I.6) presented good 
binding affinity and it lacked significant intercalation into the dsDNA.136 Other examples 
of anthraquinone derivatives includes molecules that present a fourth aromatic 
ring.137,138 Fluorenones and derivatives can also be included among the anthraquinone 
derivatives, e.g. I.15 (Figure I.6).139-142 
Anthracene derivatives. In contrast with acridines or anthraquinones, anthracene is 
not characterized by the presence of a localized charge density on the aromatic system 
what should grant high flexibility of location over the G-quartet. As in anthraquinones, 
different regioisomers showed distinct binding affinities for human telomeric G4 DNA: 
the most effectives were the 1,5- (I.16, Figure I.6) and 1,7-bis-substituted analogues 
while the 1,8-regioisomer was poorly effective. Besides that, the 1,5-regioisomer 
presented a better selectivity (difference in affinity by one order of magnitude) for G4 
vs. dsDNA binding when compared with bis-substituted anthraquinone and acridine 
congeners. Additionally, G4 binding was clearly related to telomerase inhibition in this 
class of compounds.143 Based on this data, constrained analogues of the 1,5-regiosiomer 
have been synthesised.144  
Phenanthrolines derivatives. Several structures containing 1,10-phenanthrolines 
have been investigated as G4 ligands (Figure I.7). Some of the compounds belonging to 
this class present the 2,9-substitutional pattern including highly potent and selective 
bisquinolinium amides (I.17),145 bistriazoles carrying tethered positive end groups,146 
analogues with cationic amino side chains147,148 and metal complexes.149,150 Besides that, 
other 1,10-phenantroline substitution patterns have also been studied,120,148,151-153 
including conjugation with carbohydrates.154 Additionally, a series of 4,7-diamino-1,10-
phenanthroline derivatives (I.18) carrying positively charged side chains showed 
appreciable G4-stabilizing properties but poor selectivity over dsDNA.153 
Tetrasubstituted phenanthrolines carrying both 4,7-diamino substituents and 2,9-
carboxamide-linked quinolines (I.19) were also studied. They showed improvements 
over both parent structures exhibiting a strong affinity, a high degree stabilization and 
selectivity for the G4 structure. N-Methylation of the quinolines and positive charges on 
the terminal 4,7-substituents were found to be essential for the G4 interaction of 
compounds of this series.155 Bis-phenanthroline ligands, containing two phenanthroline 
moieties covalently linked through an amine or thioether bond, and its metal complexes 
were also tested. In particular, Ni(II) and Cu(II) complexes showed dramatic increase 
ligand-stabilising effects on G4, promote the G4 folding and inhibit the activity of 
telomerase.156 Phenanthroimidazole derivatives157,158 and its metal complexes159-164 
were also studied. Overall Pt(II) complexes (I.20) displayed a significantly greater binding 
affinity and selectivity for G4 than dsDNA, inhibited telomerase activity in vitro, caused 
a significant dose- and time- dependent decrease in average telomere length and 
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presented antiproliferative activity on A549 lung cancer cells and to a lesser extent on 
primary MRC5 fibroblast cells.159,165,166 More recently, several cyclometalated Ir(III) 
phenanthroimidazole complexes showed to bind with low micromolar affinity to G4 
DNA sequences and exhibited enhanced luminescence upon binding to these 
sequences. Due to the this luminescence enhancement, the complexes are able to be 
used as selective G4 indicators.167  
 
 
Figure I.7. Examples of phenanthrolines derivatives G4 ligands (R: alkylamine). 
 
Carbazole derivatives. One of the most studied G4 ligands of carbazole skeleton is 
BMVC (I.21a, Figure I.8) which recognizes and stabilizes specific G4 structures, 
particularly human telomeric sequence. Besides that, it also exhibits excellent ability to 
inhibit telomerase activity and have proved to repress tumor progression. This molecule 
have also been used as fluorescent probe for G4 DNA recognition.168 Ortho-isomer of 
BMVC (I.21b, Figure I.8) is also a good G4 stabilizer but a better G4 fluorescent probe 
with greater ability to distinguish G4 DNA from dsDNA. In addition, 3,6-bis(1-methyl-4-
vinylpyrazinium)carbazole diiodide (I.21c, Figure I.8) is likely a better core molecule than 
BMVC for G4 stabilizers.169 Several other carbazole derivatives with different 
substituents present on the tricyclic ring system have been synthesised in order to study 
their activity as G4 ligand and/or G4 probe.168-172 Results suggested that the tri-cations 
of 9-substituted BMVC derivatives are better G4 stabilizers than the bi-cations.169 
Recently, benzimidazole−carbazole (I.22, Figure I.8) conjugates and their dimers 
demonstrated high binding affinity and stabilization of G4 DNA and also induce 
significant apoptotic response and antiproliferative activity toward cancer cells 
selectively when compared to the normal cells.170,171 
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Figure I.8. Examples of carbazole derivatives G4 ligands. 
 
Indoloquinoline derivatives. One of the first series of indoloquinolines tested for G4 
binding were the pentacyclic benzoindoloquinoline derivatives (I.23, Figure I.9).173 
However, the majority of indoloquinoline ligands developed for G4 recognition are 
derived from quindoline (10H-indolo[3,2-b]quinolone) or its N-methyl derivative 
(cryptolepine). The disubstituted quindoline derivatives (with two alkyl amino groups at 
the 2,7-,174,175 2,10-176 or at the 10,11-177) presented modest to good G4 stabilization 
and telomerase inhibition activity. Analogues with an electron-donating group at the 11-
position significantly improved their ability to stabilize a G4. This fact is due to the 
significant increase in the electron density at the quinoline nitrogen (N5) atom resulting 
in easy protonation under physiological pH that is an important feature to improve 
binding to external G-quartets of G4s.178-180 The most active derivative, SYUIQ-05 (I.24, 
Figure I.9), interacts with human telomere or c-MYC oncogene G4s (with relatively 
stronger affinity) and has effects on the biological functions of these two genes, resulting 
in telomere shortening, autophagy, inhibition of cell proliferation, cell senescence, and 
apoptosis.179,181 Besides the introduction of the positive charge via in situ protonation, 
an alternative pathway was N-methylation at 5-position. Cryptolepine-11-amine 
derivatives were also studied and exhibited a significant improvement in the ligand 
mediated stabilization of the G4 structure.180,182-184 In particular, trisubstituted 
quindoline derivatives presented an increased and more selective G4 stabilisation over 
dsDNA relative to the correspondent disubstituted derivatives and also some inter-G4 
selectivity.184,185 Recently, a small library of mono- and di-substituted alkyldiamine 
isocryptolepine (11H-indolo[3,2-c]quinolone)  derivatives showed very potent thermal 
stabilization of the telomeric sequence.186 Among these ligands, disubstituted 
compounds (I.25, Figure I.9) are potent and selective G4 stabilizers vs. dsDNA.187 Other 
indoloquinolines, such as neocryptolepine (5-methylindolo[2,3-b]quinoline), are weak 
telomerase inhibitors and exhibit a significant preference for triplexes over G4 or 
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dsDNA.188 Besides that, a series of peptidylbenzofuroquinoline conjugates was 
synthesized to improve the selectivity of cryptolepine analogues. The most active 
compound (I.26, Figure I.9) presented potent inhibitory effect and 50-fold higher 
selectivity for human telomeric G4 DNA against the dsDNA. Additionally, cellular 
experiments also showed a promising anticancer effect.189 Recently, metal complexes 
containing indoloquinoline moiety have been synthesised,190-192 higlightning a Ru(II) 
complex containing  which presented a significant selectivity to human telomeric over 
c-MYC G4s DNA.192  
 
 
Figure I.9. Examples of indoloquinoline derivatives G4 ligands. 
 
Isoquinoline derivatives. Berberine, palmatine, chelerythrine, coralyne, and 
sanguinarine are isoquinolines whose nucleic acid binding abilities have been studied. 
The more planar compounds (coralyne, I.27 and sanguinarine, I.28, Figure I.10) are 
better G4 ligands than the others.193-197 However, all these isoquinolines showed a 
strong binding ability to dsDNA.198 Structural modifications of these isoquinoline 
alkaloids, mainly in berberine, have greatly improved the G4 selectivity. These 
modifications include side chain introduction (positions 9198-200 and 13201,202), 
dimerization203,204 and scaffold revisions, such as quinolino-benzo-[5,6]-
dihydroisoquindolium compounds (I.29, Figure I.10), which exhibited better binding 
affinity for c-MYC G4 and excellent inhibition of its transcription and expression in cancer 
cells but not in normal cells).205 
Quinobenzoxazine derivatives. A series of quinobenzoxazines derivatives were 
patented by Whitten et al. in 2006, including over 1800 compounds. Among them, 
quarfloxin (I.30, Figure I.10) showed good selectivity toward c-MYC G4. It displayed 
antitumor activities to a broad range of tumor types, IC50 from sub-micromole to 
micromole range. Later, it was found to interact with rDNA G4 and disrupt nucleolin 
binding, which would lead to cancer cell apoptosis.24 The drug completed phase I in 
patients with advanced solid tumors and lymphoma in 2009 but it did not proceed 
beyond phase II clinical trials, due to its limited bioavailability.206 
 
17 Chapter I 
 
Figure I.10. Examples of isoquinoline derivatives G4 ligands and quarfloxin. 
 
Diimides derivatives. Perylene diimide207-211 and corenene diimide207,212 derivatives 
exhibiting different side chains were studied as G4 ligands. Based on these two scaffolds, 
some authors modified the number of condensed aromatic rings and introduced 
different side chains obtaining several series of mono-208 and tri-substituted213 
naphthalimides and di-,208,214,215 tri-214 and tetra-substituted214,216-220 naphthalene 
diimides. Disubstituted naphthalene diimide analogues showed low selectivity for G4, 
while tri- and tetra-substituted analogues exhibited high G4 affinity. Concerning the 
tetrasubstituted naphthalene diimide analogues, the binding affinity of naphthalene-
based ligands depends on structural constituents of the ligand as well as the 
arrangement of the phosphate and other polar groups in DNA structure, since the four 
substituents interact through hydrogen bonds, water bridges and electrostatic contact 
with each G4 groove. Usually bulky terminal groups improve stability of G4 structure by 
positioning itself in the G4 grooves.221 Remarkably, in spite of their size and high net 
cationic charge, these compounds are rapidly transported into MCF7 breast cancer cell 
nuclei, possibly by active transport mechanisms.222 BMSG-SH-3 (I.31, Figure I.11) is a 
potent G4 DNA stabilizing ligand with sub-micromolar cell growth inhibitory activity in a 
range of pancreatic (and other) cancer cell lines, and also inhibits telomerase in these 
cells.223 As previously observed in other derivatives, the presence of metal ions seems 
to be advantageous.224,225 An example of this is a disubstituted naphthalene diimide 
derivative incorporating Zn(II) ions into its dipicolylamine groups (I.32, Figure I.11) which 
revealed higher affinity to investigate oligonucleotides, comparing to the compound 
without the metal.224 A series of naphthalene diimides capable of reversibly binding 
human telomeric G4 DNA and alkylate it through an electrophilic quinone methide 
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moiety (I.33, Figure I.11) showed a marked stabilization and selectivity towards 
telomeric G4 DNA.226,227 Recently, carbohydrate naphthalene diimide conjugates have 
shown certain selectivity for G4 structures against dsDNA. Interestingly, a correlation 
between the more efficient cell uptake (through glucose transporters) of these 
molecules and their higher toxicity in cancerous cell lines has been observed.228 
 
Figure I.11. Examples of naphthalene diimides derivatives G4 ligands. 
 
2.4.3. Non-fused aromatic compounds 
 
The acyclic compounds tend to be characterised by a crescent shape. These molecules 
were designed with the main objectives of  potentially enhance the drug-like features 
when compared with the other families.229 Here, only some of the more relevant 
families will be described. 
Bis-quinoline derivatives. Several ligands where the two quinolinium moieties are 
connected through different aromatic or more flexible linkers were synthesised. 
Examples of aromatic linkers were 2,6-pyridine,230,231 2,6-pyridodicarboxamide,232-235 
triazine,236,237 2,2’-bipyridinecarboxamide,238  bis(vinylquinolinium)benzene239 and 1,8-
naphthyridinecarboxamide.240 
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Figure I.12. Examples of bis-quinoline derivatives G4 ligands. 
 
Among them, the compounds linked through 2,6-pyridodicarboxamide are the most 
studied, especially compounds I.34 (Figure I.12) and pyridostatin I.35 (Figure I.12). 
Generally, these compounds displayed strong specificity and selectivity for G4 structures 
and strong inhibition of telomerase in vitro. They also inhibited proliferation and 
induced apoptosis of telomerase-positive glioma cell lines with short telomeres and 
were also effective on ALT cell lines.232,234,235 Pyridostatin interacts with telomeres and 
alters the integrity of shelterin in cells through POT1 uncapping (resulting in a DNA-
damage response)235 and alters transcription and replication of particular human 
genomic loci containing high G4 clustering within the coding region.234 The successful 
design of pyridostatin prompted the synthesis of analogues with different 
substituents.234,241,242 It was described that the nature of the substitution at the pyridine 
moiety has a great influence on the stabilization potential of the molecules for human 
telomeric G4 DNA while the nature of the amine on the side chain was found to have a 
small influence on the stabilization potential of the analogues.241 Recently, a conjugate 
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of I.34 with an already identified antitumor N-heterocyclic carbene-platinum complex 
(I.36, Figure I.12) showed a strong stabilization of G4 structures in vitro binding 
preferentially and irreversibly the with the human telomeric sequence.243 
Molecules having the bisquinolinium moiety linked through more flexible central 
linkers such as vinyl bridge,244 diene spacer,244 heptamethylene and decamethylene 
linkers245 and a series of bisaryldiketene derivatives246 were also tested. Among this 
compounds, one of the bisaryldiketene derivatives (I.37, Figure I.12) stood out since it 
was 200 times more selective for c-MYC over telomeric G4 DNA.244,246  
Dimer I.38 (Figure I.12) and tetramer I.39 (Figure I.12) presented different FRET 
results. While the compound I.38 is a poor G4 ligand the helical trimer I.39 is a 
moderately strong G4 stabilizing ligand with apparent selectivity relative to dsDNA.247 
Bis- and tris-triazoles derivatives. Bis-triazole ligands linked by a benzene248,249 or a 
naphthalene250,251 scaffold are described in Chapter II. A series of symmetric phenyl 
derivatives containing three triazole moieties (I.40, Figure I.13) did not stabilize neither 
G4 DNA nor dsDNA.252   
Bis-indole derivatives. Bis-indole carboxamides exhibiting a pyridine (I.41, Figure I.13) 
as planar central core and N,N-dimethylpropylamine side chains were evaluated. 
Pyridine bis-indoles exhibited moderate stabilization potential for four different G4 
forming oligonucleotides studied and showed better selectivity for promoter G4 (c-KIT2 
and c-MYC) over human telomeric G4 DNA. In addition, a diminished dsDNA stabilization 
was observed for the ligand I.41.253,254 Analogues of these ligand with variations in amine 
side chains (different substitution position, length and stereochemistry) also exhibit 
significant selectivity for G4 DNA over dsDNA. Besides that, the substitution of pyridine 
by a fluorobenzene ring on the bis-indole scaffold was found to enhance the stabilisation 
potential for human telomeric and c-KIT2 G4s.254  
 
 
Figure I.13. Examples of bis-triazoles and bis-indole derivatives G4 ligands (R: amine). 
 
Bis-benzimidazole derivatives. Bis-imidazole ligand I.42 (Figure I.14), one of the first 
ligands of these class tested, only stabilized the human telomere G4 DNA at high 
concentrations.255  Conjugation of I.42 with neomycin enhances its binding to G4 DNA.256  
 
21 Chapter I 
 
Figure I.14. Examples of bis-benzimidazole derivatives G4 ligands. 
 
Different bis-benzimidazole derivatives linked through an aromatic cores were also 
developed.257,258 Among them, compounds presenting pyridine (I.43a) and 1,8-
naphthyridine (I.43b) as a central core specifically bind to and stabilize promoter G4 DNA 
having parallel topology over any of the human telomeric G4 DNA topologies and 
dsDNAs.257 Substituted benzenes245,259 and Tröger’s base (I.44, Figure I.14)260 are other 
examples of core group that were used to link the two benzimidazoles.  
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A series of monomeric and dimeric m-phenylene-bis(piperazinylbenzimidazole) 
derivatives (respectively I.45 and I.46, Figure I.14) were also studied. Monomeric ligands 
presented a significant stabilization and selectivity for G4 DNA while the dimeric ones 
induced less stabilization. In vitro studies showed that both ligands have concentration-
dependent cytotoxicity toward cancer cells and selectively toward cancer cells over 
normal cells.245  
Some tolyl derivatives and metal complexes (I.47, Figure I.14) were also synthesised. 
The crucial effect of the metallic cation was once again confirmed since the free organic 
ligand present little or no stabilizing effect.230 
Bis-oxazoles derivatives. The pentacyclic BOxaPy (I.48, Figure I.15) and heptacyclic 
TOxaPy (I.49, Figure I.15) were the first examples of bis-oxazole derivatives studied as 
G4 ligands. The heptacyclic derivative I.49 was found to be totally devoided of affinity 
for dsDNA while exhibiting a binding preference for certain G4 topologies over others. 
In contrast, the pentacyclic oligomer I.48 appears to be unable to stabilize human 
telomeric G4 DNA. Consistent with the previously stated, compound I.49 was found to 
inhibit strongly the proliferation of the cell lines with IC50 values lying down to the 
nanomolar range. Conversely, the pentacyclic analogue I.48 was poorly efficient even at 
high concentration.261  
A series of triazole-centred ligands flanked by phenyloxazoles (I.50, Figure I.15) were 
also synthesised but demonstrated to be quite poor binding to G4 DNA.262 
 
 
 
 
 
 
 
 
 
 
 
Figure I.15. Examples of bis-oxazole derivatives G4 ligands (R: amine). 
 
Diarylureas derivatives. G4 stabilizing ability of diarylurea ligands depends on 
different structural features of these ligands, namely the urea bond substitution pattern, 
the length of alkylamino side chain and the terminal amine (Figure I.16). For example, in 
a series of diarylurea ligands with a triazole linker, ortho- and meta-analogues have 
significantly enhanced stabilising affinity to telomeric and non-telomeric G4 DNA over 
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the more extended para-analogues, suggesting that the ‘square-planar’ conformation 
of the ligand core is critical for efficient G4 interaction. In this series and in another 
without triazole, the meta-substituted analogue with pyrrolidino side chains presented 
the best results as G4 ligands (respectively I.51 and I.52).263,264 
Smaller diarylurea compounds I.53 and I.54 were identified by high-throughput 
screenings.244,265 Other urea-based G4 targeting ligand (I.55) presenting significant 
selective stabilisation of telomeric G4 was also identified.244 
 
 
Figure I.16. Examples of diarylureas derivatives G4 ligands. 
 
Diethynylamides derivatives. Bis-phenylethynyl amide derivative linked through a 
pyridine ring and containing N,N-dimethylpropylamine side chains (I.56, Figure I.17) 
showed moderate stabilization for three promoter G4 DNA with no detectable 
stabilization of dsDNA.266 In order to achieve enhanced binding ability and differential 
recognition towards diverse G4 sequences, substituted analogues were synthesised. 
These analogues significantly increased the stabilisation potential and selectivity for a 
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particular G4 target compared to the parent ligand I.56, being I.57 the best G4 DNA 
stabilising ligand in this series.267 
 
Figure I.17. Examples of diethynylamides derivatives G4 ligands. 
  
Terpyridine derivatives. Terpyridine derivatives were studied as G4 ligands.230,268-274 
Some of them showed a high G4 stabilization and a good selectivity profile over dsDNA, 
especially compounds with tetraalkylammonium pendants in the central pyridine ring 
(I.58, Figure I.18).269  
A series of metal–terpyridine complexes using transition metals230,269,270,272 were also 
synthesised. A striking difference between the binding ability of different metal 
complexes was observed. This indicates that the nature of the metal and consequently 
the different geometries of the complexes are strong determinants for target 
recognition. For example, Pd(II), Cu(II) and Pt(II) complexes are more potent G4 binders 
than the corresponding free terpyridines derivatives. In contrast, Zn(II) and Ru(II) 
complexes are poor G4 stabilizers. Complex I.59 also strongly inhibited the proliferation 
of the three tested cancer cell lines with IC50 values in the nanomolar range.230  
A series of terpyridine-based dimetallic complexes (I.60, Figure I.18) were also 
evaluated. Once again, the free ligand showed poor G4 DNA binding affinity while the 
dinuclear Cu(II) (I.60a) and Pt(II) (I.60b) complexes display higher affinity toward G4 
DNA, highlighting the importance of the metal centers in defining ligands binding 
ability.275 Recently, another terpyridine-based metallic complexes with different cyclic 
amine substituents in different positions showed to stabilize G4 DNA and displayed 
cytotoxicity similar of cisplatin. Among them, dimetallic complexes I.61 showed higher 
affinity towards G4 DNA compared to their monometallic counterparts.273  
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Figure I.18. Examples of terpyridine derivatives G4 ligands. 
 
Triphenylpyridine derivatives. Triphenylpyridines derivatives presented a wide 
variation in G4 binding affinity. The nature of the 4-aryl substituents along with side 
chain governs the G4 DNA stabilizing ability of these compounds. For example, the 
absence of 4-aryl substituent (I.62, Figure I.19) had a negative effect stabilization of G4. 
Compounds with a para-bromophenyl or para-thiomethylphenyl substituent on the 
central pyridine ring (I.63a and I.63b, respectively) exhibited the highest stabilizations 
for all G4 DNA sequences studied. However, these compounds presented a medium 
specificity for G4 over dsDNA. On the other hand, compounds containing 5-membered 
aromatic substituents (I.64, Figure I.19) or piperonal substituent (I.65, Figure I.19) on 
the central pyridine ring exhibited mid-range stabilizations for G4 DNA and have high 
specificity for G4 over dsDNA. Cytotoxicity studies of these compounds in HeLa 
adenocarcinoma cells showed that the majority of compounds which display high to 
mid-range stabilization of G4 DNA exhibit significant cytotoxicity.268,276,277  
Polyamides. This family of compounds were designed having distamycin A (I.66, 
Figure I.20) as lead molecule. The majority of 2,4-pyrrole polyamides and its 2,5-pyrrole 
counterparts (I.67 and I.68, respectively) tested displayed 2 to 4-fold selectivity for 
dsDNA over G4 DNA.278 In contrast, analogues with biaryl building blocks showed 
significant selectivity towards G4 compared to dsDNA and the best molecule of the 
series (I.69, Figure I.20) has no significant action on dsDNA.279 Polyamides I.70 and I.71 
were also identified as G4 binding ligands.244 
Isaindigotone derivatives. Isaindigotone derivatives with different cationic amino 
side chains attached to the unfused aromatic chromophore, different aliphatic ring sizes 
and different substitution patterns in the aromatic fused ring were developed and 
evaluated as G4 ligands. Compounds with two side chains (I.72, Figure I.21) proved to  
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Figure I.19. Examples of triphenylpyridine derivatives G4 ligands. 
 
 
Figure I.20. Examples of polyamides G4 ligands. 
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be better G4 ligands than compounds with a single side chain (I.73, Figure I.21). Among 
ligands with two side chains, it was apparent that increasing size chains resulted in a 
weaker G4 stabilizing effect being. It was also apparent that all 4′,6-disubstituted 
isomers had generally an enhanced G4 DNA stabilization compared to those with 4′,7-
disubstituted isomers. The selectivity of these compounds for G4 over dsDNA was also 
confirmed. 280,281 A molecule based on thiazole orange and isaindigotone skeleton (I.74, 
Figure I.21) showed to stabilize G4 DNA without affecting dsDNA, suggesting its excellent 
selectivity to G4.282 
 
 
Figure I.21. Examples of isaindigotone G4 ligands (R: amine). 
 
Quinazoline and Quinazolone derivatives. A series of 2,4-disubstituted quinazoline 
derivatives were very selective to G4 over dsDNA but had varying effects in stabilizing 
the telomeric G4 DNA. For example, the existence and the length of the amide side chain 
at the ortho- position of the aromatic group had a significant effect on its stabilizing 
ability: while ligand I.75 without the amide side chain did not show any effect on G4 
stability, compounds I.76 with side chains increased telomeric G4 DNA stabilization. On 
the other hand, alterations of the basic terminus of the amide side chains showed that 
the N-methyl piperazino analogues had strongly enhanced affinity for G4 DNA while the 
less basic morpholino analogues had the weakest effect. The existence of an additional 
benzene ring (I.77) or the presence of the chlorine substituent (I.76b) greatly increase 
the telomeric G4 DNA stabilizing ability of these compounds Moreover, the 
disubstituted quinazoline derivatives were found to be strong telomerase inhibitors, and 
cellular experiments demonstrated a remarkable decrease in the population of cells 
with a shortening of the telomere length.283,284 
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Another class of quinazolone derivatives (I.78 and I.79, Figure I.22) targeting c-KIT G4 
DNA were synthesised. The stabilizing ability of these compounds also increased with 
the length of the side chains. These derivatives demonstrated an excellent selectivity 
between G4 DNA and dsDNA and inhibited the transcription and expression of c-KIT 
gene.285 
 
 
Figure I.22. Examples of quinazoline and quinazolone derivatives G4 ligands. 
 
2.5. Methodologies for structural analysis of G-quadruplex/ligand 
interactions 
 
A number of experimental methods are able to study the G4-ligand interactions. 
Optical spectroscopic methods (Ultraviolet-visible, circular dichroism, fluorescence), 
competition dialysis, electrospray ionisation mass spectrometry, isothermal titration 
calorimetry and surface plasmon resonance (SPR) are among the more common used 
ones. These methods provide a wealth of information about stabilization potency, 
selectivity and stoichiometry of the complexes formed by G4s and small organic 
molecules. However, in order to determine structural parameters for these interactions, 
high-resolution techniques such as nuclear magnetic resonance (NMR) spectroscopy 
and X-ray crystallography are required. Such information could be of immense value for 
improving the properties of existing ligands or designing new ones. However, it should 
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be mentioned that the structural parameters obtained using both methods might differ 
even for the same molecule, which again emphasizes the versatility of G4 topology.286  
 
2.5.1. Optical spectroscopy  
 
These methods are rapid, require small amounts of material and are non-destructive. 
In addition, the spectrometers used for optical studies are routinely available in 
laboratories.286 
Ultraviolet-visible absorption spectroscopy is the simplest instrumental technique. 
The study of G4-ligand interactions is carried out by monitoring the changes in the 
absorption properties of the G4 (which depends on base stacking and temperature) at 
295 nm, a wavelength that maximizes the hypochromic shift between the folded and 
unfolded states.11 In addition to this qualitative information, experiments involving 
titration of the DNA with the ligand (or vice versa) provide quantitative information such 
as stoichiometry and binding constants. A different strategy for detecting interactions 
between G4 and drugs is to study the thermodynamic parameters calculated from UV-
monitored melting experiments. The melting temperature (Tm), i.e. the point at which 
half of the bases in the G4 have unstacked, and thermodynamic parameters are 
determined from the changes in the absorbance as a function of temperature. 
Comparing the Tm values in the absence and presence of a ligand is a tool for establishing 
the existence and type of interaction (stabilization or destabilization) between the ligand 
and the G4.287 
Circular dichroism has been extensively used as a G4 analysis tool, namely to detect 
the presence of a G4 structure in an oligonucleotide sequence. It is commonly accepted 
that the conformation of a G4 structure can be roughly assigned from the position and 
magnitude of the CD bands. Hence, a positive band at 260 nm is commonly assigned to 
a parallel conformation, whereas a positive band at 295 nm and a negative band at 260 
are indicative of an antiparallel conformation. CD is also used to study interactions 
between G4 and ligands by measuring the Tm. This is usually performed by plotting the 
measured ellipticity at the wavelength corresponding to the maximum of a positive band 
versus temperature. Besides that, this method has been used extensively as a G4 
analysis tool being its primary use to detect the presence of a G4 structure for a given 
NA sequence 287 
Molecular fluorescence is probably one of the techniques most commonly used to 
study interactions between ligands and G4 structures. The advantages of molecular 
fluorescence over other techniques are: its high sensitivity, large linear concentration 
range and selectivity.287 When studying G4-ligand interactions, there are several 
different approaches to molecular fluorescence spectroscopy. One requires the use of a 
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chemically modified fluorescent base, such as 2-aminopurine (an adenine analogue) –, 
in the NA sequence of interest. This purine can be incorporated in any G4 NA without 
changing its conformation and only slightly affecting its stability. The overall 
fluorescence of a G4 changes if a small molecule interacts in the proximity of 2-
aminopurine.11 An alternative fluorescence method that evaluate the affinity of a 
compound for G4 and its selectivity towards dsDNA is called G4 fluorescent intercalator 
displacement. This assay is based on the loss of fluorescence of thiazole orange upon 
competitive displacement from NA by a putative ligand under steady-state.62,287,288 
Another technique for studying ligand-G4 interactions, which has become very popular, 
is fluorescence (or Förster) resonance energy transfer (FRET) spectroscopy. In this 
method, oligonucleotides are labelled at 3’- and 5’-ends using a two dyes (e.g., 5’-
carboxyfluorescein, FAM, and 3’-carboxytetramethylrhodamine, TAMRA). When G4 is 
formed, the two dyes are close and energy is transferred from the excited dye to the 
other dye, which then re-emits at a longer wavelength (Figure I.23a). However, as the 
G4 undergoes thermal denaturation, the two dyes move apart and direct emission is 
restored (Figure I.23b). The amount of direct emission versus FRET emission indicates 
how close the dyes are. This variation in fluorescence is measured to obtain melting 
curves. FRET systems are very used due to a large difference between the fluorescence 
properties of the folded and unfolded forms and therefore this method provides well-
resolved melting curves. However, it should be noted that melting temperature studies 
do not allow precise measurements of affinity constants.286  
 
Figure I.23. FRET melting spectroscopy: a) Quenching occurs when the two probes are close; 
b) Direct emission occurs when the two probes are apart (adapted from [289]). 
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2.5.2. Other methods 
 
Competition dialysis is used to determine the preferential conformation of nucleic 
acids for small molecule recognition. The method is fast and allow the determination of 
the apparent affinity constant of a ligand.32,79  
Electrospray ionisation mass spectrometry is another useful tool to determine the 
properties and the structures of G4s, and to study ligand-G4 interactions in the gas 
phase. The relatively soft ionisation conditions of this system ensures that non-covalent 
interactions are preserved, allowing G4 structure, stability, kinetics, strand 
stoichiometry and ligand binding strengths to be determined using a small amount of 
compound. The determination of ligand binding dissociation constants is a particularly 
useful capability of this method, as this allows rapid, cheap and accurate screening of 
potential G4 ligands. Additionally, it is possible to measure ligand binding constants in 
the presence of multiple targets (e.g. G4 and dsDNA) in order to give a measure of 
ligand-binding specificity.11 
Isothermal titration calorimetry is used to measure thermodynamic parameters – like 
change in enthalpy and entropy during a binding interaction –, along with the affinity 
constant and stoichiometry of interaction. 287  
Surface plasmon resonance is used to characterize the G4 structure and study 
interactions between G4 and ligands using surface-immobilized oligonucleotides. It 
provides a quantitative analysis of the binding parameters, that is, thermodynamic 
(equilibrium constant, Gibbs energy of binding, and stoichiometry) and kinetic 
parameters of the interaction of small molecules. The current instrumentation allows 
the interaction of a certain ligand to be studied with several oligonucleotides 
simultaneously. This makes it possible to compare the binding of a number of different 
ligands with different G4 quickly and easily.287  
X-Ray diffraction is an important technique in the structural elucidation of complex 
formed between the small molecule and G4, as it provides details of strand orientation 
and G-tetrad arrangement, determines the hydrogen bonds involved in stabilization of 
the complex, and allows the structural arrangement to be studied at the atomic level. 
As the acquisition is made in the solid state, using a crystal of the complex, it reflects the 
state of matter in a condensed state. In consequence, the crystal structures may or may 
not fairly represent the solution.11  X-ray crystallography also showed that it is 
theoretically possible to design molecules that can discriminate between RNA and DNA 
quadruplexes: the hydroxyl group at the C2’ position of a sugar moiety in the RNA 
modifies interaction by preventing the formation of hydrogen bonds.290  
NMR spectroscopy is a powerful experimental technique that allows a rapid 
qualitative analysis, confirming G-tetrad formation and the folded topology of the DNA 
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or RNA in solution. Interaction between the G4 and ligands is confirmed from the 
comparison of the experimental NMR spectra from samples with different ratio of 
concentrations of G4 and the ligand. Depending on the changes observed in the NMR 
signals, the binding mode and the strength of the binding between the ligand and G4 
can be proposed. NMR main advantage over crystallography is the fact that the structure 
is studied in solution and not in a crystal lattice.287  
Molecular modelling and molecular dynamics have been used to understand and 
improve the recognition of G4 by small organic molecules. Models have been used as 
starting point for structure-based design of selective and potent G4 binders. Molecular 
dynamics simulations have been also applied to the study of complexes between G4 and 
small organic molecules, in order to complement experimental data lacking atomic 
resolution.286 
 
3.  Peptide Nucleic Acids (PNAs) 
 
 The possibility to control the expression of specific genes at the level of NA has 
attracted great interest since Stephenson and Zamecnik reported that the replication of 
Rous sarcoma virus was inhibited by a synthetic 13-mer oligodeoxynucleotide 
complementary to a specific mRNA.291 Following this discovery, NAs became the bases 
for the development of synthetic compounds (oligonucleotide analogues, OAs) with the 
potential to maintain complementary interactions between nucleobases with higher 
affinity than the natural NAs while displaying sufficient specificity to distinguish single 
base mismatches. In addition, OAs should overcome the drawbacks inherent to natural 
NAs, which mean increasing the stability in biological media and in cells and furnishing 
the ability to cross cell membranes. From a chemical point of view, it would be also 
important to develop efficient preparative methods for the synthesis of OA in sufficient 
amount for their practical use. With these purpose a huge variety of new oligonucleotide 
derivatives with modifications in the phosphodiester backbone, the sugar ring, and/or 
the nucleobase have been synthesized and analysed.292  
OAs have been classified into three generations based upon variation of these 
modifications (Figure I.24): 
First generation:  based on backbone modification of natural NAs (such as 
replacement of an oxygen atom of the phosphate linkage by sulphur (phosphorothiolate 
oligonucleotides, PS, I.80) or methylation of an oxygen (methylphosphonate 
oligonucleotides). PS are the major representative of this generation. Their main 
advantages: (a) are resistance to nucleases, (b) ease of synthesis, and (c) their attractive 
pharmacokinetic properties. However, their lower binding affinities and nonspecific 
interactions lead to undesirable side effects in vivo, such as immune stimulation and 
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cellular toxicity.293 Despite these limitations – partly overcome by further 
modifications294-296 – Vitravene™ was an approved drug belonging to this group.  
Second generation: presents an electronegative substituent at the 2’-position of the 
ribose ring (2’-OMethyl (I.81) and 2’-O-methoxyethyl (I.82) RNAs are the major 
representatives). These building blocks conferred an RNA-like C-3’-endo conformation 
to the oligonucleotide that greatly increases its binding affinity. They also show 
increased nuclease resistance and reduced toxicity. Mixed backbone oligonucleotides 
(known as ‘gapmer’ chimeras) were developed by surrounding a phosphorothioate-
modified core (gap) with nuclease resistant arms such as 2’-OMe ribonucleosides. 
Kynamro™, a FDA- approved drug, and a vast number of OAs undergoing multiple clinical 
trials are exploring this ‘gapmer’ chimera to achieve improved therapeutic properties.293 
Third generation:  mainly contains modified phosphate linkages and modified ribose 
rings or different chemical moiety replacing the ribose ring. This group is mainly 
represented by locked nucleic acids (LNAs, I.83), phosphorodiamidate morpholino 
oligomers (PMOs, I.84) and peptide nucleic acids (PNAs, I.85). LNAs possess a methylene 
bridge that connects the 2’-oxygen of the ribose moiety with the 4’-carbon. PMOs are 
noncharged OA in which the ribose sugar is replaced by a six-membered morpholino 
ring and the phosphodiester bond is replaced by a phosphorodiamidate-linkage.293  
 
 
Figure I.24. Monomers of OAs from different generations. 
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PNAs were originally designed and developed as a ligand for the recognition of dsDNA 
by Nielsen and collaborators.297 The goal was that PNAs binded as a third strand to a 
dsDNA major groove via Hoogsteen base pairing and thereby modify its properties in 
transcription or translation. In order to obtain this OA, the Danish group detached the 
negatively charged sugar-phosphate backbone in a computer model and replaced it with 
a pseudopeptide composed of N-(2-aminoethyl)glycine units in which the four 
nucleobases are anchored to the glycine nitrogen by means of a methylene carbonyl 
linker. Although formally is neither a peptide nor a NA, PNAs embody structural features 
from each of these classes of biomolecules. Unlike NAs, PNAs have uncharged peptide 
backbones that is achiral  and contain the same number of backbone bonds between 
the bases (i.e. 6) and the same number of bonds from the backbone to the base (i.e. 3) 
as in DNA (Figure I.25).297-299 
 
 
Figure I.25. Chemical structure of DNA, PNA and a peptide (R: amino acid side chain; green: 
amide bond characteristic of peptides; blue: nucleobases; red: Watson-Crick bonds.). 
 
3.1. PNAs stability 
 
In contrast to DNA, which depurinates on treatment with strong acids, PNAs are 
completely acid stable and are also sufficiently stable to weak bases. It is thus possible 
to synthesise these molecules using standard protecting groups from peptide chemistry 
(that require acid-cleavage) and base-cleavable nucleobase protecting groups. However, 
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when PNA has the nucleophilic amino functionality free at the N-terminus, a slow N-acyl 
migration of the nucleobase acetic acid, or detachment of the N-terminal PNA monomer 
by ring closure can occur, predominantly under basic conditions. Such migration would 
result in a free secondary amine which could continue the chain upon coupling of the 
next monomer. This side-reaction can be suppressed by capping the final N-terminal 
amino function, for example with an acetyl group.300 
In terms of biologic stability, while unmodified oligonucleotides are digested relatively 
rapidly by nucleases in serum, PNAs have a remarkably high stability in both human 
serum and in cell extracts301 and exhibits little or no binding to serum proteins.302 This 
high stability was confirmed after intravenous injections in rat where approximately 90% 
of the PNA was recovered as intact molecules in the urine within 24 hours after 
administration.303  
 
3.2. PNAs solubility and cellular uptake 
 
Although the results with PNAs in cell-free systems are very encouraging, their poor 
cellular uptake is, at present, the main obstacle to their effective use.  
One of the contributors for this poor uptake is PNAs solubility. As PNAs are neutral 
and relatively hydrophobic molecules, single-stranded PNAs have poor water solubility 
compared to DNA and tend to aggregate in aqueous solution. PNA solubility is 
dependent on the length and sequence of the oligomer, dropping when length and 
purine:pyrimidine ratio increases. Surprisingly, however, it was found that a 
homoadenine PNA polymer to be highly water soluble. The introduction of charged 
amino acid residues such as lysines,304 and negative charges such as in the PNA-DNA 
chimeras, showed to increase water solubility.300  
In addition, the lack of charges in the backbone make the passive diffusion of PNA 
over anionic surface of the cell membrane extremely slow. In bacteria the diffusion is 
even worse because they have thick cell barriers that are composed of a low-
permeability cell wall. Furthermore, many pathogens occupy host vesicles or form 
biofilms that provide added protection.302 This problem has prompted a variety of 
strategies to improve uptake. One strategy is transiently disrupt the cellular membrane, 
e.g. by electroporation,305-309 pore forming agents (such as streptolysin-O,310 
lysolecitin311 or detergents like Tween 20312), or physical scrape loading.313 These 
methods have proven useful for unmodified PNA delivery in several systems, but are 
limited to cells in culture and also exert a significant stress on the cells.314 Otherwise, 
liposome vehicles were exploited. Although cationic liposomes are very efficient in 
delivering anionic oligonucleotides to eukaryotic cells, the uncharged nature of the PNA 
difficult the creation of stable complexes needed to its transport into cells using 
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traditional transfection protocols.302 The use of liposomes has, however, been 
successful when PNA was partly hybridized with a complementary “carrier” DNA,315-317 
conjugated with the DNA intercalating dye 9-aminoacridine316 or with a lipophilic moiety 
(adamantly acetic acid).318 In addition, PNAs were also conjugated with small cationic 
peptides, so called cell-penetrating peptides (CPPs) or cell-specific receptors ligands. 
CPPs have been reported to display capacity to transport a cargo over the cell membrane 
in an energy and receptor independent manner. The efficiency of the CPP strategy 
seems to depend on the nature and size of the CPP and on the target cell line. Despite 
intense studies the mechanisms of translocation are not completely understood.319 
Natural peptides derived from viral (such as the trans-acting activator of transcription 
of the human immunodeficiency virus-1),320 insect (such as penetratin)321 and synthetic 
peptides (such as transportan,320,322 R6-penetrin320,322 and (R/W)9 nonapeptide319) have 
been used for this purpose. Also, synthesizing the PNA as a chimera with a highly basic 
peptide, the classic SV40 large T antigen nuclear localization signal,323,324 polylysine313 or 
polyarginine325 tails, seems to be enough to promote increased cellular uptake in vitro. 
Finally, other groups have chosen the strategy of coupling PNA to cell-specific receptors 
ligands. The targeting approach has the advantage of directing PNA delivery to specific 
cell types avoiding the risk of adverse side-effects in non-targeted cells. Examples of 
targeted receptors are the transferrin receptor,326 the insulin-like growth factor 1 
receptor,327 and the liver-specific ascialoglycoprotein receptor.328  
Another problem can occur in delivery strategies that uses endocytosis as a route of 
cellular entry. In these cases, PNA confinement to endosomes can occur resulting in very 
weak biological effects. This problem can be solved via peptide linkers containing 
specific amino-acid sequences that will be cleaved by cellular proteases in the 
endosome. After being released from the PNA, these peptides will induce endosomal 
rupture and release PNA into the cytoplasm.329 Alternatively, photochemical 
internalization can also be used. This approach is based on irradiation of a 
photosensitizing compound (photosensitizer) that localizes preferably in endosomal and 
lysosomal membranes. Irradiation initiates an oxidative process of the photosensitizer, 
resulting in formation of reactive oxygen species that destroy the endosomal 
membranes. As endosomal escape is induced only in the presence of a light-trigger, the 
delivery process can be temporally and spatially modulated and controlled.330,331 
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3.3. PNA–Nucleic acids complexes 
 
3.3.1. Binding affinity 
 
The PNA molecule is capable of recognizing its complementary sequence in DNA and 
RNA as well as in PNA, according to the Watson-Crick base-pairing rules.332,333 Depending 
on sequence and experimental conditions, PNA-NA duplexes or (PNA)2-NA triplexes can 
be formed. In order to measure their binding affinity, one of the most common methods 
is to observe the Tm. In this case, Tm is defined as the temperature at which half of the 
oligonucleotide strands are in the helical state and half are in the random coil states and 
is from it that the thermodynamic parameters are derived.334 
 
3.3.2. Triple helix formation with complementary DNA and RNA 
 
As PNAs are uncharged, they appear to be predestined to form triple helical structures 
with dsDNA (PNA/(DNA)2, Figure I.26a). However, PNA/(DNA)2 is only observed in the 
case of C-rich PNAs and GC-rich dsDNA while (PNA)2/DNA triple helix (Figure I.26c) 
formation is observed for homopyrimidine PNAs with a minimum of 10-mers, as well as 
PNAs containing a high proportion of pyrimidine.300 The (PNA)2/DNA complex is 
comprised of a PNA–DNA double helix formed by Watson–Crick hydrogen bonds with a 
second PNA strand lying in the major groove of the duplex formed by Hoogsteen 
hydrogen bonds (Figure I.26d). The formation of (PNA)2/DNA triplexes require the 
opening of the dsDNA with a DNA strand displacement highly sequence specific – via a 
so-called “strand invasion” mechanism – leading to the formation of a single-stranded 
loop structure (P-loop).335 The binding rate is increased by permanent or transient 
opening of the dsDNA at or near the PNA binding site in actively transcribed genes 
caused by: passing RNA polymerase,336 negative DNA supercoiling,337 or adjacent strand 
displacement complex338 that facilitated binding of PNA not only to the sense but also 
to the template strand. The explanation for the DNA/(PNA)2 triplexes formation can be 
found on its extraordinarily stability which depends on the length of the oligomers in a 
regular manner.300 The Tm of triplexes containing cytosine in their sequences is pH-
dependent, being more stable at pH 5, since the N3 of cytosine must be protonated for 
the Hoogsten pairing (triad CG*C+ in Figure I.26d). To ensure pH independence of 
binding of the Hoogsteen strand, cytosines in the “Hoogsteen-pairing” strand are 
exchanged to pseudo-isocytosines (also called J bases), which mimics N3-protonated 
cytosine (triad CG*J in Figure I.26d).302 In contrast to DNA, PNAs lack 3’ to 5’ polarity and 
can bind in either parallel (N/5’) or antiparallel orientation (N/3’). Nevertheless, if only  
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Figure I.26. Examples of binding modes of PNA when targeting dsDNA: (a) triplex formed with 
cytosine-rich PNAs binding to complementary homopurine DNA targets, (b) duplex invasion 
complex formed with some homopurine PNAs and, (c) triplex invasion complex, leading to the 
displacement of the second DNA strand into a P-loop; (d) chemical structures of CG*C+ and CG*J 
triads with Hoogsteen – represented by *– and Watson-Crick bonds present in the triplex 
invasion complex; adapted from [339]). 
 
one PNA sequence is used to form a (PNA)2/DNA triple helix, then both strands are 
necessarily either antiparallel (more stable) or parallel to the DNA strand. When two 
different homopyrimidine PNA sequences are used, the most stable complex is formed 
when the Watson-Crick PNA strand is oriented antiparallel and the Hoogsteen strand is 
parallel to the purine strand of the DNA.300 
The construction of bis-PNA increased the possibility for PNA strand invasion under 
physiological conditions. Bis-PNA or “PNA clamp” is a palindrome sequence with a 
flexible linker in the middle designed such that one strand is antiparallel (“Watson–Crick-
pairing” strand) and the other strand is parallel (“Hoogsten-pairing” strand) to the DNA 
target.  This leads to a small increase in the Tm, which presumably arises from a slight 
reduction in the entropy loss on triple helix formation. The high local concentration of 
the third strand presumably leads to much more rapid triple helix formation. Sequence 
discrimination in bis-PNAs is extremely high due to the double recognition process (by 
both PNA strands).300,302 Alternatively, the rate of binding can be increased several 
orders of magnitude by using cationic PNAs or by conjugating the DNA intercalator 9-
aminoacridine to a PNA.302   
In the case of duplex invasion (Figure I.26b), PNAs form very stable complexes via 
Watson–Crick base pairing of the homopyrimidine target DNA and the homopurine PNA 
sequence.339 
Otherwise, pseudocomplementary PNAs (pcPNAs, Figure I.27a) exhibit a distinct 
binding mode, double-duplex invasion, which is based on the Watson-Crick recognition 
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principle supplemented by the notion of pseudocomplementarity. 
Pseudocomplementarity means that the base pairing between two mutually pcPNA 
oligomers is not possible but pcPNAs are capable of a stable Watson-Crick-type pairing 
with the natural nucleobase counterparts. 2,6-diaminopurine (D, Figure I.27b) and 2-
thiouracil (sU, Figure I.27b) were used instead of adenine and thymine, respectively, 
because they satisfied both criteria. PcPNAs have been found to be capable of targeting 
the designated dsDNA sites with mixed sequence of purines and pyrimidines, with the 
exception of very GC-rich (A+T content <40%) sites.340 
Likewise, homopyrimidine PNAs also form stable (PNA)2/RNA triple helices with RNA 
with Tm values that appear to be similar to those of (PNA)2/DNA triple helices.339 
 
 
Figure I.27. (a) Double-duplex invasion of dsDNA by pcPNA and (b) schematic drawing of 
nucleobase pairing: adenine-thymine (A-T), diaminopurine-thymine (D-T), adenine-thiouracil (A-
SU), diaminopurine-thiouracil(D-sU), and how diaminopurine can form an extra hydrogen bond 
with thymine, whereas a steric clash occurs between diaminopurine and thiouracil) (adapted 
from [339]). 
 
3.3.3. Duplex Formation with Complementary DNA and RNA 
 
PNA-NA duplexes are generally more stable than the corresponding NA complexes 
due to the uncharged nature of PNA that prevents any electrostatic repulsion during the 
complexation of the target. The antiparallel orientation of the PNA is more stable332 and 
is also kinetically favoured, the antiparallel complex is formed immediately (<30 s), 
whereas the formation of the parallel complex require several hours. An interesting 
aspect of PNA/DNA duplexes is its independence on ionic strength. In contrast with 
dsDNA, these complexes are stable under low salt conditions because no cations are 
needed to counteract the interstrand repulsion typical of the duplex formation between 
the two negatively charged strands of natural oligonucleotides. However, at high salt 
concentration (>1 M), where electrostatic contributions saturate, similar trends in the 
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decrease in Tm were observed for the DNA/DNA and DNA/PNA duplexes. PNAs show 
also a remarkable specificity in binding to complementary natural oligonucleotides; 
indeed, sequence discrimination is generally higher for a PNA/DNA duplex than for a 
DNA/DNA mismatch.300 The restriction of the flexibility of the PNA molecule can improve 
selectivity with respect both to binding and to the preferred formation of 
complementary complexes with DNA or RNA. The replacement of the glycine unit in PNA 
building blocks by other amino acids has various effects on duplex stability that depend 
upon the amino acid side-chain. Small, uncharged side chains, such as those of alanine341 
and serine,304 do not influence duplex stability. Positively charged side-chains, such as 
in lysine304,342 and arginine,343 have a stabilizing effect, whereas negatively charged side-
chains, such as in glutamic acid,304 have a destabilizing effect. 
 
3.3.4. PNA homoduplexes  
 
PNAs form extremely stable duplexes with complementary PNA sequences when 
compared with the corresponding DNA/PNA or DNA/DNA duplexes. Also in this case, 
the antiparallel strand orientation is characteristically more stable.300 
 
3.4. Other PNA monomers 
 
Attempts to understand the structure-activity relationship (SAR) of PNA and 
improving its solubility, cell permeability, bioavailability, and binding orientation with 
RNA and DNA have resulted in several structural modifications of N-(2-
aminoethyl)glycine (Figure I.28). Polyamide backbone suffer several modifications such 
as: (a) extension by one methylene group using monomers such N-(2-aminoethyl)-β-
alanine or a N-(3-aminopropyl)glycine (I.86a and I.86b, respectively);344 (b) replacement 
of the amide linkage to the nucleobase by a tertiary amine (I.87);345 (c) introduction of 
other aminoacids in the glycine place, e.g. arginine (I.88)346 or phenylalanine (I.89);347  
and (d) introduction of cyclic structures (I.90 and I.91).348,349 The majority of the 
modifications had as goal to restrict the PNA conformational flexibility in order to obtain 
derivatives with better binding orientation and that bind even tighter to the NAs. As a 
drawback, the introduction of stereocenters into the PNA oligomer, makes the synthesis 
more complex since enantiomeric purity of both the monomers and oligomers needs to 
be assured.  
According to Falkiewicz,350 the PNA analogues can be divided in two types depending 
on the manner of attachment of nucleobase to polyamide backbone. The first category 
is a polyamide with alternating peptide–pseudopeptide bonds as backbone, consisting  
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Figure I.28.  Chemical structures of some monomers of PNA analogues (B: nucleobase). 
 
of N-(aminoalkyl)amino acid units to which secondary nitrogen nucleobases are 
attached with the linker. PNA analogues of the second category contain a backbone 
consisting of amino acid residues carrying the nucleobase in their side chains, named 
nucleoamino acids or chimeric amino acids. In this second group is included the alpha-
PNA (α-PNA). 
      
3.4.1. Alpha-PNA 
 
α-PNA has a backbone consisting of α-amino acids, some of them carrying a 
nucleobase in their side chain (Figure I.29).  
Although the nomenclature of α-PNA is recent, the concept of nucleoamino acids is 
not new. Some authors described the synthesis of nucleobase-bearing α-amino acids 
(such as alanines351,352 and homoalanines353,354) some decades ago. In order to obtain 
peptides in which the nucleobases are correctly spaced for interaction with NAs, various 
spacer amino acids have been used. 
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Figure I.29. Chemical structures of PNA and α-PNA (B: nucleobase; R: amino acid side chain). 
 
In alanine-based building blocks (Figure I.30), nucleobases are covalently linked to 
alanyl side chains in the β-position (I.92a). Dipeptides and/or polypeptides composed of 
nucleobase-bearing alanine with  glycine,355 serine356 and proline357 as spacers (I.93a, 
I.93b and I.94, respectively) were reported. The experimental attempts to obtain 
complementary complexes of oligonucleotides with some of these α-PNAs presented 
different results and in some cases were not successful.358 Interestingly, the synthesis of 
dipeptides composed of adenine- and uracil-containing alanines and glycines by multi-
component reaction (U-4CR) was described.359 Not less important, new α-PNA, made of 
L-β-(thymin-1-yl)alanine at (i, i+3) positions separated by α-amino acids such as alanine 
(I.95a) and aminoisobutyric acid (I.95b), were presented recently.360,361 Some of these 
compounds were able to penetrate the cells and reach the nucleus without cytotoxic 
effects.361 In alanyl-PNAs (I.96), the backbone is composed of nucleobase-bearing 
alanine units with alternating configuration. These oligomers are able to form linear 
double strands, with collinear strands, based on hydrogen bond recognition and stacking 
of the nucleobases. The distance of two base pairs (3.6 Å) results from the distance of 
consecutive side chains in peptides with β-strand conformation and is close to stacking 
in DNA (3.4 Å).362 Alanyl-PNA/DNA chimera that can serve as a tool for very sensitive 
DNA detection following the molecular beacon concept was also synthesised.363 
Proteins containing some alanyl residues with nucleobase side chains were also 
synthesied.364 
Homoalanines containing nucleobases covalently bounded at ɣ position were also 
synthesized (I.92b, Figure I.30). Monomers with different chiralities were synthesised 
from different aminoacids: D-monomers derived from D-glutamic acid;365 methionine 
was used as starting material in L-, D- and DL-monomers synthesis;365 L-homoserine was 
used to synthesise L-monomers.367 α-PNAs with D-monomers in which the glycine 
residue was used as spacer (I.93c) showed a defined Tm suggesting the possibility of a 
DNA-like self-aggregation in solution.365,368 α-PNAs of opposite chirality were also 
described.367 The L-monomers containing adenine were alternated with several α-amino 
acids: glycine (I.93c), serine (I.93d), threonine (I.93e) and tyrosine (I.93f) to give 
different tetrapeptides. The tetrapeptides interacted base-specifically with 
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polynucleotides – poly (dT) or poly (U) – to form 1:2 complexes, in the same manner as 
adenylyladenosine, but more potently. The tetrapeptides that do not present the glycine 
unit as spacer showed higher potencies, so further modification at this position may be 
feasible to increase the stability of the complexes or to modulate the DNA recognition 
ability.369 Three decapeptides adenine-bearing homoalanines were synthesised: one 
made up of DL-monomers, the second one composed of homoalanyl units with 
alternating configuration, and the third resulting from the oligomerization of the L-
monomers. The preliminary Tm data obtained by hybridization experiments 
demonstrated that these α-PNAs annealed to their complementary NA strand and the 
peptide composed of both enantiomers with alterning configuration had stronger 
affinity to the complementary dT10 strand than the peptide made of L-monomer.334 
Different α-PNAs made of nucleobase-bearing homoalanines alterned with glycine were 
also synthesised in order to study the impact of Cu(II) and Ni(II) on their structures.370,371 
The synthesis of α-PNAs, with seven-residue periodicity, through a self-replication 
reaction where the nucleobase-functionalized homoalanine separated by six amino 
acids were also reported.372,373  
Furthermore, an α-PNA based on adeninyl D-homoalanine alternated with thyminyl L-
alanine residues showed to be a self-pairing in a stable double strand and there might 
be an excellent potential for specific binding of a third strand.374 Additionally, a series of 
α-PNAs based on nucleobase-containing norvalyl (I.92c, Figure I.30) monomers without 
other aminoacids as spacers were also synthesised.362 
 
 
Figure I.30. Chemical structures of alanine-, homoalanine- and norvalyl-based building blocks 
of α-PNA (B: nucleobase). 
 
Serine-based building blocks where the nucleobase is attached to a L-serine residue 
via a hemiaminal linkage (I.97, Figure I.31) were also prepared. These building blocks 
were used in the synthesis of PNA, made of serine-based amino acids at (i, i+4) positions  
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Figure I.31. Chemical structures of serine-, tyrosine-, lysine- and proline-based building blocks 
of α-PNA (B: nucleobase). 
 
separated by other α-amino acids (I.98, Figure I.31) to favor α-helix formation.375-377 
These α-PNAs exhibited excellent water solubility with no evidence of self-aggregation. 
In this media, helical nature of α-PNAs was confirmed. It was also found that these α-
PNAs form complexes with complementary DNA targets with higher Tm than the 
corresponding dsDNA but with the parallel orientation being favoured both 
thermodynamically and kinetically over the antiparallel.376-378 Dithymine tetrapeptide 
made of both thymine-containing and unfunctionalized L-serine units alternated in the 
sequence were also synthesised. In this case, the nucleobases were anchored to the 
hydroxyl groups of the L-serine units by means of ester bonds (I.99a). This analogue 
showed a good solubility in water and it was more resistant in plasma than standard 
tetrapeptides (and oligopeptides) but the interaction with complementary DNA was 
weak.379 
A short tetrapeptide based on both thymine-containing and underivatized L-tyrosine 
moieties alternated in the sequence (I.99b) was also synthesised.380  
An hexathymine nucleopeptide, obtained by alternating thyminyl lysine monomers 
and unfunctionalized L-lysine units in the sequence (I.99c) was also reported.381 This 
basic nucleopeptide proved to be well soluble in water and able to interact with both 
DNA and RNA.382  
In another approach, D- and L-proline with nucleobases incorporated at the 4-position 
with cis- and trans-stereochemistry were synthesized and interspaced with glycine 
residue in an α-PNA (I.100, Figure I.31). The α-PNA with cis-stereochemistry in the L- and 
D-series bound strongly to poly(dA) but trans series failed to hybridized. Using a mixed 
sequence decamer of the four nucleobases it was found that the thermal stability of the 
α-PNA/oligonucleotide complex was comparable to that formed by N-(2-
aminoethylglycine).383 Two 8-mer (one using the L-proline with nucleobases 
incorporated at the 4-position with cis-stechiometry and the other using a similar 
chimeric amino acid but in trans-stereochemistry) both with glycine as spacer were 
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synthesised and no hybridization was observed with the complementary 
oligodeoxynucleotides.384 
 
3.5. PNA Synthesis 
 
Different protocols for the assembly of PNA monomers to oligomers have been 
reported.  PNAs incorporate repetitive elements which are readily amenable to 
assembly via solid-phase peptide synthesis (SPPS), pioneered by Robert Bruce 
Merrifield.385 Specifically, protecting group strategies, SPPS protocols, deprotection 
methods and purification procedures developed for peptide synthesis may be directly 
applicable to the synthesis of PNAs and their analogues. This is one of the strengths of 
PNA technology because it allows the automation of the process using commercial 
peptide synthesizers, under controlled and standardized conditions.  
  
3.5.1. Protecting Group Strategies 
 
In the PNA synthesis, the protection of the primary amino group of the backbone and 
of the exocyclic amino groups of the nucleobases with orthogonal protecting groups is 
necessary. Protection at these sites not only blocks undesired side reactions in the 
oligomerization, but also increases the solubility of the monomers, especially the 
purines.386 Different protection schemes have been tested as exemplified in Table I.1. 
 
3.5.2. Solid-Phase Synthesis and Characterization of the Oligomer 
 
The general principle of solid-phase synthesis is based on the repetition cycles of 
elongation, capping of unreacted free amines, and deprotection of the primary amino 
group of the backbone (Scheme I.1). 
 
 
Scheme I.1. A SPPS cycle of N-(2-aminoethylglycine)PNA synthesis (B: Nucleobase; PG1: 
Terminal N-protecting group; PG2: Exocyclic nucleobase N-protecting group). 
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The solid-phase synthesis starts with the attachment of the first monomer of the chain 
to a solid polymer by a covalent bond. The elongation of the PNA oligomer takes place 
through condensation of the carboxy function of the building block with the deprotected 
amino function of the growing chain, aided by a condensing agent. The succeeding 
monomers are added until the desired sequence is assembled. Then, the PNA oligomers 
are deprotected, removed from the solid support and purified by reverse-phase high-
performance liquid chromatography.387 While sequencing is not yet a routine option, 
the oligomers are conveniently characterized by MALDI-TOF mass spectrometry.388 
 
Table I.1.  Protecting groups used in PNA monomer synthesis and orthogonal strategies 
employed. 298,386,389-397 
 
 
 
Terminal N- 
protecting 
group 
Exocyclic 
nucleobase N- 
protecting 
group 
 
Terminal N- 
protecting 
group 
Exocyclic 
nucleobase N- 
protecting 
group 
Boc Acyl  Alloc Bhoc 
Fmoc Acyl  Azoc Bhoc 
Nvoc An  4-N3Cbz Bhoc 
Mmt An  Boc Cbz 
Azoc Boc   Fmoc Cbz 
4-OTBSCbz Boc  Fmoc Dde 
Fmoc Boc  Fmoc Mmt 
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3.6. Potential Applications 
 
3.6.1. Therapeutic Applications 
 
3.6.1.1. Effects on DNA 
 
The capacity of PNA to invade into dsDNA has opened the possibility of interfering 
directly with gene regulation, either as a transcription activator or inhibitor (antigene). 
In addition, PNA may also interfere with gene expression by acting as a decoy molecule 
binding different transcription factors or targeting DNA G4 Structures. 
PNA as Transcriptional Activator Agent. P-loop structures, formed via strand 
displacement, have been found able to initiate transcription of genes downstream of 
the PNA-binding site in vitro309,398,399 and in vivo,309,400 either with bacterial or eukaryote 
RNA polymerases. In fact, the (PNA)2/DNA complex is recognized by RNA polymerases, 
and RNA transcription is initiated. Thus PNA oligomers may function as artificial 
transcription factors using the PNA target as a promotor.309 The optimal length of a PNA, 
to act as artificial promoter, is 16-18 bases in a HeLa nuclear extract in vitro and in GFP-
reporter plasmid in cell culture.400 This principle should be therapeutically applicable in 
place of a protein substitution therapy, provided that the appropriate gene (which is not 
or only weakly expressed) is not defective in the coding region. 
PNA as Antigene agent. In an antigene approach, PNAs are designed to hybridize to 
complementary DNA sequences in a particular gene in order to inhibit transcription 
either at the level of transcriptional initiation and/or RNA polymerase elongation (Figure 
I.32a).401 In PNA designed to target transcriptional initiation site, the structural 
hindrance may effectively suppress overall expression of the gene due to the blockage 
of DNA recognition by proteins, such as transcription factor and RNA polymerase.402 It 
should be mentioned that although the antigene PNA was targeted against the sense 
strand of the DNA, it inhibited transcription from both strands of the DNA template 
equally well. This contradicts the results of studies in cell-free systems, and may result, 
for example, from the RNA polymerase II elongation complex in vivo being much larger 
than the polymerase II complex in reconstituted systems, or to the additional influence 
exerted by the nucleosomal structures of the chromatin template used.300 
Antigene effects of PNA have been reported from in vitro transcription 
experiments,403 as well as in cell cultures311,404,405 and in live animal studies.406,407 One 
interesting application of the antigene therapy would be the treatment of patients with 
diseases caused by heteroplasmy of the mitochondrial DNA (mtDNA) – where the 
mutated and wild-type DNA are both present in the same cells. It has been shown that 
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the use of PNAs under physiological conditions can inhibit the replication of the mutated 
mtDNA without affecting the wild-type mtDNA.300,408 The main obstacle appears to be 
the access of the PNA to the DNA under physiological conditions which include the 
presence of cations that stabilize the dsDNA and therefore dramatically reduces the rate 
of helix invasion by the PNA. Furthermore, the effect of chromatin structure on PNA 
binding would be expected to decrease the access to the DNA binding sites.409  
PNA containing “decoy” Transcription Factor Responsive Elements. Transcription 
factors recognize double-stranded consensus sequences within gene promoter regions 
(Figure I.32b). Decoy molecules are short double-stranded NAs designed to mimic 
genomic transcription factor-binding sites and sequester factors that may be overactive 
in disease. This approach could be very useful to alter the gene expression. As double-
stranded PNA/PNA and PNA/DNA hybrids exhibit structural features significantly 
different from those of dsDNA, they are not suitable for transcription factor decoy. On 
the contrary, PNA-DNA chimeras are active as TFD decoy reagents.410,411 
Targeting DNA G4 Structures with PNAs. PNA probes can provide a powerful 
instrument to target guanine-rich regulatory DNA sequences. These sequences can be 
target in different ways: (a) guanine-rich PNA can invade a DNA G4 and simultaneously 
bind to the complementary cytosine-rich strand, thus facilitating G4 formation; (b) PNA 
can bind exclusively to the complementary cytosine-strand, thus providing additional 
stabilization of the G4-PNA complex and (c) short PNA oligomers can be designed to bind 
to the ssDNA in the exposed loops of G4 structures. The goal of using PNA probes is to: 
(a) interfere with G4 recognition by protein factors; (b) lead to stabilization of native G4 
structures and promote binding of G4 specific protein factors which can switch on or off 
gene transcription, depending on that particular protein function.  
Until now, targeting G4 structures with PNA has been demonstrated only in vitro, and 
in many cases only models containing single-stranded guanine rich DNA were used.412 
 
3.6.1.2. Effects on RNA 
 
All cellular RNAs are potential targets for recognition and inhibition with PNAs.  PNAs 
can affect gene expression and RNA processing (antisense), ribonucleoprotein activities 
and inhibit microRNA (miRNA). Also, PNA binding can potentially alter RNA abundance 
by triggering nonspecific degradation of unused or structurally altered RNAs.302 
PNA as Antisense agent. Antisense mechanisms have attracted great interest as 
selective mRNA inhibitors by inducing a blockade or alteration in the transfer of genetic 
information from DNA to protein.413 As PNAs duplexes are not substrates for RNAse H 
(an ubiquitous enzyme that hydrolyzes the RNA strand of an RNA/DNA duplex) or other 
RNAses, the primary mechanism of action for PNA on RNA is almost certainly steric 
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hindrance (Figure I.32c).401,414 However, RNase H-mediated degradation can occur in the 
case of DNA-PNA chimeras (Figure I.32d).415 The antisense agents can inhibit mRNA 
splice site selection or block translation.  
Following transcription, splicing of pre-mRNA into their mature can be inhibited by 
PNA/mRNA duplex formation at the entron-exon junction.413 In consequence, down 
regulation of a mature protein416,417 or the correction of aberrant splicing and the 
restoration of a functional protein306,418 can occur.  
In steric blockage of translation, both duplex and triplex-forming PNA molecules can 
inhibit the translation initiation (around or upstream the start codon of the mRNA), 
where ribosomal components and translation factors assemble prior to elongation.419 
However, only triplex-forming PNAs, can be used to cause the translation elongation 
arrest. When working with this antisense oligonucleotides, it is advisable to perform an 
mRNA scanning (gene-walk) by testing a series of PNAs targeting different regions of the 
mRNA.302 
Antisense oligonucleotides can attenuate aberrant gene expression, such as occurs in 
many cancers, but can also be applied against infectious diseases caused by viruses, 
bacteria and parasites. Growth inhibition has been well demonstrated in several 
bacterial species using PNAs targeting mRNAs of growth essential genes.420-422 In 
addition, PNAs are not effectively exported from the bacteria by the efflux pumps that 
normally eliminate antibiotics such as penicillins.423 On the other hand, viral RNA also 
presents susceptible targets for recognition and steric hindrance, such as genes essential 
for viral growth ( in RNA viruses) or internal ribosomal entry sites (in DNA viruses).302  
 
Figure I.32. Possible therapeutic effects of PNA or PNA-DNA chimera (adapted from [293]). 
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Besides that it was reported that PNAs can inhibit elongation of viral reverse 
transcriptases on RNA templates.401 Over time, several laboratories have shown that 
PNAs can inhibit viral replication in infected cells.424,425 Moreover, PNAs were found to 
be very efficient tools in correction of aberrant splicing and the restoration of a 
functional protein. One of the examples is the restoration of dystrophin expression in 
Duchenne muscular.418  
Inhibition of ribonucleoprotein interactions by PNA. Ribonucleoproteins are 
nucleoprotein that contains RNA, like ribosomes and telomerase. 
rRNA, which makes up approximately 40% of total mass of ribosome, plays an active 
role in translation. While most rRNAs are inaccessible to sequence recognition, the 
active regions are often exposed. As many useful antibiotics target rRNA, this can be one 
of the main applications of this approach since these sequences are accessible to 
hybridization. In fact, some PNA targeting bacterial rRNA functional domains have 
already been tested.426,427 
In telomerase, the internal RNA moiety, which serves as a template for the synthesis 
of repeating sequences of telomeres, is an accessible target for PNA. Several studies 
show that PNAs can inhibit telomere extension in vitro428-430 and in human cells307 with 
low-nanomolar IC50 values.  However, anti-telomerase PNAs were only effective if 
present before assembly of the full RNA–protein complex.302 Nevertheless, inhibition of 
telomerase interactions may have impact in cancer treatment, as seen before. 
miRNA Inhibitors. miRNAs are a family of small (ca. 21 nucleotides) noncoding RNAs 
implicated in post-transcriptional gene expression regulation by sequence-selective 
targeting of mRNAs. At least 30% of protein-coding genes are estimated to be regulated 
by miRNAs430establishing them as one of the largest classes of regulatory molecules. 
These miRNAs/mRNAs interactions lead to the regulation of very important biological 
processes, including cell metabolism, inflammation, pathogen infection, and cancer. The 
reports available demonstrate that PNAs targeting specific miRNAs lead to de-
repression of the major endogenous mRNA targets of miRNAs. This might have 
important therapeutic applications, in consideration of the involvement of miRNAs in 
important human diseases.410 The potential of PNA as miRNA antagonists in cell cultures 
has been illustrated for some miRNA, such as miRNA-210431 (associated with hypoxia 
that is modulated during erythroid differentiation), miRNA-122432 (a liver-specific miRNA 
that has direct control over cholesterol biosynthesis and which is required for hepatitis 
C infection) or miRNA-155433 (expressed in the haematopoietic system). 
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3.6.2. Molecular diagnosis and imaging 
 
PNAs have been widely proposed in protocols aimed at performing highly sensitive 
hybridization with NA due to the higher stability of the PNA/DNA complex and the higher 
specificity of PNA binding to DNA. Techniques, such as polymerase chain reaction (PCR) 
clamping, and hybridization probes have benefited from the unique properties of PNA 
PNA-mediated PCR clamping. This method is based on the inefficiency of PNA as a 
primer for DNA polymerases. As a consequence, PNAs are very specific blockers of PCR 
amplification, as they compete with DNA primers for binding to the template strand, 
and can prevent the amplification of the mutated fragment or specific amplify the 
mutated and not the wild-type sequence (Figure I.33a). Due to extremely high-sequence 
discrimination of mismatches in PNA–DNA hybridization, it is possible to obtain a specific 
signal from a single-base mismatch, as occurs in single nucleotide polymorphisms, in the 
presence of a 1,000-10,000 fold excess of the non-mutated wild type normal gene. PNA 
clamping has the advantages of higher sensitivity, speed, simplicity and lower cost 
compared with the standard direct sequencing, although it cannot be used to detect 
new mutations.434,435 This method can be used to detect mutations affecting the BRAF, 
epidermal growth factor receptor, k-RAS, and BCR-ABL quickly and accurately and 
consequently diagnose tumors in the early stages to enable effective treatment.410 
Hybridization Probes. In diagnostics and in research, hybridization probe molecules 
are required for the detection of target bioanalytes. The most important strategies are 
the unimolecular probes, e.g. molecular beacon, forced intercalation probes and binary 
probes.  
Molecular beacons are probes with a fluorophore with intrinsically strong 
fluorescence (e.g. fluorescein and rhodamine derivatives) at one terminus and a 
quencher group at the other. If a beacon remains unhybridized the fluorophore and 
quencher lie next to each other and the molecule does not emit a signal because the 
energy emitted by the fluorophore is absorbed by the quencher. On hybridization the 
molecule stretches out, separating the quencher and the fluorophore, leading the 
fluorescent dye to emit a signal, reporting the occurrence of hybridization.436 The first 
reported use of PNA to detect PCR products used a chimeric DNA–PNA probe,437 but the 
method was rapidly improved to involve pure PNA probes.438 In contrast with DNA 
beacons, PNA beacons do not require the hairpin structure since the hydrophobic 
structure and lack of charge repulsions in the PNA is sufficient to favour a condensed 
structure with quenched signals from the free PNA probe. Besides that, PNA probes are 
also less dependent on salt concentrations, and less sensitive to the presence of proteins 
that bind to ssDNA.439 This enables the usage of PNA beacons to immobilize on both flat 
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surfaces and optical fibres,440 as well as, detection of NAs directly in different buffers 
and protein-containing solutions.441  
Fluorogenic PNA-based forced intercalation probes lack a stem-loop structure and 
contain a hybridization responsive fluorophore. On hybridization with a target, a duplex 
structure is formed; the fluorophore intercalates in this structure and the probe 
becomes brightly fluorescent.436 So far, thiazole orange containing PNA have been used 
as fluorophore, for example, to detect viral mRNA in H1N1 influenza A infected live 
cells,442,443 to localize miRNA-122 in live Huh7 cells,432 in detection of k-RAS mRNA within 
living cells444 and cancer associated transcript in living cells and human adenocarcinoma 
of colon tissues.445 
Binary probes use two single-labelled PNAs complementary to the target 
oligonucleotide. Typically, one oligonucleotide is labelled with a donor fluorophore and 
the other is labelled with an acceptor molecule. After hybridization to complementary 
oligonucleotide at the adjacent locations, the labels were close enough to enable strong 
fluorescence quenching. This probes have been used as mRNA imaging agents to know 
its expression levels in living cells.446 
Fluorescence in situ hybridization using PNA probes. PNA probes are highly effective 
in fluorescence in situ hybridization applications because their neutral backbone 
provides a high specificity in situ, requires less concentration and hybridizes quickly. 
Additional advantages of using PNA probes in situ are reduced background binding, i.e. 
excellent signal-to-noise ratio, low photobleaching and a mild washing procedure 
resulting in morphologically better samples.447,448 Thus, this technique has been 
developed for telomere analyses,449 multiple gene abnormalities identification450 and 
viral,451 yeast452-454 and bacterial455-462 diagnostics both in medical as well as 
environmental samples. Recently, peptide nucleic acid-colorimetric in situ hybridization 
has been proposed. Chromogenic visualization (colorimetric method) is typically based 
on enzyme-conjugated antibodies that recognize the targeted probe. Then, the addition 
of the correct substrate to the enzyme used leads to chromogenic precipitates. The 
colorimetric method have some advantages over the fluorescent one: only requires a 
standard light microscope, the stability of the probes allows slide storage at room 
temperature for extended periods of time, and the cellular morphology of the specimen 
is maintained, markedly aiding in the interpretation of result. Nonetheless, in this 
colorimetric technique, future improvements are necessary in order to solve the 
permeabilization issues in bacteria and improve the detection limit of the 
procedure.455,463 
Surface plasmon resonance (SPR). PNA-based molecules have also been used in 
combination with SPR. This procedure is a nonradioactive methodology, rapid, 
informative, and does not require gel electrophoresis and/or dot-spot analysis.  The 
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combined employment of SPR-based instruments and PNA probes has been used to 
detect point mutations, for example, k-RAS gene mutations464 or in diagnosis of a cystic 
fibrosis mutation.465 Alternatively, SPR imaging couples the sensitivity of spectral SPR 
measurements with spatially-controlled imaging capabilities. A nanoparticle-enhanced 
SPR imaging sensing strategy in non-amplified genomic DNA proved to be ultrasensitive 
(attomolar concentrations of target genomic DNA are detected), specific and the 
sensitive to detect point mutations466 and identification of bacteria (Figure I.33b).467 The 
direct detection of genomic DNAs with no need for PCR amplification represents an 
important step toward the development of simpler, cheaper and more reliable 
detection methods.468  
 
 
Figure I.33. (a) PCR clamping technique (blue - taqman probe; red – PNA clamp); (b) SPR 
imaging method using a nanoparticle conjugated to an oligonucleotide complementary to a tract 
of the target DNA not involved in the hybridization with the PNA probe (adapted from 
[469,470]). 
 
3.6.3. Tools for molecular biology and functional genomics  
 
PNAs can be used in combination with a nuclease for the modulation of enzymatic 
cleavage. Indeed, PNAs can be designed and prepared to hybridize a complementary 
target on a dsDNA and locally unwind this NA by strand displacement rendering the 
displaced strand sensitive to S1 nuclease.471 This dsDNA cleavage is especially efficient 
when two adjacent PNA sites are targeted yielding quantitative double-strand breaks. 
Therefore PNA can be used as a cutting tool in combination with single-strand-specific 
S1 nuclease to make an “artificial restriction enzyme” system whose recognition 
sequence is determined by the PNA sequences employed. Otherwise, dsDNA can be 
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cleaved by PNA-assisted protection against enzymatic methylation. Providing that 
methylation would defend from dsDNA from enzymatic digestion, only those DNA sites 
previously bound to PNA remained susceptible for the restriction enzyme activity. 
Notably, protection against methylation was less complete when the methylation site 
was placed at the end of the PNA-binding site. Thus, PNAs used in combination with 
methylases and other restriction endonucleases can act as “rare genome cutters”. This 
method is called the PNA-assisted rare cleavage technique.340,472 More recently, a 
completely chemistry-based DNA cutter selectively cuts dsDNA at designated site with 
desired specificity. There, Ce(IV)/EDTA complex is used as molecular scissors for 
hydrolytic scission of DNA, whereas the target sequence is recognized by two strands 
pcPNA. One of the most important characteristics of this cutter is that it do the 
hydrolysis of targeted phosphodiester linkages exactly as naturally occurring nucleases 
do. Thus, the DNA fragments obtained by the completely chemistry-based DNA can be 
connected with other DNA fragments by using the DNA ligase, exactly as it is done in 
conventional molecular biology.  A possibility to create artificial restriction enzymes has 
long been highly desired in order to facilitate manipulation of large genomic DNA 
molecules.473 In contrast, PNA can reduce the number of naturally occurring enzyme 
cleavage sites in a stretch of genomic DNA since short PNA sequences, preferably bis-
PNAs, can efficiently block restriction enzymes.474 
Southern hybridization is a routine technique used daily in most molecular biology 
laboratories for predicting size and sequence information on DNA and information 
regarding the genetic context. As PNA binding, in contrast to DNA binding, is largely 
independent of the ionic strength, it is possible to dissociate dsDNA at low salt 
concentrations and hybridize it with fluorescent-labelled PNA before gel 
electrophoresis. The neutral backbone of PNA renders higher mobility to the complex 
PNA/DNA compared with the excess unbound PNA.  Pre-gel hybridization using PNA 
provides a solution to reduce the number of steps in the process of southern 
hybridization, as the cumbersome post separation, probing and washing steps are 
eliminated. Consequently, the analysis is much faster than with the conventional 
southern hybridization technique.475 
Because of their unique high binding affinity, PNAs are also useful for the sequence-
specific purification of NAs and for the isolation of active genes. For instance, 
methodologies to perform sequence-specific separations of oligonucleotides using PNA 
linked to alkane chains – discriminated by hydrophobic interaction chromatography475 
– and PNA probes with biotin label at 5’ end attached to strepavidin coated 
superparamagnetic iron oxide beads were developed.476 
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4. Scope and general objectives of this thesis  
 
The dream of modern drug research is to discover biologically active molecules that 
are absolutely specific and able to act efficiently only on the molecular targets 
responsible for the disease progression.  
As NA lesions or mutations are involved in most of the diseases, these essential cell 
molecules are attractive targets for drug design. Over the years different approaches 
were used to target DNA and RNA. However, due to the high homogeneity of B-DNA, it 
is rather difficult to achieve a selective effect on particular DNA region.  
In order to overcome that situation, non-canonical DNA structures, such G4, were 
chosen as new targets in drug research. Despite several molecules have already been 
tested as G4 ligands but there is room for improvements. In order to increase the 
structural diversity among the G4 ligands, this thesis describes the design, synthesis and 
biological evaluation of two libraries of novel compounds based in distinct aromatic core 
scaffolds. Chapter II describes a library of novel symmetric derivatives belonging to non-
fused aromatic family (I.101) in which it was explored the: (a) benzene, naphthalene and 
2,7-biphenylnaphthtlene scaffolds as aromatic core structures and (b) side-chains 
containing sulphur and oxygen in order to obtain chemical diversity. To accomplish this 
purpose, one of the methodologies explored to construct the side-chains was the thiol-
ene click chemistry. Chapter III is focus on a more rigid family of compounds based on 
benzo[h][1,6]naphthyridin-2(1H)-one scaffold (I.102). As far as we know, this aromatic 
core structure was not yet explored as G4 ligand. 
Alternatively to the non-canonical DNA structures, different OAs (including α-PNAs) 
were synthesised to target specific sequences on NAs. Chapter IV described the 
synthesis of new chimeric cysteines with nucleobase side chains that can be used as 
building blocks of α-PNAs (I.103) also using thiol-ene click chemistry.  
 
 
Figure I.34. General structures of the compounds described in this thesis (Ar: non-fused 
aromatic core; B: Nucleobase; R: side chains).  
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II. SYNTHESIS AND BIOLOGICAL EVALUATION OF 
NON-FUSED AROMATIC COMPOUNDS AS G4 
LIGANDS  
 
1. Introduction 
 
As described in chapter I, different non-fused aromatic compounds have been 
synthesised and tested as G4 ligands. Some members of these family share chemical 
features, namely a symmetric structure comprising: 
i. An aromatic core to establish interactions through π-π stacking; 
ii. Two side chains with amine end-groups to interact with the loops and grooves 
and ensure sufficient solubility of the molecules. 
The aromatic core is composed, in the majority of the compounds, by one-ring 
aromatic nucleus (benzene or pyridine) substituted in positions 1 and 3 by two other 
aromatic groups. A series of disubstituted bis(vinylquinolinium)benzene derivatives (II.1 
and II.2, Figure II.1) were synthesised.239 The FRET-melting data indicated that 
derivatives presenting a “bent” shape (II.1) had higher stabilizing ability to G4 DNA than 
linear compounds (II.2) and compounds with more rigid cyclic amine (II.1c-d, II.1g and 
II.2g) displayed stronger stabilizing ability for G4 than those with flexible acyclic amine 
(II.1e-f and II.2e-f). Interestingly, II.1e-f could destabilize c-1 G4 DNA structures. 
Moreover, these derivatives had good selectivity on G4 DNA over dsDNA.239 Bis-triazole 
ligands (II.3, Figure II.1) linked by a benzene were selective for G4 DNA vs. dsDNA over 
the given concentration range and also showed high activity telomerase inhibition.248,249 
Phenylene bis-indoles (II.4, Figure II.1) exhibited stabilization potential for four different 
G4 forming oligonucleotides studied and showed better selectivity for promoter G4 (c-
KIT2 and c-MYC) over human telomeric G4 DNA.253 Ligands incorporating carboxamide 
side chains at the meta position relative to the indole NH (II.4g-h) were found to show 
very weak stabilisation of G4 compared to the para substituted analogues (II.4a-b). 
Although ligands II.4e and II.4f (prepared from (R)- and (S)-quinuclidin-3-amines) 
showed comparable stabilisation of telomeric G4 DNA, ligand II.4e showed slightly 
better stabilisation of c-KIT2 G4 and a reduced stabilisation of dsDNA when compared 
with its isomer. Comparing the length of the side chains, aminopropyl-substituted 
ligands (II.4b and II.4h) demonstrated improved stabilisation over the corresponding 
aminoethyl derivatives (II.4a and II.4g). UV/Vis titration studies revealed that bis-indole 
ligands binded tightly to G4 and showed a three- to fivefold preference for c-KIT2 over 
telomeric G4 DNA. These ligands also had good selectivity on G4 DNA over dsDNA.254 
Comparing two bis-benzimidazoles (II.5 and II.6, Figure II.1), the compound II.5 with a 
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“bent” shape showed higher affinity toward the G4 than compound II.6 with a linear 
shape.259 Phenyl bis-oxazoles compounds without side chains (II.7 and II.8, Figure II.1) 
were synthesised but  none of the compounds stabilised either the G4  nor the dsDNA.477 
In contrast, a library of phenyl bis-oxazoles with terminal tertiary amines in the para 
position (II.9, Figure II.1) showed significant stabilization of the two HSP90 G4, yet no 
stabilization of a human telomeric G4 DNA sequence or dsDNA.478 Surprisingly, the 
weakly basic di-morpholine derivative (II.9d) presented a significant activity, in contrast 
with the majority of other G4 ligands with the same amine. The selectivity of the most 
efficient ligand, II.9f, was examined further and showed modest stabilisation of the k-
RAS G4 DNA but none with the c-KIT2 G4 DNA. Compound II.9f also shows low-
micromolar cell growth inhibitory activity in cancer cells, yet only modest selectivity 
compared to its effect on normal fibroblast cells. In addition, II.9f only changed modestly 
HSP90 expression in these cell lines and was not an inhibitor of human telomerase 
activity.478 Analogue compounds having phenyl bis-oxazoles with side chains in the meta 
position II.10 did not stabilize G4 sequence tested or only stabilize at high 
concentrations. The cellular evaluation of these compounds showed IC50 values in low 
micromolar range in four cancer cell lines and one fibroblast cell line.251 The 
regioisomeric compound II.11 showed no significant increase in melting temperature 
using five G4 sequences.478 Two diethynyl amide derivatives containing N,N-
dimethylpropylamine side chains and presenting benzene as aromatic nucleus (II.12, 
Figure II.1) showed moderate stabilization for three promoter G4 DNA with no 
detectable stabilization of dsDNA. This compound also showed discrimination capacity 
between intramolecular promoter G4, showing c-KIT1 the higher ΔTm values. 266  
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Figure II.1. Structures of non-fused aromatic compounds with benzene aromatic core, ΔTm  
values (0 C) for FRET melting analysis with a series of G4 forming DNA sequences [human 
telomeric (hTelo), a set of promoters (HSP90A, HSP90B, c-KIT1, c-KIT2, k-RAS and c-MYC)]  and 
dsDNA (ds) ([ligand]/[oligonucleotide] = 5) and short-term antiproliferative activity (IC50 in µM) 
in a cancer cell line panel [MCF7 (breast), 786-O/RCC4 (renal), A549 (lung) and Mia-Pa-Ca2 
(pancreas)] and WI38 (fibroblast) cell line. a: ΔTm obtained by CD with the G4 forming sequence  
5’-(TTGGGG)4-3’; b: [ligand]/[oligonucleotide] = 4. 
 
Few molecules has a naphthalene ring as central nucleus. However, these could be a 
good alternative to one-ring aromatic nucleus as it is sufficiently small to overcome 
some of the druggability problems associated with large polycyclic groups, yet of 
sufficient surface area to interact with G-quartet. Among the compounds tested as G4 
ligands with naphthalene in its structure are a series of derivatives with disubstituted 
triazole side-arms.250 One of these compounds (II.13, Figure II.2) shows a high level of 
selectivity for renal, osteo- and Ewing’s sarcomas that express the HIF-1a transcription 
factor. Furthermore, it also interacts selectively with the G4 DNA located in the 
promoter of the HIF genes (according to the SPR data) what suggests that the mechanism 
of action involves inhibition of transcription by drug-mediated G4 stabilization in these 
regions.250 In order to further develop a SAR study on II.13, other bis-triazoles and bis-
oxazole derivatives (respectively II.14 and II.15, Figure II.2) were synthesised.251 
Compound II.14a, presenting the terminal tertiary amines in the para position, did not 
stabilized any of the G4 DNA sequences tested and showed IC50 values above 25 µM for 
all lines in a small panel of cancer cell lines. Modifying the substitution pattern on the 
terminal phenyl ring system from para to meta resulted in a slightly better performance 
on G4 stabilization and in a significant decrease in IC50 value for the two renal cancer cell 
lines. This is in accord with previous findings for compound II.13 which has highly 
selective activity in renal compared to a number of other carcinoma cell lines and 
suggests that the meta substitution may be a critical factor in this selectivity. When the 
linking heterocyclic moiety was changed from a triazole to an oxazole ring (II.15, Figure 
II.2) a significant improvement in antiproliferative activity was observed. However, this 
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compound did not stabilize the G4 sequences tested.251 Comparing ∆Tm II.10e with II.15, 
it is possible to conclude that variation in the aromatic core does not have a huge effect 
neither in the G4 stabilization nor in the antiproliferative effect of the compounds. 
 
 
Figure II.2. Structures of non-fused aromatic compounds with naphthalene aromatic core, 
ΔTm  values (0 C) for FRET melting analysis with a series of G4 forming DNA sequences [human 
telomeric (hTelo), a set of promoters (HSP90A and c-KIT2)]  and dsDNA (ds) 
([ligand]/[oligonucleotide] = 5) and short-term antiproliferative activity (IC50 in µM) in a cancer 
cell line panel [MCF7 (breast), HOS/MG63/MNNG/U2OS/SaOS/OST (osteosarcoma), 
TC135/TC71/TC32 (Ewing’s sarcoma), 786-O/A498/RCC4/RCC4VHL (renal), A549 (lung)] and WI38 
(fibroblast) cell line. 
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In order to further explore the importance of the above mentioned aromatic cores in 
new G4 ligands, this chapter will focus on the synthesis and biological evaluation of a 
group of compounds (Figure II.3) with a symmetrical structure comprising: 
(a) An aromatic core with benzene (II.16), naphthalene (II.17, II.18) or 2,7-biphenyl 
naphthalene core (II.19, II.20) to establish interactions through π-π stacking; 
(b) A side chain containing a terminal tertiary amine group to interact with the loops 
and grooves and ensure sufficient solubility of the molecules (with exception of 
II.20); 
(c) Different side chain lengths to observe their influence on G4 stabilizing ability of 
the ligands; 
(d) Sulphur (II.16-II.19) or oxygen (II.19) atoms in the side chains conferring chemical 
diversity to the structures. 
 
 
Figure II.3. Structure of the compounds synthesised to be tested as G4 ligands (in blue the 
aromatic core; in orange the basic group of side chains). 
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2. Methods, Results and Discussion 
 
2.1. Synthesis of ligands based on benzene and naphthalene core 
 
2.1.1. Retrosynthetic analysis 
 
Compounds II.16, II.17 and II.18 were obtained according to the proposed synthetic 
pathway illustrated in Scheme II.1, in which benzene derivatives were substituted in 
position 1 and 3 and naphthalene derivatives were substituted in position 2 and 7. 
 
Scheme II.1. Proposed synthetic pathway for the synthesis of benzene and naphthalene 
derivatives. LG: leaving group; in blue the aromatic core; in orange the positively charged 
moiety. 
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In order to form a new C-C bond between the aromatic ring and the future side chain, 
two different palladium-catalyzed cross-coupling reactions (either a Suzuki-Miyaura or 
a Stille reaction) were used. These palladium-catalyzed cross-coupling reactions involve 
the reaction of organic halides or pseudohalides (for example triflates) (R-X) with alkenyl 
and aryl organometallics (R’-M) in presence of a catalytic amount of Pd (0) complex to 
furnish the alkenyl- and aryl-substituted compounds (R-R’) (Scheme II.2). In both 
reactions, the transition metal-catalyzed coupling reaction occurs by a sequence of: (a) 
oxidative addition, (b) transmetalation (usually rate determining step), and (c) reductive 
elimination. Various phosphine ligands (L) are effective in stabilizing the Pd(0) 
intermediates, but the stoichiometry, size, and electronic effect of the phosphines all 
contribute to the reactivity of catalysts toward oxidative addition and reductive 
elimination.479,480  
The main difference between these two reactions resides in the metal present in the 
organometallic reagent used for transmetalation: while in Suzuki-Miyaura is boron 
[organoboranes, boronic acids: RB(OH)2 or boronate esters: R’B(OR’’)2], in Stille is tin 
(mixed stannanes, R’SnR’’3).479,480 Another difference between the Suzuki’s and Stille’s 
cross-coupling mechanism is the need of the boronic acid activation with base. This 
activation of the boron atom enhances the polarisation of the organic ligand, and 
facilitates transmetallation.479 The main drawbacks of Stille reaction when compared 
with Suzuki-Miyaura reaction are the toxicity of the tin compounds used, and their low 
polarity, which makes them poorly soluble in water.480 
 
Scheme II.2. Mechanisms of Suzuki-Miyaura and Stille reactions: a. Oxidative addition, b. 
transmetalation, c. reductive elimination, and d. trans-cis isomerazation. 
 
In the following step, the double bond in the side chain reacted with the thiol of an 
organosulfur compound. The thiol-ene reaction can proceed under a variety of 
conditions including: (a) a radical pathway, (b) via catalytic processes mediated by 
nucleophiles, acids, bases or (c) in the absence of an added catalyst in highly polar 
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solvents. A wide range of olefines and thiols can be employed although reactivity can 
vary considerably depending on reaction mechanism, substitution pattern at the C=C 
bond, the S-H bond strength and its cleavage mechanism (i.e. homolytic vs. heterolytic 
lysis). Such reactions are generally extremely rapid (even at ambient temperature and 
pressure), and tolerant to the presence of air/oxygen and moisture.481 Although the 
wide variety of mechanisms, the thiol-ene reaction has been frequently conducted 
under radical conditions, either thermal or photochemically induced. Under such 
conditions it proceeds via a typical chain process with initiation, propagation and 
termination steps (Scheme II.3). Initiation involves the treatment of a thiol (RSH) with 
photoinitiator (under irradiation) or radical initiator (under thermal conditions) resulting 
in the formation of a thiyl radical (RS●). Propagation is a two-step process involving first 
the direct addition of the thiyl radical across the C=C bond of the olefine (yielding an 
intermediate carbon-centred radical) followed by chain transfer to a second molecule 
of thiol to give the thiol-ene addition product with anti-Markovnikov orientation and the 
concomitant generation of a new thiyl radical. Possible termination reactions involve 
typical radical–radical coupling processes.481  
 
Scheme II.3. Mechanism for the radical thiol-ene reaction: a. Initiation and b. Propagation. 
 
In order to obtain the final compounds, the methyl ester of the side chain was 
hydrolysed and the resulting carboxylic acid reacted with an amine through an amide 
coupling. 
 
2.1.2. Synthesis discussion 
 
Bis-allylbenzene II.21 was synthetized starting from: (a) 1,3-dihydroxibenzene II.22, 
that was converted to the corresponding ditriflate II.23 in 76% yield; or (b) using the 
commercially available 1,3-dibromobenzene II.24. Then, II.23 reacted through a Stille 
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reaction (using allyltributylstannane II.25 as organometallic reagents and 1,1′-
bis(diphenylphosphino)ferrocene II.26 as ligand) while II.24 reacted through Suzuki- 
Miyaura reaction using allyl boronic acid pinacol ester II.27 as organometallic reagent.  
(Scheme II.4). 
 
 
Scheme II.4. Synthesis of compound II.21. Reagents and conditions: a) (CF3SO2)2O, TEA, DCM, 
0 oC to rt, 6 h, 76%; b) II.25, II.26, Pd(PPh3)2Cl2, LiCl, DMF, reflux, 26 h, II.21: 21% and II.28: 7% 
(according to 1H-NMR); c) II.27, Pd(PPh3)4, K3PO4.H2O, dioxane, reflux, o/n, II.21: 64%. 
 
 
Figure II.4. Organometallic reagents and ligand used. 
 
As exemplified in Scheme II.4, the Stille reaction presented a worst yield and II.21 was 
impossible to purify (from the mixture of isomers) by column chromatography. In other 
hand, the Suzuki-Miyaura reaction represents a better option due to: (a) the higher 
yield, and (c) the formation of the minor product II.28 was not observed.  
The formation of compound II.28 is due to a sequential homobimetallic catalysis. 
Homobimetallic catalysis is a recent concept designed to describe a condition where a 
transition metal catalyst, with the metal in a certain oxidation state, catalyzes a given 
reaction to yield a product, which in situ undergoes a subsequent transformation, 
catalyzed by another complex of the same metal, but in a different oxidation state.482 In 
the present case, the formation of compound II.28 involves a Stille cross-coupling 
reaction followed by an in situ palladium-catalyzed conjugative isomerization (Scheme 
II.5).  
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Scheme II.5. Proposed reaction mechanism for the formation of compounds II.28 and II.32 
(reproduced from [482]). 
 
Bis-allylnaphthalene II.29 was synthetized starting from 2,7-dihydroxynaphthalene 
II.30, that was converted to the corresponding ditriflate II.31 in 92% yield. Then, II.31 
reacted through a Stille reaction (using the same reaction conditions used in II.21 
synthesis) or through Suzuki-Miyaura reaction (using the same boronic acid as 
organometallic reagent and two different bases) (Scheme II.6). 
 
 
Scheme II.6. Synthesis of compound II.29. Reagents and conditions: a) (CF3SO2)2O, TEA, DCM, 
0 oC to rt, 4 h, 92%; b) II.25, II.26, Pd(PPh3)2Cl2, LiCl, DMF, reflux, 26 h, II.29: 47% and II.32: 16% 
(according to 1H-NMR); c) II.27, Pd(PPh3)4, CeF, THF, reflux, 48 h, 20%; d) II.27, Pd(PPh3)4, 
K3PO4.H2O, dioxane, reflux, o/n, II.29: 64% and II.33: 15%. 
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As exemplified in Scheme II.6, the Stille reaction presented the same disadvantages 
reported in the benzene derivative synthesis. As seen previously, the isomerization of 
double bond in Stille reaction to afford the compound II.32 is due to a sequential 
homobimetallic catalysis. Two different reaction conditions of the Suzuki-Miyaura 
reaction were tested. A better yield was obtained when potassium phosphate tribasic 
monohydrate was used as base. In addition, in this reaction conditions product II.33 was 
obtained as minor product. In order to evaluate the influence of the side chain number, 
compound II.33 was used in the synthesis of a molecule containing only one side chain.  
In order to access the influence of the length of the side chain, bis-vinylnaphthlene 
II.34 was synthetized from the commercially available 2,7-dibromonaphthalene II.35 
and II.31 were used as starting material using the conditions presented in Table II.1.  
 
Table II.1. Conditions explored in the Suzuki-Miyaura reaction to obtain compound II.34. 
 
 
Entry Substrate Pd catalyst Base Reaction conditions Yield 
1 II.31 Pd(PPh3)4 K3PO4●H2O  Dioxane, reflux, o/n 58% 
2 II.35 Pd(PPh3)4 K3PO4●H2O  Dioxane, reflux, o/n Vestigial 
3 II.35 Pd(PPh3)2Cl2 NaCO3 1M Dioxane, 80 oC, o/n 84% 
 
As exemplified in Table II.1, three different conditions were tested for the Suzuki-
Miyaura reaction. A better yield was obtained when II.35, 
bis(triphenylphosphine)palladium(II) dichloride as catalyst and an aqueous solution of 
sodium carbonate 1 M was used as base (entry 3). 
With the allyl and vinyl aromatic compounds in hand, the synthesis proceeded with 
the thiol-ene reaction of the alkene aromatic compounds with the thiol substrate, under 
thermal (using AIBN II.36) or photochemical conditions (using DPAP II.37). 
 
 
Figure II.5. Chemical structures of AIBN II.36 and DPAP II.37. 
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To obtain the thiol-substituted benzene derivative II.38, photochemical conditions 
were used (Scheme II.7) and compound II.21 was initially reacted with thioglicolic acid 
II.39 but the desired product was obtained in low yield (13%) because it was difficult to 
follow-up the reaction and the purification revealed to be very difficult. Alternatively, 
compound II.21 was reacted in the same conditions with methyl thioglycolate II.40 and 
the corresponding methyl ester II.41 was obtained in moderate yield (54%). Subsequent 
hydrolysis resulted in the desired compound II.38 with an overall yield of 52% over two 
steps.  
 
 
Scheme II.7. Synthesis of compound II.38. Reagents and conditions: a) II.37, DCE, hν, rt, 1 h, 
13%;  b) II.37, DCE, hν, rt, 1 h, 54%; c) LiOH, H2O: THF (1:1), rt, 4 h, 96% (52% over two steps).  
 
As exemplified in Scheme II.8, bis-allylnaphathelene II.29 was reacted with thiol 
substrates in both thermal and photochemical conditions. Once again, both thermal- 
and photochemical-induced thiol-ene reaction with thioglicolic acid II.39 originated the 
desired product II.42 in low yields (10% and 20%, respectively).  Alternatively, compound 
II.29 was reacted with methyl thioglycolate II.40 under photochemical conditions, and 
the corresponding methyl ester II.43 was obtained in excellent yield (92%). Subsequent 
hydrolysis resulted in the desired compound II.42 with an overall yield of 84% over two 
steps. 
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Scheme II.8. Synthesis of compound II.42. Reagents and conditions: a) II.36, DCE, 90 oC, 70 h, 
10%;  b) II.37, DCE, hν, rt, 1 h, 20%; c) II.37, DCE, hν, rt, 1 h, 92%; d) LiOH, H2O: THF (1:1), rt, 4 h, 
91% (84% over two steps). 
 
Based on the previous results, the naphthalene derivative with only one side-chain 
II.45 was obtained with an overall moderate yield (65%) applying photochemical 
conditions and the two steps strategy described before (Scheme II.9). In a similar 
manner, the naphthalene derivative with shorter side-chains II.47 was obtained in a 
more modest yield (28% over two steps, Scheme II.10). 
 
 
Scheme II.9. Synthesis of compound II.45. Reagents and conditions: a) II.37, DCE, hν, rt, 15 
min, 77%; b) LiOH, H2O: THF (1:1), rt, 4 h, 84% (65% over two steps). 
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Scheme II.10. Synthesis of compound II.47. Reagents and conditions: a) II.37, DCE, hν, rt, 4 h, 
51%; b) LiOH, H2O: THF (1:1), rt, 3 h, 54% (28% over two steps). 
 
The synthesis of the final benzene (II.16) and naphthene (II.17, II.18, II.48) derivatives 
were obtained using an uronium-based coupling reagent (TBTU), to obtain the activated 
carboxylic acid, and a non-nucleophilic base (DIPEA) as displayed in Schemes II.11 and 
II.12. 
Scheme II.11. Synthesis of benzene (II.6) and naphthalene (II.17, II.48) derivatives. Reagents 
and conditions: a) 1. TBTU, DIPEA, DCM, rt, 15 min; 2. Amine, DCM, rt, o/n. 
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Scheme II.12. Synthesis of naphthalene derivative II.17. Reagents and conditions: a) 1. TBTU, 
DIPEA, DCM, rt, 15 min; 2. Amine, DCM, rt, o/n. 
 
2.2. Synthesis of ligands based on the 2,7-biphenyl naphthalene core 
 
2.2.1. Retrosynthetic analysis 
 
Although the compounds belonging to this series share the naphtalene core, they 
presented differences in the synthetic approach. In a retrosynthetic analysis is possible 
to observe that the desired compounds were obtained by a two-step route that only 
share the first step (Scheme II.13). The first step was the formation of a new C-C bond 
between naphtalene and the other aromatic ring via Suzuki-Miyaura cross-coupling 
reaction. In the following step, nucleophilic substitution or Chan-Lam coupling reaction 
were employed in order to obtain the final compounds.  
 
 
Scheme II.13. Proposed synthetic pathway for the synthesis of 2,7-biphenyl naphthalene 
derivatives. (X: S or O; LG: leaving group; in blue the aromatic core; in orange the basic group of 
side chains) 
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In Chan-Lam coupling reaction, the aryl carbon-heteroatom bond formation occurs 
via an oxidative coupling of boronic acids, stannanes or siloxanes (Ar1-Y) with NH or OH 
(Ar-X) containing compounds in air. The proposed general mechanism for this coupling 
reaction (Scheme II.14) shows that Ar1-Y initially undergoes transmetalation (a.) to 
generate an intermediate, which then coordinates with Ar-X (b.). In the presence of 
atmospheric oxygen or another primary oxidant, complex previously formed undergoes 
oxidation (c.), forming a Cu(III) intermediate, which undergoes reductive elimination 
(d.), yielding the coupling product and a Cu(I) complex. The latter can be reconverted 
into bis-µ-hydroxo Cu(II) complex in the presence of dioxygen and water (e.).483  
 
 
Scheme II.14. Mechanisms of Chan-Lam coupling: a. transmetalation, b. coordination, c. 
oxidation, d. reductive elimination, and e. complexation. 
 
2.2.2. Synthesis discussion 
 
Similarly to the synthesis of the compounds described in section 2.1.2., the first 
synthetic step of all compounds comprising four aromatic rings as aromatic core was the 
formation of a new C-C bond through a palladium-catalyzed cross-coupling reactions. 
As demonstrated in Table II.2, the synthesis of compound II.49 was attempted starting 
from (4-mercaptophenyl)boronic acid II.50 using different reaction conditions. 
However, the desired product was never obtained. 
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Table II.2. Reaction conditions tried to synthesise compound II.49. 
 
 
Entry Substrate Pd catalyst Base Reaction conditions 
1 II.31 Pd(PPh3)4 K3PO4.H2O Dioxane, reflux, 16 h 
2 II.35 Pd(PPh3)4 Cs2CO3 DME/EtOH/H2O, 150 oC, 150 W, 15 min 
3 II.35 Pd(PPh3)2Cl2 Na2CO3 1M Dioxane, 80 oC, 14 h 
4 II.35 Pd(PPh3)4 Na2CO3 1M Toluene/H2O, 100 oC, 50 min 
 
In contrast, the synthesis of compound II.51, starting from (4-hydroxyphenyl)boronic 
acid II.52 was straightforward and the compound was obtained in very good yield (85%, 
Scheme II.15). 
 
  
Scheme II.15. Synthesis of compound II.51. Reagents and conditions: a) Pd(PPh3)2Cl2, Na2CO3 
1M, dioxane, 80 oC, o/n, 85%. 
 
Finally, the synthesis of final compound II.19 occurred via nucleophile substitution 
(Scheme II.16), in which an sp3-hybridized electrophile must have a leaving group in 
order to the reaction occur. On the other hand, the synthesis of final compound II.20, 
occurred via a Chan-Lam coupling (Scheme II.16) using 3-quinolineboronic acid pinacol 
ester. 
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Scheme II.16. Synthesis of compounds II.19 and II.20. Reagents and conditions: a) 
Cl(CH2)2N(CH2CH3)2, K2CO3, acetone, reflux, o/n, 22%; b) 3-quinolineboronic acid pinacol ester, 
Cu(OAc)2, pyridine, molecular sieves 3 Å, DCM, rt, o/n, 12%.  
 
2.3. Antiproliferative activity and Structure-Activity Relationship 
 
Short-term antiproliferative assays were carried out using a panel of human cancer 
cell lines and IC50 values were determined using cisplatin as control (Table II.3). The 
human cancer cell lines used were: (a) breast adenocarcinoma cell line (MCF-7) that has 
wild-type K-RAS and is a telomerase-positive cell lines;484,485 (b) colorectal 
adenocarcinoma cell line (HT-29) that has wild-type k-RAS and is a telomerase-positive 
cell lines;226,486 (c) non-small cell lung carcinoma cell line (NCI-H460) that has a mutated 
k-RAS and is a telomerase-positive cell lines.487 
Cytotoxicity assays were carried out using a non-malignant human skin fibroblast cell 
line (CRL-1502) and colorectal adenocarcinoma cell line (CaCo-2). Despite CaCo-2 being 
a cancer cell line is a well-accepted model to characterize the safety profile of 
compounds.488
  
 
Table II.3. Short-term antiproliferative activity evaluated with a panel of malignant and nonmalignant cell lines.  
 
a Values represent the mean ± SD for at least 3 independent experiments; b ND: not determined;c Calculated values using the software available at http://www.molinspiration.com.
     IC
50
(µM)a  
X n R1 R2 MCF-7 HT-29 NCI-H460 CRL-1502 CaCo-2 cLogPc MW 
II.16a Ben. 2 NH(CH2)2N(CH3)2 - > 15 6.82 ± 0.33 > 15 > 20 > 20 2.63 482.76 
II.16b Ben. 2 N-MePpz - >20 > 20 > 20 NDb > 20 2.98 346.50 
II.17 Naph. 1 NH(CH2)2N(CH3)2 - >20 5.39 ± 1.27 >20 NDb > 20 2.78 504.77 
II.18a Naph. 2 NH(CH2)2N(CH3)2 - 5.15 ± 1.44 2.09 ± 0.50 4.97 ± 1.39 6.09 ± 1.30 > 20 3.81 532.82 
II.18b Naph. 2 NH(CH2)2N(CH2CH3)2 - 4.13 ± 0.45 1.35 ± 0.32 3.28 ± 0.29 9.00 ± 5.48 > 20 5.32 588.93 
II.18c Naph. 2 NH(CH2)3N(CH2CH3)2 - 13.2 ± 3.32 2.27± 0.10 6.95 ± 0.30 4.73 ± 3.57 > 20 5.86 616.98 
II.18d Naph. 2 N-MePpz - 8.45 ± 2.51 2.04 ± 0.75 3.68 ± 0.81 > 20 > 20 4.03 556.84 
II.18e Naph. 2 NH(CH2)2N-Mor - > 20 ≥ 20 > 20 NDb > 20 3.51 616.89 
II.19 - - - (CH2)2N(CH2CH3)2 2.25 ± 1.69 1.01 ± 0.57 1.44 ± 0.63 NDb 7.87 ± 0.35 8.31 510.72 
II.20 - - - 3-quinolyl >20 >20 >20 NDb > 20 9.25 566.66 
II.48 - - - - > 15 2.59 ± 0.55 9.39 ± 1.82 12.54 ± 0.40 > 20 2.98 346.50 
Cisplatin - - - - > 20 > 20 2.48 ± 1.55 NDb > 20 NDb NDb 
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The results showed that most of the compounds presented higher antiproliferative 
activity against HT-29 cells comparatively with the other cancer cell lines used. It is 
noteworthy that compounds II.16a and II.17 only presented antiproliferative against this 
cell line. Toward both MCF-7 and HT-29 cells, compounds II.18a-II.18d and II.19 
presented lower IC50 values than cisplatin. However toward NCI-H460, only compound 
II.19 presented better antiproliferative activity than cisplatin.  
Based on the antiproliferative activity of the compounds over the three cancer cell 
lines, some SAR elucidation can be made (Figure II.6). Comparing the ligands based on 
benzene and naphthalene core, naphthalene aromatic core was preferred to benzene 
(II.16a vs. II.18a). The presence of two side chains proved to have a beneficial effect 
(II.18a vs. II.48), except in the case of HT-29 cancer cell line were the antiproliferative 
activity is similar for II.18a and II.48. The antiproliferative activity of compounds was 
also affected by the length of the chain: (a) between the aromatic ring and the sulfur 
atom [three carbon chain was preferred over two carbon side chain (II.17 vs. II.18a)], 
and (b) between the two nitrogens [two carbon chain was preferred over three carbon 
side chain (II.18b vs. II.18c)]. The variation of the terminal amine group also showed to 
influence as compounds presenting dimethylamine or diethylamine (II.18a and II.18b) 
were the more cytotoxic while the less basic morfoline analogue II.18e presented the 
lower antiproliferative activity. Within naphthalene derivatives, it is also interesting to 
notice that compound II.18d was the only compound that presented good 
antiproliferative activity towards the three cancer cell lines and no cytotoxicity towards 
CRL-1502 and CaCo-2 in the tested concentration range. 
 
 
Figure II.6. SAR for benzene and naphthalene derivatives. 
 
Within all the tested compounds, compound II.19 with a higher aromatic surface core 
presented the lower IC50 values in the three cancer cell lines. The drawback of this 
compound was the cytotoxicity over CaCo-2 cell line. The substitution of the amine side 
chains of II.19 for quinoline rings II.20 resulted in lack of activity toward all the cell lines 
tested. 
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2.4. Investigation of the Mechanism of Action 
 
2.4.1. Compounds as G4 ligands 
 
The ability of the synthesised compounds to bind and stabilise G4 DNA and dsDNA 
was investigated using a FRET melting assay, with ligand concentrations ranging from 
0.1 to 5 µM. Three different DNA sequences were used (a) 26-mer double-stranded 
hairpin loop sequence (T-loop) representing dsDNA (Table II.4); (b) 21-mer DNA G4 from 
region in human k-RAS oncogene promoter (KRas21R) (Table II.5); (c) 21-mer DNA G4 
from the human telomeric sequence (F21T) (Table II.6). 
The analysis of FRET melting data revealed that only compound II.19 showed a weak 
stabilization of DNA sequences tested.  
The poor stabilizing ability of the synthesised compounds can be explained by (a) the 
small aromatic surface of the naphthalene (which is smaller than the G-quartet), and (b) 
the flexibility of the structure. Analysing the ligands presented in Figures II.1 and II.2, it 
is possible to realize that the ligands with higher stabilizing ability presented a “bent” 
shape where the benzene or naphthalene is flanked by at least one aromatic ring 
increasing the aromatic surface for π-π interactions and the rigidity of the structure. The 
better G4 stabilizing ability presented by the compound with the bigger aromatic surface 
(II.19) is in agreement with the previously stated. However, it also important to notice 
that the majority of the compounds also presented modest G4 stabilizing ability. In fact, 
the more successful G4 ligands incorporating naphthalene described in literature are 
naphthalimido and naphthalene diimides that presented a bigger aromatic 
surface.213,214,217  
 
 
 
 
  
 
Table II.4. FRET-melting temperature variations (∆Tma) of T-loop at 0.2 µM, stabilized by different derivatives in K+ cacodylate buffer (pH 7.4, 60 mM K+). 
Values represent the mean ± SD for a triplicated experience. 
 
                           [Ligand]/ µM 
0.1 0.5 1 2 3 4 5 
II.18a 0.77 ± 0.16 1.00 ± 0.19 0.75 ± 0.17 0.79 ± 0.19 0.95 ± 0.18 1.23 ± 0.18 1.08 ± 0.17 
II.18b 0.40 ± 0.17 0.09 ± 0.19 0.14 ± 0.17 - 0.09 ± 0.18 - 0.06 ± 0.17 - 0.11 ± 0.18 - 0.13 ± 0.17 
II.18c 0.02 ± 0.19 - 0.28 ± 0.21 - 0.47 ± 0.27 - 0.70 ± 0.22 - 0.97 ± 0.22 - 0.84 ± 0.29 - 0.95 ± 0.25 
II.18d - 0.74 ± 0.63 0.05 ± 0.64 - 0.41 ± 0.71 - 0.49 ± 0.19 - 0.59 ± 0.21 - 0.65 ± 0.20 - 0.62 ± 0.28 
II.18e 0.02 ± 0.17 - 0.13 ± 0.19 - 0.14 ± 0.17 - 0.40 ± 0.18 - 0.61 ± 0.17 - 0.51 ± 0.17 - 0.54 ± 0.19 
II.19 - 0.59 ± 0.18 0.04 ± 0.21 0.27 ± 0.22 0.88 ± 0.19 2.04 ± 0.19 4.04 ± 0.17 6.25 ± 0.17 
II.48 0.45 ± 0.20 0.53 ± 0.21 0.33 ± 0.19 0.52 ± 0.20 0.26 ± 0.21 0.40 ± 0.19 0.50 ± 0.20 
 
Table II.5. FRET ∆Tma of KRas21R at 0.2 µM, stabilized by different derivatives in K+ cacodylate buffer (pH 7.4, 60 mM K+). Values represent the mean ± SD 
for a triplicated eperience.  
 
                            [Ligand]/ µM 
0.1 0.5 1 2 3 4 5 
II.18a 0.68 ± 0.24 0.82 ± 0.32 0.83 ± 0.23 0.85 ± 0.23 1.04 ± 0.25 1.81 ± 0.23 1.79 ± 0.23 
II.18b 0.22 ± 0.27 0.84 ± 0.27 - 0.14 ± 0.25 - 0.01 ± 0.25 0.00 ± 0.25 0.75 ± 0.26 0.91 ± 0.24 
II.18c - 0.51 ± 0.25 - 0.36 ± 0.25 - 0.52 ± 0.24 - 0.70 ± 0.25 0.47 ± 0.23 0.23 ± 0.23 0.07 ± 0.23 
II.18d - 0.77 ± 0.25 - 0.84 ± 0.25 - 0.93 ± 0.25 - 1.06 ± 0.25 - 1.04 ± 0.25 - 0.93 ± 0.26 - 0.03 ± 0.30 
II.18e 0.03 ± 0.25 - 0.03 ± 0.26 - 0.75 ± 0.25 - 0.94 ± 0.24 - 0.85 ± 0.25 - 0.84 ± 0.25 - 0.12 ± 0.25 
II.19 - 0.16 ± 0.33 - 1.14 ± 0.34 - 0.11 ± 0.34 0.98 ± 0.35 1.94 ± 0.36 2.03 ± 0.35 4.06 ± 0.35 
II.48 0.03 ± 0.28 0.78 ± 0.27 0.34 ± 0.28 0.16 ± 0.27 0.11± 0.30  0.81 ± 0.25 0.85 ± 0.25 
             8
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 Table II.6. FRET ∆Tma of F21T at 0.2 µM, stabilized by different derivatives in K+ cacodylate buffer (pH 7.4, 60 mM K+). Values represent the mean ± SD for a 
triplicated experience. 
 
 [Ligand]/ µM 
0.1 0.5 1 2 3 4 5 
II.18a 1.87 ± 0.27 2.05 ± 0.29 1.36 ± 0.27 2.22 ± 0.25 2.79 ± 0.26 2.89 ± 0.27 2.87± 0.29 
II.18b - 0.33 ± 0.24 0.44 ± 0.24 - 0.19 ± 0.22 - 0.46 ± 0.22 - 0.57 ± 0.22 - 0.99 ± 0.27 -1.22 ± 0.23 
II.18c - 0.13 ± 0.21 - 0.41 ± 0.24 - 0.98 ± 0.22 - 0.99 ± 0.22 - 1.11 ± 0.22 - 1.04 ± 0.21 0.60 ± 0.24 
II.18e - 0.08 ± 0.26 - 0.24 ± 0.27 - 0.13 ± 0.25 - 0.21 ± 0.24 - 0.20 ± 0.25 - 0.13 ± 0.26 - 0.12± 0.30 
II.19 - 0.01 ± 0.40 - 1.05 ± 0.45 - 1.01 ± 0.39 1.08 ± 0.40 0.95 ± 0.37 0.08 ± 0.52 2.17 ± 0.43 
II.48 - 0.25 ± 0.21 - 0.24 ± 0.22 - 0.13 ± 0.22 - 0.29 ± 0.21 - 0.38± 0.20 - 0.53 ± 0.21 - 0.22 ± 0.23 
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2.4.2. Apoptosis 
 
It is well established that chemotherapeutic agents act by triggering mechanisms of 
cell death by apoptosis. In this context, apoptosis induction was assessed by flow 
cytometry analysis using the Guava Nexin assay. As illustrated in Figure II.7, exposure of 
HT-29 cells to compounds II.18a, II.18b and II.19 at the IC50 concentration, for 48 h, 
resulted in a significant increase of apoptosis levels (p<0.05). In particular, compound 
II.19 at IC50 concentration was able to increase apoptosis up to 50%, as compared to 
vehicle control exposure (p<0.005). When cells were exposed to the same compounds 
at 2-fold IC50 concentration, the percentage of cells undergoing apoptosis further 
increased, especially for compound II.19. Taken together, these results suggest that 
induction of apoptosis is an important mechanism underlying compounds effects. 
 
Figure II.7. Apoptosis induction of HT-29 cells (measured by flow cytometry analysis) after 
exposure to II.18a, II.18b and II.19 at the IC50 and 2-fold IC50 concentrations, for 48 h. DMSO was 
used as vehicle control. Results are expressed as percentage of apoptotic cells ± SEM, from at 
least 3 independent experiments. §p < 0.05 and *p <0.005 from respective DMSO treatment. 
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3. Conclusion 
 
A library of eleven novel simetric compounds presenting three different aromatic 
cores (benzene, nafthalene and 2,7-biphenyl naphthalene) flanked by side chains with 
heteroatoms and amine terminal groups were synthesised with moderate to good 
yields. Based on the antiproliferative activity of the compounds and on the cytotoxicy 
assays results, some SAR elucidation was made. Among the synthesised compounds, 
four naphthalene based derivatives (II.18a-II.18d) and one 2,7-biphenyl naphthalene 
derivative (II.19) stood out by the their interesting antiproliferative activities over three 
cancer cell lines, specially against HT-29 where the five compounds presented lower IC50 
values than cisplatin. Within the four naphthalene based derivatives, it is also interesting 
to notice that despite compound II.18d not presenting the lower IC50 values, it was the 
only compound that presented good antiproliferative activity towards the three cancer 
cell lines  and no citotocixicity towards CRL-1502 and CaCo-2 in the tested concentration 
range. Within all the tested compounds, compound II.19 with a higher aromatic surface 
core presented the lowest IC50 values in the three cancer cell lines. The drawback of this 
compound was its citotoxicity over CaCo-2 cell line. These good results have encourage 
the search for the mechanism of action of these molecules. As they were inicially 
designed to act as G4 ligands, a FRET-melting assay was carried out. However, the 
antiproliferative activity did not seem to result from its action as G4 ligands since the 
compounds tested only presented a minor effect on G4 stabilization. Their poor action 
as G4 stabilizers can be explained by the small aromatic surface of these compounds 
(compared to the G-quartet) and by the flexibility of the compounds. In order to obtain 
better and more selective G4 stabilizers, molecules with bigger aromatic surface or with 
a higher electronic density in the aromatic rings should be synthesised. Based on the 
antiproliferative activity of the compounds, II.18a, II.18b and II.19 were choosen to 
assess apoptosis induction. In agreement with the lower IC50 values of compound II.19 
toward HT-29 cell line, this compound presented particularly interesting results as at 
IC50 concentration it was able to increase apoptosis up to 50%, as compared to vehicle 
control exposure. When cells were exposed to the same compounds at 2-fold IC50 
concentration, the percentage of cells undergoing apoptosis further increased. Taken 
together, these results suggest that induction of apoptosis is an important mechanism 
underlying compounds antiproliferaive effects. 
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III. SYNTHESIS AND BIOLOGICAL EVALUATION OF 
POLYAROMATIC FUSED COMPOUNDS AS G4 LIGANDS  
 
1. Introduction 
 
Despite the variety of polyaromatic fused scaffolds present in compounds evaluated 
as G4 ligands, benzo[h][1,6]naphthyridin-2(1H)-one scaffold (a tricyclic aromatic 
scaffold) was never been used for this purpose. As illustrated in Figure III.1., this tricyclic 
scaffold is the core structure in Torin1 (III.1a) and Torin2 (IIII.1b), a selective ATP-
competitive mammalian target of rapamycin (mTOR) kinase inhibitor.489,490 More 
recently, our group demonstrated that these compounds are extremely potent 
antimalarial drugs. Torin2 has single-digit nanomolar potency in both liver and blood 
stages of infection in vitro and is likewise effective against both stages in vivo, with a 
single oral dose sufficient to clear liver stage infection Parasite elimination and 
perturbed trafficking of liver stage parasitophorous vacuole membrane-resident 
proteins are both specific aspects of Torin-mediated Plasmodium liver stage inhibition, 
indicating that Torins have a distinct mode of action compared with currently used 
antimalarials.491 
 
 
Figure III.1. Torin1 (III.1a) and Torin2 (III.1b). 
 
The benzo[h][1,6]naphthyridin-2(1H)-one scaffold, chosen due to its extended 
aromatic core scaffold and thus potential to establish interactions through π-π stacking. 
In order to explore the importance of this aromatic core as G4 ligand, this chapter will 
focus on the synthesis and evaluation of the G4 stabilizing ability of a library of 
compounds (Figure III.2) with either aromatic (III.2) or aliphatic (III.3 and III.4) amine 
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side chains with different lengths. Besides that, the effect of a cationic center on the 
aromatic core (III.4), which would interact with the negative electrostatic center of the 
G4 by electrostatic interaction, was also studied. 
 
 
Figure III.2. Library of Torin-based compounds synthesised to be tested as G4 ligands (in blue 
the aromatic core; in orange the basic group of of side chains). 
 
2. Methods, Results and Discussion 
 
2.1. Retrosynthetic analysis  
 
The compounds of this series were obtained according the proposed synthetic 
pathway illustrated in Scheme III.1.  
These compounds share an aromatic core that was accomplished through a Gould-
Jacobs quinoline synthesis and subsequent chlorination of the 4-hydroxyquinoline. The 
Gould-Jacobs quinoline synthesis (Scheme III.2) involved: (a) the condensation of aniline 
III.5 with diethyl(2-ethoxymethylene)malonate III.6 to afford an enamine II.7, and (b) 
the intramolecular cyclization to quinolin-4-one nucleus III.8.492  
In contrast with the synthesis of III.3 and III.4 (which used commercially available 
amines), synthesis of III.2 started with a three-reaction sequence to obtain the aromatic 
side arm. The fluorine was first substituted by nucleophilic aromatic displacement with 
piperazine to give the corresponding substituted product. This reaction took place by a 
two-step reaction: in the first step, the nucleophile (in this case an amine group) 
attacked the carbon bearing the leaving group forming a carbanion intermediate 
(addition); in the second step of the reaction, the leaving group departed, reestablishing  
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Scheme III.1. Proposed synthetic pathway for the synthesis of Torin-based compounds.  
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Scheme III.2. Mechanism of Gould-Jacobs quinoline synthesis. 
 
the aromaticity of the ring (elimination). Although being a poorer leaving group than 
chloride or bromide, fluorine reacts faster than them in nucleophilic aromatic 
substitution because it accelerates the rate-determining step (addition) by its large 
inductive effect. Being the most electronegative element in the periodic table,  it 
stabilizes the anionic intermediate, assisting the acceptance of electrons by the benzene 
ring. The presence of two electron-withdrawing groups in ortho and para to the halogen 
also contribute to this reaction by activating the benzene ring.493 Subsequently, the 
amine group was protected with Boc group, which was choosen due to its stablility to 
bases and nucleophiles as well as to catalytic hydrogenation.494 In the last step, the nitro 
functional group was  reduced by catalytic hydrogenation to give the corresponding 
aniline. 
The synthesis of both III.2, III.3 and III.4 proceeded with a nucleophilic aromatic 
substitution at C-4 of the quinoline ring III.9 with an aniline or amine, respectively 
(Scheme III.3). In this case, the carbanion intermediate was stabilized by resonance. The 
reaction took place in the desired position mainly because the most stable intermediate 
is formed since resonance contributor obtained has the greatest electron density on 
nitrogen. In addition, the ester group in ortho position to the halogen also have a 
contribution to the reaction.493 
Reduction of the ester to aldehyde needs to be performed before proceed to the 
Tandem Horner-Wadsworth-Emmons (HWE) olefination/cyclisation. However, this is a 
real problem in synthetic chemistry inasmuch as the aldehydes are more readily reduced 
than the ester, the reduction carries on to the alcohol oxidation level. In order to try to 
solve this situation, there are two options: (a) use selective reduction reagentes (e.g. 
DIBAL) or (b) reduce the compound to alcohol, and oxidize the alcohol back to the 
aldehyde.495 
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Scheme III.3. Mechanism of nucleophilic aromatic substitution.  
 
DIBAL can perform the oxidation of esters to aldehydes in a single step. It exists as a 
bridged dimer and it becomes a reducing agent only after it has formed a Lewis acid–
base complex. DIBAL reduces esters even at – 70 °C, and at this temperature the 
tetrahedral intermediate may be stable. Only in the aqueous work-up does it collapse 
to the aldehyde when excess DIBAL has been destroyed so that no further reduction is 
possible.495 
Ester reduction to primary alcohol followed by its oxidation is the other alternative. 
To reduce the ester, different nucleophilic reducing agents, such as: lithium aluminum 
hydride (LiAlH4), sodium borohydride (NaBH4) or lithium borohydride (LiBH4), can be 
employed.496  
The alcohol oxidation can be done using different approaches. The most commonly 
used methods for oxidizing alcohols are based around metals in high oxidation states, 
often chromium (VI) or manganese(VII), which mechanistically are quite similar because 
both rely on the formation of a bond between the hydroxyl group and the metal. Due to 
the toxicity associated with the use of these heavy metals, new methodologies for the 
oxidation of alcohols to aldehydes have been developed. An important modern reagent 
(discovered in 1983) is known as the Dess–Martin periodinane (DMP). This reagent has 
several advantages over Cr(VI)-based oxidizing reagents, including: relative easy 
preparation, near 1 to 1 stoichiometry, shorter reaction times, simplified workups, and 
lower toxicity.495,496 
The tandem HWE olefination/cyclisation was used to obtain the tricyclic core scaffold. 
The HWE olefination (Scheme III.4) consists in the synthesis of olefins from the 
condensation between carbonyl compounds (both aldehydes and ketones) and 
carboanions derived from phosphonates. Despite the similarity of HWE olefination 
reaction mechanism to the mechanism of the Wittig reaction, the former reaction 
conditions have obvious advantages over the original Wittig Reaction, such as: (a) the 
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higher nucleophilicity and the basicity of phosphonate-stablized carbanion compared to 
the corresponding phosphonium ylides;  (b) the easy removal of dialkylphosphate salt 
(by-product of this reaction) by simple aqueous extraction. Although this reaction give 
preferencially E-olefins, both Z-olefins and E-olefins are possible products, and the ratio 
depends on the stereochemical outcome of the initial addition and the ability of the 
intermediate to equilibrate. For disubstituted olefins (from aldehydes), the E:Z ratio 
increases: (a) at higher reaction temperatures; (b) cation order of Li+ > Na+ > K+; (c) with 
increasing α-substitution of the aldehyde.497 
 
 
Scheme III.4. Mechanism of HWE (in green the carbonyl compounds; in blue carboanions 
derived from phosphonates). 
 
The HWE olefination is followed by straightforward intramolecular N-acylation of the 
amine, proton loss, and electronic reorganisation to provide the annulated product 
III.10 (Scheme III.5). It is important to refer that only the E-olefin is able to be converted 
to the annulated product. 
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Scheme III.5. Mechanism of tandem HWE olefination/cyclisation. 
 
As can be seen in the retrosynthetical Scheme III.1, in order to synthesise III.2, Boc 
deprotection took place followed by the amine methylation. tert-Butyl carbamates are 
cleaved under anhydrous acidic conditions with the production of tert-butyl cations. The 
most common removal conditions for Boc are 25-50% TFA in DCM, but other acids, such 
as 1 M trimethylsilyl chloride, phenol in DCM, and 4 M HCl in dioxane have been 
successfully used. Scavengers such as thiophenol and triethylsilane (TES) may prevent 
nucleophilic substrates from being alkylated.494 
Amine methylation (also required of the synthesis of III.3b and III.4) can be done using 
different methodologies, such as: (a) nucleophilic substitution with methyl triflate; or 
(b) Eschweiler–Clarke reaction.498 The latter reaction allows the preparation of tertiary 
methylamines from secondary amines via treatment with formaldehyde in the presence 
of formic acid (Scheme III.6). The formate anion acts as hydride donor to reduce the 
imine or iminium salt, so that the overall process is a reductive amination. The formation 
of quaternary amines is not possible. 
 
 
Scheme III.6. Mechanism of Eschweiler–Clarke reaction. 
 
The preparation of III.2b, III.3a and III.3c required the formation of a C-N bond. 
Traditional methods for the synthesis of arylamines, such as nucleophilic aromatic 
substitution and Ullmann-type couplings, are typically conducted using relatively harsh 
reaction conditions and have limited generality. On the other hand, the palladium-
catalyzed C-N bond formation of arylamines (Buchwald-Hartwig amination) can be 
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conducted under relatively mild conditions, is regioselective, and does not require 
activating groups.499 In this reaction (Scheme III.7), aryl halides or pseudohalides (Ar-X) 
and primary or secondary amines (R2NH) react to form an aryl amines (Ar-NR2). It starts 
with the oxidative addition, in common with most palladium-catalyzed coupling 
mechanisms. In the next step, the amine nucleophile is coordinated to the metal and 
deprotonated by the base. The catalytic cycle is closed by reductive elimination, yielding 
the final arylated amine product while regenerating the active catalyst. As in the 
previous examples of cross-coupling reactions, various ligands can be used.500 
 
 
Scheme III.7. Mechanisms of Buchwald-Hartwig amination: a. Oxidative addition, b. amine 
binding and deprotonation, c. reductive elimination. 
 
2.2. Synthesis discussion  
 
2.2.1. Synthesis of starting materials III.9 and III.11 
 
The synthesis of ethyl 6-bromo-4-chloroquinoline-3-carboxylate III.9 (Scheme III.8) 
was accomplish starting from the condensation of 4-bromoaniline III.5 with malonate 
III.6 to afford enamine III.7 in excellent yield (99%). This enamine underwent a thermally 
induced intramolecular cyclisation in diphenyl ether to form the corresponding 4-
hydroxiquinoline III.8, which was then reacted with phosphoryl chloride to afford III.9 in 
excellent yield. 
To synthesise III.11 (Scheme III.9), the fluorine of III.12 was first substituted by 
nucleophilic aromatic displacement with piperazine (III.13) to give the corresponding 
substituted product III.14 in excellent yield (95%) followed by the amine protection with 
Boc2O in the presence of a catalytic amount of DMAP affording compound III.15 in 
excellent yield (96%). The effect of DMAP is rationalized in terms of increasing the 
nucleophilicity of an intermediate N-Boc-DMAP complex (nucleophilic catalysis) 
compared with that of the anhydride. Simultaneously CO2 gas is released driving the 
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reaction towards completion.501 In the last step, the nitro functional group was reduced 
by catalytic hydrogenation to give the corresponding aniline III.11. 
 
 
Scheme III.8. Synthesis of compound III.9. Reagents and conditions: a) 115 oC, 1.5 h, 99%; b) 
Ph2O, 250 oC, 2 h, 80%; c) POCl3, 0 to 115 oC, 2.5 h, 100%. 
 
 
Scheme III.9. Synthesis of compound III.11. Reagents and conditions: a) K2CO3, DMSO, 90 oC, 
o/n, 96%; b) Boc2O, DMAP, rt, o/n, 94%; c) H2, Pd/C, rt, o/n, 97%. 
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2.2.2.  Synthesis of intermediates III.16, III.17  and III.18 through 
nucleophilic aromatic substitution  
 
To obtain compounds III.16, III.17 and III.18 it was performed a nucleophilic aromatic 
substitution at the C-4 of the quinoline ring by reaction with the corresponding amines 
(Scheme III.10). 
 
 
Scheme III.10. Synthesis of III.16, III.17 and III.18. Reagents and conditions: a) III.11, dioxane, 
110 oC, o/n, III.16: 65% and III.19: 17%; b) Methylamine solution 2.0 M in methanol, dioxane, 
110 oC, o/n, 99%; c) N,N-dimethylethylenediamine, dioxane, 110 oC, o/n, 95%; d) Boc2O, DMAP, 
rt, o/n, 75%. 
 
In the reaction to obtain III.16, it occurred a partial thermal deprotection of the Boc 
group, originating compound III.19 as a minor by-product (20% yield), which has been 
already described in literature.502 Therefore compound III.19 was reprotected with Boc 
(Scheme III.10). 
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2.2.3.  Synthesis of intermediates III.20, III.21  and III.22 through ester 
reduction to alcohol  
 
As oxidation of alcohol to aldehyde in the previously reported synthesis of Torin1489,490 
was not reproducible, the ester redution to alcohol was performed using LiAlH4 (Scheme 
III.11). Since LiAlH4 reacts violently with protic solvents, esters were reacted with LiAlH4 
in an aprotic dry solvent (THF) affording the corresponding alcohols III.20, III.21 and 
III.22, in moderated to excellent yields (62-96%).  
 
 
Scheme III.11. Synthesis of III.20, III.21 and III.22. Reagents and conditions: a) LiAlH4, THF, 
rt, 1 h. 
 
2.2.4.  Synthesis of compounds III.23, III.24 and III.25 through alcohol 
oxidation and tandem HWE olefination/cyclisation  
 
The oxidation of alcohol to aldehyde in the previously reported synthesis of Torin1 
have been done with MnO2 .489,490 MnO2 could be advantageous if the molecule had 
more than an alcohol group since this oxidant is highly chemioselective (allylic, benzylic, 
and propargylic alcohols  are oxidized faster than saturated alcohols). However, the 
molecules only presented an alcohol group and the oxidations with MnO2  presentes 
other disadvantages such as the need of a large excess of reagent for complete 
conversion of the alcohol, long reaction times, and the difficulty associated with 
obtaining highly activated MnO2.496 For those reasons, o-iodooxybenzoic acid (IBX, 
III.26), a periodinane that is also an intermediary in DMP synthesis, was choosen as 
oxidizing reagents.503 III.26 was obtained by oxidation of 2-iodobenzoic acid (III.27) as 
displayed in Scheme III.12. 
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Scheme III.12. IBX synthesis. Reagents and conditions: a) H2O, 70 oC (3 h) to 0 oC (1 h), 79%. 
 
As exemplified in Scheme III.13, the oxidation of  III.20 to aldehyde III.28 was 
performed with good yields. The synthesis of  compounds III.29 and III.30 was more 
challenging. The oxidation of III.21 with IBX in the previous conditions gave poor yields, 
however the yield improved when trifluoroacetic acid was added to the reaction. In fact, 
secondary amines must be temporarily protonated in situ with acid since the propensity 
for IBX to selectively act on the amine moiety to give the respective imine is truly 
remarkable.504,505 Under this conditions, aldehydes III.29 and III.30 were obtained with 
excellent yields. Having the aldehydes in hand, the HWE olefination/cyclisation was 
tried. Starting with aldehyde III.28, the tandem HWE olefination/cyclisation  was 
performed and III.23 with good yields. Compounds III.24 and III.25 were obtained in low 
yields being the Z-alkenes  (III.31 and III.32, respectively) the other products of the 
reactions. Alternativelly, higher reaction temperature (150 oC) using a solvent with an 
higher boiling point (DMF) was tested but only degradation products were formed. In 
order to obtain the annulated product, isomerization and cyclisation of E-alkene 
proceeded in a basic reaction media in ethanol. 
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Scheme III.13. Synthesis of compounds III.23, III.24, III.25. Reagents and conditions: a) IBX, 
DMF, rt, 3 h; b) Triethyl phosphonoacetate, K2CO3, EtOH, 100 oC, o/n; c) IBX, TFA, DMF, rt, 3 h; 
d) Triethyl phosphonoacetate, K2CO3, EtOH, 100 oC, o/n; e) K2CO3, EtOH, 125 oC, o/n. 
 
2.2.5. Synthesis of the target compounds  
 
To synthesise III.2a, the Boc deprotected compound was easily obtained using TFA in 
DCM. This product was directly used in the Eschweiler–Clarke procedure to obtain III.2a 
(Scheme III.14). 
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Scheme III.14. Synthesis of III.2a. Reagents and conditions: a) TFA, DCM, rt, 3h; b) (CH2O)n, 
HCOOH, MeOH, reflux, 24 h, 52%. 
 
Buchwald-Hartwig amination was employed to prepare III.2b. As the proper choice of 
catalyst (Pd source, ligand choice), base, and solvent are crucial for the success of a given 
amination, different conditions were tested as shown in Table III.1. The ligands tested in 
this synthesis were CyJohnPhos (III.33), (R)-Binap (III.34) and Xantphos (III.35) (Figure 
III.3). 
 
Table III.1. Reaction conditions explored to obtain compound III.2b. Reagents and conditions: 
a) NH2CH2CH2N(CH3)2, Pd(OAc)2, toluene, 100 oC. 
 
 
 
 
 
 
 
 
 
 
 
Entry Ligand Base Reaction time Yield 
1 III.33 NatOBu 48 h 12% 
2 III.34 Cs2CO3 24 h No reaction 
3 III.35 K2CO3 24 h 35% 
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Figure III.3. Ligands used in the Buchwald-Hartwig amination. 
 
A better yield was obtained when Xantphos was used as ligand and potassium 
carbonate was used as base. As exemplified in Schemes III.15 and III.16, methyl 
trifluoromethanesulfonate was choosen as methylating agent to synthesise III.3b and 
III.4. While III.3b was obtained in very low yield, III.4 was obtained with good yield. 
Buchwald-Hartwig amination was choosen to synthesise III.3a and III.3c. To obtain these 
compounds, solvent and temperature used in III.2b synthesis were changed after an 
unsuccessful atempt to obtain III.3a.  
 
 
Scheme III.15. Synthesis of III.3a and III.4. Reagents and conditions: a) NH2CH2CH2N(CH3)2, 
Pd(OAc)2, III.35, K2CO3, dioxane, 120 oC, o/n; b) CF3SO2OCH3, toluene, rt, o/n.  
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Scheme III.16. Synthesis of III.3b and III.3c. Reagents and conditions: a) CF3SO2OCH3, toluene, 
rt, o/n; b) NH2CH2CH2N(CH3)2, Pd(OAc)2, III.35, K2CO3, dioxane, 120 oC, o/n. 
 
2.3. Compounds as G4 ligands 
 
The ability of the synthesised compounds to stabilize G4 and their selectivity to G4s 
over dsDNA was investigated using FRET-melting assay, with ligand concentrations 
ranging from 0.1 to 5 µM. Three different DNA sequences were used (a) 26-mer double-
stranded hairpin loop sequence (T-loop) representing dsDNA (Table III.2); (b) 21-mer 
DNA G4 from region in human k-RAS oncogene promoter (KRas21R) (Table III.3); (c) 21-
mer DNA G4 from the human telomeric sequence (F21T) (Table III.4). 
These compouds are better G4 stabilizers than the compounds described in the 
previous chapter. 
All compounds present a similar ∆Tm trend of KRas21R≈F21T>T-loop, suggesting that 
they are better G4 DNA stabilizers when compared with dsDNA.  
Analising the effect of the different side chains on position N1 (III.2b,  III.3a and III.3c) 
revealed that the:  (a) compound with the smaller side chain III.3a presented the worst 
G4 DNA stabilizing ability; (b) compound III.2b presented a better G4 DNA ability when 
compared with III.3a (probably due to the increase of the aromatic surface that could 
be good for the interaction with the G-quartet); (c) compound with an aliphatic side 
chain III.3c presented a better G4 stabilization ability when compared with the 
compound with a higher aromatic surface III.2b and the best dsDNA stabilizing ability 
within these three compounds. The better results observed for   III.3c can be explained 
 Table III.2. FRET ∆Tm of T-Loop at 0.2 µM, stabilized by different derivatives in K+ cacodylate buffer (pH 7.4, 60 mM K+). Values represent the mean ± SD for 
a triplicated experience. 
 
 [Ligand]/µM 
0.1 0.5 1 2 3 4 5 
III.2a 1.04 ± 0.23 1.12 ± 0.25 1.00 ± 0.21 1.06 ± 0.20 1.06 ± 0.21 - 1.97 ± 0.22 - 2.13 ± 0.22 
III.2b - 0.86 ± 0.34 0.28 ± 0.37 - 1.54 ± 0.58 - 0.67 ± 0.36 - 0.62 ± 0.36 - 1.12 ± 0.35 - 1.63 ± 0.33 
III.3a 0.01 ± 0.18 0.07 ± 0.18 0.26 ± 0.18 0.44 ± 0.21 0.52 ± 0.18 0.66± 0.18 0.56 ± 0.19 
III.3b - 0.56 ± 0.24 - 0.53 ± 0.25 - 0.70 ± 0.24 - 0.66 ± 0.24 - 0.67 ± 0.22 - 0.73 ± 0.23 - 0.48 ± 0.27 
III.3c - 0.10 ± 0.18 0.43 ± 0.19 0.68 ± 0.19 1.69 ± 0.29 1.62 ± 0.21 1.85 ± 0.20 2.77 ± 0.17 
III.4 - 0.10 ± 0.23 - 0.10 ± 0.21 - 0.31 ± 0.24 - 0.19 ± 0.21 - 0.21 ± 0.21 - 0.17 ± 0.21 - 0.16 ± 0.21 
 
Table III.3. FRET ∆Tm of KRas21R at 0.2 µM, stabilized by different derivatives in K+ cacodylate buffer (pH 7.4, 60 mM K+). Values represent the mean ± SD 
for a triplicated experience. 
 
 [Ligand]/µM 
 0.1 0.5 1 2 3 4 5 
III.2a 0.66 ± 0.31 0.76 ± 0.29 0.71 ± 0.28 2.67 ± 0.30 2.90 ± 0.29 3.76 ± 0.28 5.83± 0.32  
III.2b 2.16 ± 0.52 1.28 ± 0.53 2.01 ± 0.51 2.27 ± 0.46 1.10 ± 0.65 4.17 ± 0.48 3.97± 0.58  
III.3a 0.96 ± 0.23 1.64 ± 0.24 0.86 ± 0.24 0.63 ± 0.27 0.91 ± 0.24 0.93 ± 0.23 0.87 ± 0.24 
III.3b 0.10 ± 0.24 - 0.16 ± 0.24 - 0.02 ± 0.24 - 0.02 ± 0.25 0.98 ± 0.25 1.20 ± 0.27 0.72± 0.25  
III.3c 0.67 ± 0.25 0.98 ± 0.24 1.86 ± 0.24 2.98 ± 0.24 3.98 ± 0.24 4.77 ± 0.24 6.97 ± 0.25 
III.4 0.22 ± 0.24 0.22 ± 0.24 0.16 ± 0.25 0.02 ± 0.25 0.07 ± 0.24 0.07 ± 0.24 0.05± 0.25  
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 Table III.4. FRET ∆Tm of F21T at 0.2 µM, stabilized by different derivatives in K+ cacodylate buffer (pH 7.4, 60 mM K+). Values represent the mean ± SD for a 
triplicated experience.. 
 
 [Ligand]/µM 
 0.1 0.5 1 2 3 4 5 
III.2a 0.78 ± 0.24 1.00 ± 0.24 1.60 ± 0.25 2.09 ± 0.27 5.08 ± 0.28 6.09 ± 0.28 5.38 ± 0.27 
III.2b 0.06 ± 0.28  -0.03 ± 0.37 0.19 ± 0.35 0.31 ± 0.37 1.88 ± 0.27 4.03 ± 0.29 4.22 ± 0.30  
III.3a 0.00 ± 0.25  0.20 ± 0.27 0.82 ± 0.23 1.13 ± 0.23 1.82 ± 0.23 1.86 ± 0.26 2.07 ± 0.28  
III.3b -0.04 ± 0.28 -0.01 ± 0.28 -0.01 ± 0.28  0.81 ± 0.26 1.88 ± 0.28 0.86 ± 0.28 0.86 ± 0.34 
III.3c 0.27 ± 0.29 1.19 ± 0.31 2.40 ± 0.29 4.09 ± 0.28 5.06 ± 0.31 6.04 ± 0.28 7.97 ± 0.33 
III.4 -0.06 ± 0.25 0.64 ± 0.26 0.76 ± 0.24  1.66 ± 0.24 1.65 ± 0.24 1.69 ± 0.28 2.60 ± 0.30 
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by the flexibility of the alkyl chain that allows a better positioning for amine terminal 
group to interact with the anionic phosphate groups. 
In contrast, ∆Tm of compounds with the aromatic ring substituent on position N1 (III.2a 
and III.2b) are compared is possible to observe that the additional amine moiety present 
in III.2b did not seem to have a significant impact on G4 stabilization.   
The compound with a cationic center on the aromatic core (III.4) only presented a 
weak stabilizing of F21T what can be explianed by the lack of alkylamine side chains. 
 
3. Conclusion 
 
A library of six novel benzo[h][1,6]naphthyridin-2(1H)-one derivatives with different 
terciary amine side chains were synthesised. While the synthesis of compounds with an 
aromatic side chain (III.2) was straightforward, the synthesis of derivatives with 
alkylamines (III.3 and III.4) presented more challenges.   
When tested as G4 ligands, these compounds presented better stabilizing capacity 
when compared with the compounds described in the previous chapter. This difference 
can be ascribed to their higher aromatic surface which can allow a better π-π interaction 
between the G-quartet and the aromatic surface of ligands. Based on FRET-melting 
assays data, there was possible to perceive some of the structural features that these 
derivatives present and are important in G4 ligands.   
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IV. SYNTHESIS OF CYSTEINE-BASED BUILDING BLOCKS OF PNA 
 
1. Introduction 
 
Despite the huge variety of PNA and α-PNA monomers, there is only one presenting 
a sulphur atom in its structure: a chemically dynamic oligomer in which the nucleobase 
is attached via a thioester bond and spaced by a variety of α-amino acids (IV.1). The 
most exciting characteristic of this system was its ability to adapt to the DNA 
complement in terms of the nucleobase sequence. As exemplified in Scheme IV.1, the 
oligomers efficiently self-assembles by means of reversible covalent thioester bond 
formation between thioester-functionalized nucleobase (IV.2) and simple oligopeptide 
backbone containing cysteine (IV.3). Although, this α-PNA cross-pair with RNA and DNA 
in Watson-Crick their nucleobase recognition hybridization properties were inferior to 
N-(2-aminoethylglycine)PNA.506 
 
 
Scheme IV.1. Reversible thioester formation between thioester-functionalized nucleobase 
and oligopeptide backbone containing cysteine (B: nucleobase; R: amino acid side chain). 
 
This chapter is focus on the development of synthetic strategies to obtain new 
chimeric amino acids based on cysteine’s functionalization with nucleobase side chains, 
which can be used as building blocks of α-PNAs (IV.4, Figure IV.1). Dipeptides 
incorporating these chimeric amino acids and glycine were also synthesised. The 
benefits of this strategy are the: (a) chemical diversity it confers to the structures and 
(b) flexibility of the side chain, which may be important in allowing the oligomer to adopt 
the appropriate DNA binding conformation.  
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Figure IV.1. Chimeric amino acid containing sulphur (n = 1-3, in blue is the nucleobase and in 
orange is the sulphur atom). 
 
2. Methods, Results and Discussion 
 
2.1. Retrosynthetic analysis 
 
As previously stated in Chapter I (pages 45-46), it is mandatory an orthogonal strategy 
for the protection of the primary amino group of the backbone and of the exocyclic 
amino groups of the nucleobases. To synthetise the desired compounds, it was applied 
the Fmoc/Boc strategy,393,394 where the Fmoc group was used as the protective group 
of the amino groups of the amino acids and the Boc group was chosen to protect 
exocyclic amino groups of the nucleobases.  
To obtain the designed chimeric amino acids and dipeptides, three different pathways 
could be pursued (Scheme IV.2): (a) firstly, reaction of the linking chain with the 
protected nucleobase followed by the reaction with cysteine, both through nucleophilic 
substitution; (b) reaction of the linking chain with cysteine followed by the reaction with 
the protected nucleobase, both through nucleophilic substitution; or (c)  reaction of the 
linking chain with the protected nucleobase through nuclephilic substitution followed 
by the thiol-ene reaction with cysteine. To obtain the dipeptides containing the chimeric 
amino acids, a similar pathway can be followed using cysteinyl-glicine dipeptide instead 
of cysteine amino acid. 
N-alkylation of nucleobases is usually conducted using alkyl halides,507 alkyl 
tosylates508 and mesylates.509 Furthermore, this reaction with other carbon 
electrophiles such as epoxides,510 Michael acceptors,511 carbonates,512 and allylic esters 
catalyzed by Pd(0)513 are also well-known procedures. A few reports describing 
conditions that are suitable for accessing N-alkylated nucleobases from alcohols, have  
also been reported, mostly using Mitsunobu reaction.514 This reaction is the dehydrative 
coupling of mainly primary or secondary alcohol to a pronucleophile, which is mediated  
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Scheme IV.2. Retrosynthetic scheme for chimeric amino acid synthesis (BPG: Boc-nucleobase 
nucleobase, Y: Cl, Br, I). 
 
by the reaction between a dialkyl azodicarboxylate (usually DIAD) and a trialkyl- or 
triaryl-phosphine (usually triphenylphosphine). The Mitsunobu reaction usally proceeds 
under mild and neutral conditions, and typically at 0 °C to rt.515  
Relatively to the S-alkylation of thiols, due to increasing application of thioethers in 
various fields, many methods have been reported for the formation C-S bond, mainly 
using aromatic thiols as starting materials.516 However, the approaches for the 
alkylation of the thiol group of cysteine are scarcer. S-alkylation of cysteine or cysteine 
derivatives is mainly obtain through substitution nucleophilic bimolecular (SN2) or thiol-
ene reactions.  
S-alkylation of unprotected and protected cysteine amino acids via SN2 requires the 
formation of thiolate anions. Thiols are much more acidic and nucleophilic in 
comparison to alcohols, and these properties can be explained by the weakness of the 
S-H bond and the greater likelihood that the negative charge will be distributed within 
sulphur 3d orbitals. Relatively to cysteine, it can be considered a triprotic acid in which 
the pKa of thiol group has been determined to be 8.2 (Scheme IV.3).517  
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Scheme IV.3. Protonation states of cysteine (pKa values depend on temperature, ionic 
strength, and the microenvironment of the ionisable group).517,518 
 
To obtain the cysteine thiolate (IV.5) different bases have been employed in 
literature.519-528 However, unsatisfactory yields, poor selectivity, problems with 
solubility and purification, formation of side-products and racemisation were among the 
difficulties encountered.522 
Alternatively, thiol-ene reaction (previously discussed in Chapter II, pages 67-68) can 
also be used in S-alkylation of cysteines.524,529-531 In order to obtain the chimeric amino 
acid, first the linking chain reacted with protected nucleobase to form a nucleobase allyl 
derivative. As these derivatives are considered to be of great importance in 
pharmaceutical industry,532  literature offers multiple examples of procedures dedicated 
to N-allylation of nucleobases or its derivatives by reaction with: (a) allyl bromide using 
different bases;532-534 (b) hexamethyldisilazane to form 2,4-bis((trimethylsilyl)oxy) 
derivative which will then react with allyl bromide;533  (c) N,N-dimethylformamide diallyl 
acetal;533   (d) triallyl phosphite;534  (e) allyl acetate through Pd(0)-catalyzed allylation;535 
or (f) 1,2-dibromoproane to alkylate the nucleobase followed by 
dehydrobromination.535 The main problem reported for the majority of this procedure 
is the formation of a mixture of regioisomers.533,535  Having the N-allylated nucleobase 
in hand, it can react with cysteine via thiol-ene reaction. To synthesise the cysteine-
based building blocks, reaction were conducted under radical conditions which 
mechanism is described in Scheme IV.4 (both thermal and photochemically induced). In 
order to obtain the final compounds, both SN2 and thiol-ene reactions were tried. 
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Scheme IV.4. Mechanism of synthesis of target compounds via radical thiol-ene reaction. 
 
2.2. Synthesis discussion 
 
2.2.1. Preparation of Fmoc-cysteine (IV.6) and Fmoc-cysteinyl-glicine 
dipeptides (IV.7) 
 
According to the protecting groups strategy selected to synthesise the chimeric amino 
acids and dipeptides, N-Fmoc-S-Trt-L-cysteine IV.8 was used as starting material. As 
exemplified in Scheme IV.5a, the trityl group was deprotected with TFA and TES as 
scavenger to prevent retritylation. Silanes are usually most efficient in removing the 
trityl cations as they reduce them to inert triphenylmethane.494  
Fmoc-cysteinyl-glicine dipeptides (IV.7, Scheme IV.5b) were synthesized starting from 
N-Fmoc-S-Trt-L-cysteine IV.8 and glycine ethyl ester hydrochloride (IV.9a) or glycine 
benzyl ester hydrochloride (IV.9b). These starting materials were chosen having in mind 
the concept of orthogonality: (a) trityl, as seen previously, is usually removed in acidic 
conditions; (b) ethyl ester is removed under basic conditions; and (c) benzyl ester can be 
removed by catalytic hydrogenolysis. Comparing the two protected glycine amino acids 
used, the ethyl ester is more affordable but epimerization and degradation of cysteine 
can occur under the basic conditions of deprotection, while glycine benzyl ester is more 
expensive but  the deprotection under catalytic hydrogenolysis is less prone to 
epimerization.494  
Amide coupling to obtain IV.10a and IV.10b were performed using TBTU/HOBt as 
coupling agents and DIPEA as base, which provides fast couplings and reduces 
racemization.536 Finally, the thiol group was deprotected to afford the desired 
dipeptides IV.7a and IV.7b in very good yields.  
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Scheme IV.5. Synthesis of a) IV.6 and b) IV.7. Reagents and conditions: a) TFA, TES, DCM, rt, 
3h; b) TBTU, HOBt, DIPEA, DMF, rt, o/n; c) TFA, TES, DCM, rt, 3h.  
 
2.2.2. Boc-protection of the exocyclic amine group of nucleobases  
 
Boc-protection of cytosine and adenine (respectively IV.11 and IV.12, Scheme IV.6) 
was accomplished through a two-step procedure already described in literature.537,538  
First the tris-Boc compounds IV.13 and IV.14 were synthesised, followed by the selective 
deprotection, under basic conditions, of N1 in cytosine and N9 in adenine, to afford the 
bis-Boc compounds IV.15 and IV.16 in good overall yields. To overcome guanine 
drawbacks (such as its insolubility in almost all solvents and its polyfunctional nature 
with imidazole, amide, and guanidine substructures), 2-amino-6-chloropurine IV.17, a 
guanine analogue, was used as starting material. Bis-Boc-protection of the exocyclic 
amine of 2-amino-6-chloropurine (to obtain IV.18) was performed following the above 
described methodology. As seen before, this procedure has the tris-Boc derivative IV.19 
as intermediary (Scheme IV.4).537,538  Thymine does not need any protection. 
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Scheme IV.6. N-protection of cytosine, adenine and guanine with Boc. Reagents and 
conditions: a) Boc2O, DMAP, THF, rt, o/n, 90%; b) NaHCO3, MeOH, 50 oC, 1 h, 83%; c) Boc2O, 
DMAP, THF, rt, o/n, 93%; d) NaHCO3, MeOH, 50 oC, 1 h, 75%; e) Boc2O, DMAP, THF, rt, o/n, 68%; 
f) NaHCO3, MeOH, 50 oC, 1 h, 95%.  
 
2.2.3. Synthesis of final chimeric amino acids and dipeptides  
 
During the search for the ideal reaction conditions to obtain the final chimeric 
cysteines, IV.16 was the nucleobase elected in the majority of the cases. In addition, not 
only IV.6 and IV.7a but also unprotected cysteine (IV.20) and acetylcysteine (IV.21), 
were used as reagents. These reagents were choosen since they are cheaper reagents 
and do not the need the additional step of trityl removal. 
 
2.2.3.1. Starting with N-alkylation of nucleobases followed by S-
alkylation of cysteine through SN2 reaction (Pathway a) 
 
Firstly, the N-hydroxymethylation of bis-Boc adenine IV.16 was tried. The N-
hydroxymethylation has been already described for N-unsubstituted benzimidazoles 
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with formaldehyde and paraformaldehyde.539 Besides that, 9-hydroxymethyladenine 
was obtained by chance when methoxyethoxymethyl chloride was added to an alkaline 
aqueous solution of adenine.540 The planned design would be to convert the hydroxyl 
group of the expected product IV.22 in a good leaving group (mesilate, triflate or 
halogen).  
Two reaction conditions (Table IV.1) were tried to obtain IV.22, but in both cases, 
although IV.16 was partially consumed during the reaction with the formation of several 
compounds, the 1H NMR spectra of the crude did not present the CH2 peak compatible 
with the hydroxymethylene.  
 
Table IV.1. Reactions condition tried for N-hydroxymethylation of bis-Boc adenine IV.16. 
 
Entry Base Alkylating agent Reaction conditions 
1 - 
Formaldehyde solution 
(37% in H2O) 
EtOH, rt, 20 h 
2 NaOH 1M Paraformaldehyde Absolute EtOH, rt, 48 h 
 
Alternatively, as exemplified in Scheme IV.7, N-alkylation of bis-Boc adenine IV.16 was 
successfully accomplish with 1-bromo-2-chloroethane IV.23, affording the expected 
product IV.24 in moderate yield.  
 
 
Scheme IV.7. Synthesis of compound IV.24. Reagents and conditions: a) K2CO3, DMF, rt, o/n, 
71%. 
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Then, S-alkylation with IV.24 was tried using different basic conditions. To synthesise 
the cysteine derivative IV.25 (Table IV.2), TMG (entry 1 and 2) was tested as a base as 
described in literature.522 However, S-alkylation did not occur neither with IV.20 nor 
with IV.6. S-alkylation of IV.21 was also tried using sodium methoxide (entry 3) but 
without any success.  
 
Table IV.2. Reaction conditions tried to obtain compound IV.25. 
 
 
Entry R Base Reaction conditions 
1 H (IV.20) TMG MeOH:THF, rt, 24 h 
2 Fmoc (IV.6) TMG MeOH:DMF, rt,  24 h 
3 Ac (IV.21) NaOCH3 MeOH, rt, 30 h 
 
To syntheside the dipeptide derivative IV.26 (Table IV.3), DIPEA was used as base in 
entries  1-3). Since the product was not obtained when only the base was used (entry 
1), the reaction conditions were replicated but with the addition of sodium iodide (entry 
2). With the addition of this salt, the substitution of chloride by iodine in IV.24 should 
occur via SN2 because iodide is a stronger nucleophile than chloride – Finkelstein 
reaction.541  As iodide is also a better leaving group than chloride it was expected that 
the following S-alkylation reaction worked better with this modification. Since IV.26 was 
not obtain again, a third attempt (entry 3) was done using a higher reaction 
temperature, but once again the desired product was not obtained. Finally, potassium 
carbonate was also tried as base (entry 4) but again without success.  
 
 
120  Chapter IV 
Table IV.3. Reaction conditions tried to obtain compound IV.26.  
 
 
 
 
 
 
 
 
2.2.3.2. Starting with S-alkylation of cysteine  followed by N-alkylation 
of nucleobases through SN2 reaction (Pathway b) 
 
As the final products were not obtained using the reaction conditions reported in the 
previous section, it was decided to test pathway b, in which the first step involves the S-
alkylation of cysteine with the linking chain.  
As exemplified in Table IV.4, S-alkylation of cysteine was attempted with 
bromochloromethane IV.27. 
 
 
 
 
 
 
 
 
 
 
 
Entry Base NaI Reaction conditions 
1 DIPEA - DMF, rt, 24 h 
2 DIPEA  DMF, rt, 24 h 
3 DIPEA  DMF, 50 oC, 7 h 
4 K2CO3  DMF, rt, o/n 
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Table IV.4. Reaction conditions tried in the S-alkylation of cysteine with IV.27. 
 
 
Entry R Base 
Equiv. of 
alkylating agent 
Reaction conditions 
1 H (IV.20) TMG 1 MeOH:THF, 50 oC, 2 h 
2 H (IV.20) TMG 20 MeOH:THF, 50 oC, 2 h 
3 Fmoc (IV.6) K2CO3 2 DMF, 0 oC to rt, o/n 
 
In this case, two different bases were used. Using the reaction conditions described 
in literature for TMG522  (entry 1), the desired product was not obtained and instead it 
occurred double alkylation resulting in a cysteine dimer liked through a methylene  
brigde. In order to try to avoid the formation of this product, an excess of alkylating 
agent was used (entry 2). However, in this case a complex mixture of products were 
obtained maybe due to the formation of O- or N-alkylated side-products. The S-
alkylation of IV.6 was also tried using potassium carbonate (entry 3) but the desired 
product IV.28 was not obtained. 
Alternatively, cysteine S-alkylation was attempted using 1-bromo-2-chloroethane 
IV.23 (Table IV.5). 
 
Table IV.5. Reaction conditions tried in the S-alkylation of cysteine with IV.23. 
 
Entry R Base Reaction conditions 
1 H (IV.20) TMG MeOH:THF, 50 oC, 3 h 
2 Ac (IV.21) NaOCH3 MeOH, reflux, 3 h 
3 Ac (IV.21) TEA DMF, rt, 3 h 
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In this case three different conditions were tested (Table IV.5) but IV.29 was not 
formed. Using the reaction conditions described in literature for TMG522  (entry 1), a 
complex mixture of products were obtained maybe due to the formation of O- or N-
alkylated side-products. Based in literature reports,  sodium methoxide528 and 
triethylamine521 were also tried as base (entry 2 and 3, respectively) but again without 
success. 
 
2.2.3.3. Starting with N-allylation of nucleobases via SN2 reaction 
followed by thiol-ene reaction with cysteine (Pathway c)  
 
As it was not possible to obtain the desired final chimeric products using the reaction 
pathways described in the previous sections, a pathway c was tested.  
 
2.2.3.3.1.  N-allylation of nucleobases 
 
The first step of this synthetic pathway consists in the regioselective synthesis of N-
allyl derivatives of nucleobases. N-allylation of bis-Boc citosine IV.15, bis-Boc adenine 
IV.16 and thymine IV.30 was performed by using allyl bromide and potassium carbonate 
as base (Scheme IV.8). In line with the higher acidity of N1-H versus N3-H of IV.15,542 
selective allylation took place at amide nitrogen N1 originating IV.31. In the case of N-
allylation of IV.16 and IV.30, two regioisomers were obtained. In both cases, the major 
product were the desired one (IV.32 and IV.33) and they were isolated from their by-
products (IV.34 and IV.35) using flash column chromatography.  
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Scheme IV.8. N-allylation of IV.15, IV.16 and IV.30. Reagents and conditions: a) BrCH2CHCH2, 
K2CO3, DMF, rt, o/n, 68%; b) BrCH2CHCH2, K2CO3, DMF, rt, o/n, IV.32: 58% and IV.34: 36%; c) 
BrCH2CHCH2, K2CO3, DMF, rt, o/n, IV.3: 60% and IV.35: 20%. 
 
The development of an easy and successful synthesis of N-allylated-Boc-protected 
guanine was the major challenge. Two different reaction conditions (Table IV.6) were 
tried to obtain the N-allylation of IV.18.  
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Table IV.6. Reaction conditions explored to obtain compound IV.36. 
 
 
Entry Base Reagents and conditions 
Yield 
IV.36 IV.37 IV.38 
1 NaH BrCH2CHCH2,THF, 0 
o
C to rt, o/n 20% 22% - 
2 K2CO3 BrCH2CHCH2,  DMF, 0 
o
C to rt, o/n 51% - 26% 
 
Using the conditions described in entry 1, the desired compound IV.36 was obtained 
as minor product and an interesting occurrence was the cleavage of one of the Boc 
group of the bis-Boc compound IV.36 to afford the N2- Boc-protected compound IV.37. 
The isolation of this product had been already described in literature using NaOH in EtOH 
at room temperature.538  Despite that, there are very few methods for the selective 
deprotection of di-Boc protected to mono-Boc protected amines.543-545 The mechanism 
proposed in literature543-545 based on the formation of a six-membered chelate seems to 
be applicable to this situation (Scheme IV.9). So, the initial chelation between the metal 
ion and two oxygen of the carbonyl group is followed by abstraction of proton from the 
methyl group led to the loss of isobutene, CO2 and formation of mono-Boc-protected 
group.  
 
 
Scheme IV.9. Mechanism of selective deprotection of a Boc group in the presence of sodium 
ion. 
 
When potassium carbonate was used as base (entry 2), IV.36 was obtained with a 
better yield. Under this conditions, the N7-allyl derivative IV.38 was obtained as minor 
product. 
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Having compound IV.36 in hand, the next step would be conversion of the 6-chloro 
moiety to a 6-oxo function of guanine. Some methods described in the past for this 
conversion have  employed vigorous acidic (such as refluxing hydrochloric acid)546 or 
basic conditions (such as refluxing NaOH solution)547 that could easily remove both Boc 
protecting groups. Milder conditions include treatment of protected 2-amino-6-
halopurine with trimethylamine in the presence of 3-hydroxypropionitrile and 1,8-
diazabicycloundec-7-ene which lead to the corresponding guanine via intermediate 6-
trimethylammonium IV.39 and 6-(2-cyanoethoxy) derivatives.548 Alternatively, the same 
authors explored the use of a ethanolic solution of trimethylamine (35% in EtOH/H2O, 
95:5) at 0 °C to room temperature, and they were able to obtain directly the desired 
final compound (instead of the ammonium salt) with good yields.537 Having in mind 
these reports, this reaction condition (Table IV.7, entry 1) was used for the conversion 
of IV.36 into the guanine derivative IV.40. 
 
Table IV.7. Reaction conditions to obtain compound IV.40 using an ethanolic solution of 
trimethylamine. 
 
Entry Solvent Conditions 
1 
Ethanolic solution of trimethylamine 
(35% in EtOH/H2O, 95:5) 
0 oC to rt, o/n 
2 
Ethanolic solution of trimethylamine 
(35% in EtOH/H2O, 95:5) + H2O (1:1, v/v) 
0 oC to rt, o/n 
 
In order to access if IV.40 was formed, mass spectrometry analysis played an 
important role. The product formed when using the reaction conditions described in 
entry 1 did not afford compound IV.40, contrary to what is described in literature.537  
Knowing the nucleophiles presented in the reaction media, other possible products from 
this reaction would be IV.41 or IV.42 (the product of the reaction of IV.39 and ethanolic 
solution of trimethylamine which have been already described in literature as by-
product).548  
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Figure IV.2. Possible products from the reaction between IV.36 and the ethanolic solution of 
trimethylamine. 
 
The mass spectrum (which presented a peak at 419.28) and 1H NMR spectrum (which 
presented a broad singlet at 3.49 ppm, a value similar to the chemical shift of the 
dimethyl group of 2-amino-6-N,N-dimethylaminopurine derivative described in 
literature549) indicated that the compound formed was IV.42. In order to try to obtain 
the desired product, the amount of water was increased to avoid the reaction of the 
trimethylammonium compound with trimethylamine (entry 2, Table IV.7), but neither 
the desired product nor the reported by-products were isolated. 
Some authors reported the high volatility of the ethanolic solution of trimethylamine 
as a drawback of this method. Therefore, they have explored the use of bicyclic tertiary 
amine DABCO, which has a higher melting point. In addition,  the resulting intermediate 
IV.43 was easily hydrolysed in refluxing water or by using aqueous sodium hydroxide in 
dichloromethane at room temperature to provide the 9-substituted guanine.550 
Therefore, these reaction conditions were tried but IV.40 was again not obtained (entry 
1, Table IV.8).550 Alternativelly, the amount of water and DABCO were increased and the 
solvent was changed to THF (entry 2 and 3, Table IV.8). However, once again, the 
product was not detected by mass spectrometry. 
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Table IV.8. Reaction conditions to obtain compound IV.40 using DABCO. 
 
 
Entry 
Equiv. of 
DABCO 
Solvent Water Conditions 
1 1 DMSO 4 equiv. rt, o/n 
2 1.2 THF Excess rt, o/n 
3 2.4 THF Excess rt, o/n 
 
As it was not possible to obtain IV.40 in the previous attempts, an alternative route 
was tried. In this pathway (Scheme IV.10), the first step was the N-allylation of 
unprotected 4-chloro guanine IV.17, followed by the convertion of the 6-chloro moiety 
of IV.44 into the 6-oxo function of guanine (IV.45), using refluxing hydrochloric acid.386 
 
 
Scheme IV.10. N-allylation of IV.17 and conversion of the N-allylated product (IV.44) into 
IV.45. Reagents and conditions: a) BrCH2CHCH2, K2CO3, DMF, rt to 50 oC, o/n, 68%; b) 1 N 
aqueous HCl, rt to reflux, 2 h, 71%. 
 
Having the N-allylated 4-chloro guanine derivative IV.45, Boc-protection of the 
exocyclic amine was performed by following the previously described 
methodology.537,538 In a first attempt (entry 1, Table IV.9), only 2.2 equivalents of Boc2O 
were used in order to try to protect exclusively the exocyclic amine. However, three 
compounds were obtained: bis-Boc IV.40, mono-Boc IV.46, and tris-Boc IV.47 protected 
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derivatives. In order to improve the yield of IV.40, 4 equivalents of Boc2O (entry 2, Table 
IV.9) were used leading to the formation of the desired bis-Boc derivative IV.40 in 
moderate yield (45%). 
 
Table IV.9. Reaction conditions for Boc-protection of the exocyclic amine of IV.46. Reagents 
and conditions: DMAP, THF, rt.  
 
Entry 
Equiv. of 
Boc2O 
Reaction time 
Yield 
IV.40 IV.46 IV.47 
1 2.2 4 h 20% 16% 12% 
2 4 24 h 45% 42% 7% 
 
In an attempt to avoid the formation of product IV.47, the O6-protection of IV.45 
(Scheme IV.11) with benzyl group, which deprotection could easily be achieved either 
by hydrogenation or acidolysis with TFA,394 was also tried. 
 
 
Scheme IV.11. O-benzylation of IV.45. Reagents and conditions: a) C6H5CH2Br, NaH, DMF, rt, 
o/n, IV.48: 16% and IV.49: 26%. 
 
Due to the low yield of the desired compound IV.48, its Boc protection of the exocyclic 
amine was not performed since this  this method would not present any advantage over 
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the previous one. This low yield can be explained by the formation of by-products such 
as N2-benzylate product IV.49. 
 
2.2.3.3.2. Thermally induced thiol-ene reactions 
 
Given the successful thermally induced coupling of cysteine with different alkenes 
reported in literature,524 thiol-ene of N-protected cysteines and different alkenes was 
carried out in refluxing dichloroethane (DCE) in the presence of AIBN, the radical 
initiator. As exemplified in Table IV.10, initially diferent reaction conditions were  
screened with commercially available reagents (entry 1-3) in order to find the optimized 
conditions. 
 
Table IV.10. Reaction conditions used in thermally induced thiol-ene reactions of N-protected 
cysteines with different alkenes. Reagents and conditions: a) AIBN, DCE. 
 
Entry R1 R2 Product 
Ratio 
thiol/ene 
Temperature 
(oC) 
Time 
(h) 
Yield 
1 Ac (IV.21) (CH
2
)
4
CH
3
 IV.50a 1:3 80 1.5 62% 
2 Ac (IV.21) OH IV.50b 1:3 80 2 100% 
3 Fmoc (IV.6) OH IV.50c 1:3 80 3.5 100% 
4 Fmoc (IV.6) T (IV.33) IV.50d 1:1 90 5 31% 
5 Fmoc (IV.6) T (IV.33) IV.50d 1:3 90 3 57% 
6 Fmoc (IV.6) T (IV.33) IV.50d 3:1 90 5 63% 
7 Fmoc (IV.6) C(Boc)
2 (IV.31) IV.50e 1:3 90 3 21% 
8 Fmoc (IV.6) A(Boc)2  (IV.32) IV.50f 1:3 80 3 42% 
 
Thermally thiol-ene reaction worked well when N-protected cysteines were used. 
Comparing different N-protected cysteines, the reaction with IV.21 (entry 2) was faster 
than the reaction using IV.6 (entry 3) but the yield was excellent in both cases. Besides 
that, it was observed that a better yield was obtained when one of the reagents was in 
excess (entries 4, 5 and 6). Since yields obtained when the thiol/ene ratio was 3:1 or 1:3 
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were similar, the remaining reactions were done with a thiol/ene ratio of 1:3 because 
the reaction was faster (entries 5 and 6). The reaction duration is important since 
thermal deprotection of Boc can occur (as seen in chapter III, page 98). This can also 
explain why IV.50e and IV.50f presented a lower yield compared with the reactions of 
unprotected thymine (entries 6-8).  
When thiol-ene reactions between dipetides and alkenes were tried (Table IV.11), the 
results were quite different. In these conditions, the only product successfully obtained 
was IV.51a (entry 1). Even though, this reaction took longer reaction times and 
presented a lower yield when compared with the correspondent reaction with cysteine 
IV.21 (entry 1, Table IV.10).  
 
Table IV.11. Reaction conditions used in thermally induced thiol-ene reaction of dipeptides 
with different alkenes. Reagents and conditions: a) AIBN, DCE. 
 
 
Entry R1 R2 Product 
Ratio 
thiol/ene 
Temperature 
(oC) 
Time 
(h) 
Yield 
1 Et (IV.7a) OH IV.51a 1:3 80 20 21% 
2 Et (IV.7a) Br  IV.51b 1:3 90 19 - 
3 Et (IV.7a) Br  IV.51b 1:3 90 3 - 
4 Et (IV.7a) T (IV.33) IV.51c 1:3 90 23 - 
5 Et (IV.7a) C(Boc)
2 (IV.31) IV.51d 1:3 90 23 - 
6 Et (IV.7a) A(Boc)2  (IV.32) IV.51e 1:3 90 20 - 
7 Bn (IV.7b) T (IV.33) IV.51f 1:3 90 23 - 
8 Bn (IV.7b) C(Boc)
2 (IV.31) IV.51g 1:3 90 23 - 
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When allyl bromide was used (entries 2 and 3, Table IV.11), the desired thiol-ene 
coupling product IV.51b was not obtained and instead it was obtained the S-alkylated 
dipeptide IV.52 in low yield (19%). The mechanism that can explain the formation of this 
product is displayed in Scheme IV.12. 
 
Scheme IV.12. Proposed mechanism for the formation of IV.52 (R= GlyOEt). 
 
The inability to obtain chimeric dipeptides with nucleobase side chains (entries 4-8, 
Table IV.11) can be related either with thermal deprotection of Boc or with thermal 
decomposition of the dipeptide due to the extended reaction times. 
 
2.2.3.3.3. Photochemically induced thiol-ene reactions 
 
Otherwise, experiments under photochemical conditions were also performed. 
Similarly to what occurred with the thermally induced reactions, the conditions were 
initially optimized with cysteines bearing different protecting groups and with different 
alkenes. As exemplified in Tables IV.12 and IV.13, the reactions occurred at room 
temperature by irradiation at maximum wavelength of 365 nm, under inert atmosphere, 
and in the presence of DPAP as sensitizer.551 
These reaction conditions gave better yields and are shorter than thermally-induced 
ones. Besides that, the excess of alkene turned out to be a key element in this approach 
since reactions with a thiol/ene ratio of 1:3 presented consistently better yields (entries 
3 and 6, Table IV.12).  
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Table IV.12. Reaction conditions used in photochemically induced thiol-ene reaction of N-
protected cysteines with different N-allylated Boc-protected nucleobases. Reagents: a) DPAP, 
DCE. 
 
 
Using the photochemically induced thiol-ene reaction, it was possible to obtain the 
final chimeric dipeptides, functionalized with all nucleobases, in moderate yields (Table 
IV.13).  
 
 
 
 
 
 
 
 
 
 
 
Entry R1 R2 Product 
Ratio 
thiol/ene 
Conc. 
[M] 
Time 
(h) 
Yield  
1 Ac (IV.21) (CH
2
)
4
CH
3
 IV.50a 1:3 0.6 1 100% 
2 Fmoc (IV.6) T (IV.33) IV.50d 1:1 0.6 4 66% 
3 Fmoc (IV.6) T (IV.33) IV.50d 1:3 0.6 2 87% 
4 Fmoc (IV.6) T (IV.33) IV.50d 3:1 0.3 2 57% 
5 Fmoc  (IV.6) C(Boc)
2 (IV.31) IV.50e 1:1 0.6 3 57% 
6 Fmoc (IV.6) C(Boc)
2 (IV.31) IV.50e 1:3 0.6 2 78% 
7 Fmoc (IV.6) C(Boc)
2 (IV.31) IV.50e 3:1 0.3 4 47% 
8 Fmoc (IV.6) G(Boc) (IV.46) IV.50g 1:3 0.6 3 30% 
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Table IV.13. Reaction conditions tried photochemically induced thiol-ene reaction of 
dipeptides with different N-allylated Boc-protected nucleobases. Reagents: a) DPAP, DCE. 
 
 
Entry R1 R2 Product 
Ratio 
thiol/ene 
Time (h) Yield 
1 Et (IV.7a) T (IV.33) IV.51c 1:3 2 51% 
2 Et (IV.7a) A(Boc)2  (IV.32) IV.51e 1:3 3 48% 
3 Bn (IV.7b) T (IV.33) IV.51f 1:3 3 49% 
4 Bn (IV.7b) C(Boc)
2 (IV.31) IV.51g 1:3 3 62% 
5 Bn (IV.7b) A(Boc)2  (IV.32) IV.51h 1:3 3 57% 
6 Bn (IV.7b) G(Boc) (IV.46) IV.51i 1:3 3 44% 
 
Relatively to chimeric dipeptides, two routes could be followed (Scheme IV.13): (a) 
the thiol-ene reaction was performed between the dipeptide and the N-allylated 
nucleobase or (b) the chimeric cysteine amino acid was initially synthesise and then 
coupled with glycine, Comparing the overall yields of the two routes (36% vs. 53%, 
respectively), route b proved to be more efficient. 
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Scheme IV.13. Comparison of two synthetic pathways to obtain IV.51f. Reagents and 
conditions: a) TBTU, HOBt, DIPEA, DMF, rt, o/n, 92%; b) TFA, TES, DCM, rt, 3h, 80%; c) IV.33, 
DPAP, DCE, hv, rt, 3h, 49%; d)TFA, TES, DCM, rt, 3h, 87%; e) IV.33, DPAP, DCE, hv, rt, 2h, 87%; f) 
IV.9a, TBTU, HOBt, DIPEA, DMF, rt, o/n, 70% 
 
3. Conclusion 
 
Chimeric cysteine and cysteine-based dipeptides, functionalized with all nucleobases 
were successfully accomplished yielding a library of 10 new α-PNA building blocks. The 
formation of the C-S bond was the most challenging step of this synthesis but was 
successfully overpassed when the thiol-ene reaction was used. The first step of this 
pathway consisted in the regioselective synthesis of N-allyl derivatives of nucleobases. 
Then, both thermally and photochemically induced thiol-ene conditions were tried 
either with cysteine or cysteinyl-glycine dipeptides. Photochemically induced thiol-ene 
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reactions proved to be a better option since they gave better yields in shorter reactions 
times particularly for reactions with dipeptides as the chimeric products were only 
obtained in these conditions.     
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V. GENERAL CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The dream of modern drug research is to discover biologically active molecules that 
are absolutely specific and able to act efficiently only on the molecular targets 
responsible for the disease progression.  In order to try to target nucleic acids in that 
way, different approches were used such as G4 ligands and oligonucleotide analogues.  
The main goal of this thesis was to develop novel DNA ligands, more specifically, (i) to 
study new scaffolds that could act as G4 ligands (Chapter II and Chapter III) and (ii) to 
design and prepare novel monomers of α- PNA with increased structural diversity 
(Chapter IV). 
The design of the G4 ligands was based on the structural features usually identified as 
favorable for the nucleic acid-molecule interaction. A library of eleven novel simetric 
compounds presenting three different aromatic cores (benzene, nafthalene and 2,7-
biphenyl naphthalene) flanked by side chains with heteroatoms and amine terminal 
groups were synthesised with moderate to good yields. Based on the antiproliferative 
activity of the compounds and on the cytotoxicity assays results, some SAR elucidation 
was made. Among the synthesised compounds, four naphthalene based derivatives 
(II.18a-II.18d) and one 2,7-biphenyl naphthalene derivative (II.19) stood out by the their 
interesting antiproliferative activities over three cancer cell lines, specially against HT-
29 where the five compounds presented lower IC50 values than cisplatin. Within all the 
tested compounds, compound II.19 with a higher aromatic surface core presented the 
lowest IC50 values in the three cancer cell lines. II.19 is an excellent starting point for 
further optimization. The activity results herein reported for these naphthalene 
derivatives have encouraged the search for the mechanism of action of these 
compounds. As they were inicially designed to act as G4 ligands, a FRET-melting assay 
was carried out. However, the antiproliferative activity did not seem to result from its 
action as G4 ligands since the compounds tested only presented a minor effect on G4 
stabilization. Their poor action as G4 stabilizers can be explained by the small aromatic 
surface of these compounds (compared to the G-quartet) and by the flexibility of the 
compounds. In order to obtain better and more selective G4 stabilizers, molecules with 
bigger aromatic surface should be synthesised. For example, it would be interesting to 
synthesise compounds with where the naphthalene ring will be flanked by aromatic 
rings, such as benzimidazole, instead of the alkyl chain. Based on the antiproliferative 
activity of the compounds, II.18a, II.18b and II.19 were choosen to assess apoptosis 
induction. In agreement with the lower IC50 values of compound II.19 toward HT-29 cell 
line, this compound presented particularly interesting results as at IC50 concentration it 
was able to increase apoptosis up to 50%, as compared to vehicle control exposure. 
When cells were exposed to the same compounds at 2-fold IC50 concentration, the 
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percentage of cells undergoing apoptosis further increased. In addition, the percentage 
of HT-29 apoptotic cells is related to the IC50 values of II.18a and II.18b. Taken together, 
these results suggest that induction of apoptosis is an important mechanism underlying 
compounds effects. 
In order to identify compounds with improved G4 stabilizing ability, a library of six 
novel benzo[h][1,6]naphthyridin-2(1H)-one derivatives with different terciary amine 
side chains were synthesised. While the synthesis of compounds with an aromatic side 
chain (III.2) was straightforward, the synthesis of derivatives with alkylamines (III.3 and 
III.4) presented more challenges. When tested as G4 ligands, these compounds 
presented better stabilizing capacity when compared with the compounds described in 
the previous chapter. This difference can be ascribed to their higher aromatic surface 
which can allow a better π-π interaction between the G-quartet and the aromatic 
surface of ligands. Despite containing this important structural feature, the ability of 
these Torin-based ligands to stabilize G4 did not reach the binding efficiency reported 
for other polyaromatic ligands, thus highlighting the need to continue the optimization 
of the Torin scaffold as putative G4 ligands. Based on FRET-melting assays data, it would 
be interesting to synthesise compounds: (a) with a cationic center on the aromatic core 
and two alkyl side chains with terminal terciary amine groups in positions  N1 and C9; or 
(b) similar to III.2b but with an more flexible alkylamine instead of the methyl piperazine 
to try to improve the interaction of the amine tertiary group with the phosphate groups 
of DNA. Besides that, other Torin derivatives with alkyl amine substituents in other 
positions N1 and  C10 or cationic derivatives with akyl amine substituents in N1 and N13 
could also be interesting molecules. 
Chimeric cysteine and cysteine-based dipeptides, functionalized with all nucleobases 
were also successfully accomplished. To form the C-S bond, we used the reaction of the 
adequately protected allyl nucleobases with cysteine or cysteinyl-glycine dipeptides 
under thermally and photochemically induced thiol-ene conditions. The 
photochemically induced thiol-ene reactions proved to be a better option since they 
gave better yields in shorter reactions times particularly for reactions with dipeptides as 
these chimeric products were only obtained in these conditions. These chimeric 
products can be used with different purposes. The more obvious is its use in the 
synthesis of α-PNA analogues. Its sequence can be based, for example, on clinically 
relevant aptamers (short ssDNA segments). The strength of the interaction between the 
newly-developed α-PNA aptamer analogues and their complementary DNA strands, as 
well as, their protein targets can be evaluated applying several physico-chemical 
methodologies. The chimeric amino acids can also be used to synthesise fluorescein-
labelled α-PNAs, candidates for molecular recognition in biosensor design. 
Alternativelly, these chimeric aminoacids can also be important in controlling the spatial 
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arrangement of peptides and construction of conformationally rigid, cyclic peptides 
without the need for covalent-bond reinforcement such already reported.552 
In conclusion, this thesis opened new perspectives and reinforced previously existing 
perceptions over the structural feactures that G4 ligand should have. With regards to 
non-fused aromatic ligands, this work confirmed that the presence of more than one 
aromatic core (such as benzene or naphtalene) seems to be essential to: (a) have an 
aromatic surface big enough to selectively interact with the G-quartet; (b) give some 
rigidity to the structure. Respecting the polyaromatic fused compounds, a new scaffold 
was tested as G4 ligand and the FRET-melting data give precious information to be used 
in the design of new derivatives of this scaffold. Besides that, it is also essential to 
highlight the very good antiproliferative results obtained with the naphthalene 2,7-
biphenyl naphthalene derivatives. The synthesis of new α-PNA monomers containing 
sulfur was also an achivement. From a chemical point of view, this work is also 
interesting for the variety of reactions that were employed where the click thiol-ene 
reactions stood out due to its use in the synthesis of compounds from different chapters 
of this thesis. 
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VI. EXPERIMENTAL SECTION  
 
1. Chemistry 
 
All chemicals and solvents were of analytical reagent grade and were purchased from 
Alfa Aesar or Sigma-Aldrich.  
Thin layer chromatography (TLC) was performed using Merck silica gel 60F254 
aluminium plates. All reactions were monitored by TLC. Flash column chromatography 
was performed using Merck silica gel 60 (230-400 mesh ASTM) eluting with various 
solvent mixtures and using an air aquarium pump to apply pressure.  
NMR spectra were obtained on a Bruker 400 Ultra-Shield instrument (1H 400 MHz, 
13C 101 MHz) and on a Bruker 300 Avance spectrometer (1H 300 MHz, 13C 75 MHz). using 
deuterated chloroform, methanol or dimethylsulfoxide as solvents; chemical shifts are 
expressed in parts per million (ppm, δ) referenced to the solvent used and the proton 
coupling constants (J) in hertz (Hz). Multiplicities are given as: s (singlet), bs (broad 
singlet), d (doublet), dd (double doublet), dt (double triplet), t (triplet), q (quartet), quint 
(quintuplet) and m (multiplet).  
Mass analyses were determined using a Micromass Quattro Micro API spectrometer, 
equipped with Waters 2695 HPLC Module and Waters 2996 Photodiode Array Detector, 
by LCLEM, Faculty of Pharmacy from the University of Lisbon, Portugal. High resolution 
mass spectra were performed in Unidade de Espectrometria de Masas (HMRS), Santiago 
de Compostela, Spain. Elemental analysis (for C, H, and N) were determined using a 
FLASH 2000 analyser, performed by LCLEM, Faculty of Pharmacy from the University of 
Lisbon, Portugal.  
Melting points were determined using a Kofler Bock Monoscop M and are 
uncorrected. 
The household UVA lamp apparatus was equipped with four 15 W tubes (1.5 x 27 cm 
each). Photoinduced reactions were carried out in a glass vial (diameter: 1 cm; wall 
thickness: 0.65 mm), sealed with a natural rubber septum, located 2.5 cm away from 
the UVA lamp (irradiation on sample: 365 nm, 1.04 W/m2). 
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2. Synthesis 
 
2.1. Synthesis of compounds described in Chapter II 
 
2.1.1. General methods 
 
General procedure A for triflation reaction. To a suspension of an aromatic alcohol 
(1 equiv.)  in DCM (0.6 M) at 0 oC was added triethylamine (2.2 equiv.). After 15 min, 
trifluorometanesulfonic anhydride (2.2 equiv.) was slowly added to the reaction 
mixture. Then, the reaction mixture was allowed to warm to rt. After 4-6 h, the reaction 
was poured into water and extracted with DCM. The organic phase was washed with 
water, brine and dried with anhydrous Na2SO4. The solvent was removed under reduced 
pressure and the crude product was purified by flash column chromatography.  
General procedure B for the Suzuki cross-coupling reaction: To a solution of triflate 
or bromide (1 equiv.) in 1,4-dioxane (0.2 M) at rt in a sealed tube, were added 
allylboronic acid pinacol ester (2.6 equiv.), K3PO4●H2O (3 equiv.) and 
tetrakis(triphenylphosphine)palladium(0) (6 mol%). After degassing during 5 min, the 
reaction mixture was refluxed at 110 oC o/n before being cooled at rt, diluted in Et2O 
and filtered through a pad of celite. The filtrate was concentrated under reduced 
pressure and the crude product was purified by flash column chromatography.  
 
General method C for the thiol-ene reaction: Thiol (2.8 or 4 equiv.) and DPAP (0.1 
equiv.) were added to an alkene (1 equiv.). All the reagents were dissolved in DCE 
(solvent was degassed for 15 min prior to use) (0.6 M). The solution was irradiated at rt 
for 15 min-3 h under magnetic stirring and then concentrated under reduced pressure. 
The crude product was purified by flash column chromatography. 
 
General Procedure D for ester hydrolysis: To a solution of methyl ester (1 equiv.) in 
THF:H2O (1:1) (0.2 M) was added LiOH (2.5 or 5 equiv.). The reaction mixture was then 
stirred at rt during 4 h. After THF evaporation, the reaction mixture was acidified with 
1N aqueous HCl and the aqueous phase was extracted with DCM. The combined organic 
phases were washed with water, brine and dried with anhydrous Na2SO4. The solvent 
was then removed under reduced pressure to afford the desired compounds. 
 
General procedure E for amide synthesis: To a suspension of acid (1.1 equiv.) in dry 
DCM (0.25 M) was added DIPEA (2 equiv.) and TBTU (2.2 equiv.). After 10 min, the amine 
(2 equiv.) was added. The reaction mixture was then stirred at rt and under nitrogen 
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atmosphere o/n. Then, the reaction was diluted with EtOAc and the organic phase was 
washed with water. The aqueous phased was acidified with 10% aqueous KHSO4 and 
extracted with EtOAc. After that, the aqueous phase was basified with NaOH 1N and 
extracted again with EtOAc. The combined organic phases were washed with water, 
brine and dried with anhydrous Na2SO4. The solvent was removed under reduced 
pressure to afford the desired compounds. 
 
2.1.2. Synthesis of compounds II.23 and II.31 
 
1,3-phenylene bis(trifluoromethanesulfonate) (II.23) 
1,3-dihydroxybenzene II.22 (220 mg, 3.63 mmol) reacted with 
trifluorometanesulfonic anhydride (672 µL, 4.00 mmol) was 
treated under the conditions described in general procedure A. 
The crude product was purified by flash column chromatography 
(hexane/EtOAc, 95:5) to afford II.23 as a colorless oil (514 mg, 76%). 1H NMR (400 MHz, 
CDCl3) δ 7.59 (t, J = 8.4 Hz, 1H, H5), 7.37 (dd, J = 8.4, 2.0 Hz, 2H, H4, H6), 7.26 (s, 1H, H2). 
 
Naphthalene-2,7-diyl bis(trifluoromethanesulfonate) (II.31) 
To a suspension of 2,7-dihydroxynaphthalene II.30 (1 g, 6.24 
mmol) reacted with trifluorometanesulfonic anhydride (2.56 
mL, 13.74 mmol) under the conditions described in general 
procedure A. The crude product was purified by flash column 
chromatography (hexane/EtOAc, 95:5) to afford II.31 as a white solid (2.44 g, 92%). M.p. 
60-61 oC; 1H NMR (400 MHz, CDCl3) δ 8.01 (d, J = 8.8 Hz, 2H, H4, H5), 7.81 (d, J = 2 Hz, 2H, 
H1, H8), 7.48 (dd, J = 8.8, 2 Hz, 2H, H3, H6). Analytical date were in agreement with those 
already published.553 
 
2.1.3. Synthesis of compounds II.21, II.29, II.33 and II.34  
 
1,3-diallylbenzene (II.21) 
 1,3-dibromobenzene II.24 (500 mg, 2.12 mmol) was coupled 
with allylboronic acid pinacol ester (1.03 mL, 5.51 mmol) 
under the conditions described in general procedure B. The 
crude product was purified by flash column chromatography 
(hexane 100%) to afford II.21 as a colorless oil (214 mg, 64%). 1H NMR (400 MHz, CDCl3) 
δ 7.22 (t, J = 7.4 Hz, 1H, H5), 7.03 (d, J = 8.1 Hz, 3H, H2, H4, H6), 5.97 (ddt, J = 16.9, 10.1, 
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6.7 Hz, 2H, CH=CH2), 5.12 – 5.03 (m, 4H, CH=CH2), 3.38 (t, J = 8.0 Hz, 4H, CH2CH=CH2). 
13C NMR (101 MHz, CDCl3) δ 140.3 (C1, C3), 137.6 (CH=CH2), 129.0 (C5), 128.6 (C6), 126.5 
(C2,C4), 115.9 (CH=CH2), 40.3 (CH2CH=CH2). Analytical date were in agreement with those 
already published.554 
 
2,7-diallylnaphthalene (II.29) 
II.31 (800 mg, 1.89 mmol) was coupled with allylboronic 
acid pinacol ester (919 µL, 4.90 mmol) under the 
conditions described in the general procedure B. The 
crude product was purified by flash column 
chromatography (hexane/EtOAc, 9:1) to afford II.29  as a colorless oil (251 mg, 64%). 1H 
NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.4 Hz, 2H, H4, H5), 7.57 (s, 2H, H1, H8), 7.28 (d, J = 
8.4 Hz, 2H, H3, H6), 6.04 (m, 2 H, CH=CH2), 5.13 (d, J = 10.4 Hz, 2H, CH=CHtrans), 5.10 (d, J 
= 2.4 Hz, 2H, CH=CHcis), 3.54 (d, J = 6.6 Hz, 4H, CH2CH=CH2). 13C NMR (101 MHz, CDCl3) δ 
137.8 (C2, C7), 137.5 (CH=CH2), 134.0 (C9), 131.0 (C10), 127.8 (C4, C5), 127.0 (C3, C6), 126.4 
(C1, C8), 116.1 (CH=CH2), 40.5 (CH2CH=CH2). Analytical date were in agreement with 
those already published.555  
 
7-allylnaphthalen-2-ol (II.33) 
II.33 was obtained as a minor product of the previous 
reaction. White solid (53 mg, 15%). M.p. 128-133 oC; 1H NMR 
(400 MHz, CDCl3) δ 8.11 (s, 1H, H1), 7.92 (d, J = 8.4 Hz, 1H, H4), 
7.83 (d, J = 8.4 Hz, 2H, H3, H5), 7.73 (s, 1H, H8), 7.36 (d, J = 8.4 
Hz, 1H, H6), 6.16 – 6.02 (m, 1H, CH=CH2), 5.22 – 5.12 (m, 2H, CH=CH2), 3.59 (d, J = 6.4 Hz, 
2H, CH2CH=CH2). 13C NMR (101 MHz, CDCl3) δ 138.8 (C2), 138.2 (C7), 137.4 (CH=CH2), 
134.1 (C9), 131.5 (C10), 128.4 (C3), 127.9 (C4), 127.7 (C6), 127.2 (C8), 125.9 (C1), 125.3 (C5), 
116.3 (CH=CH2), 40.5 (CH2CH=CH2). MS (ESI) m/z 185 [M+H]+. 
 
2,7-divinylnaphthalene (II.34) 
To a solution of 2,7-dibromonaphthalene II.35 (300 mg, 1.05 
mmol, 1 equiv.) in dry 1,4-dioxane (0.1 M) at rt were added 
vinylboronic acid pinacol ester (463 µL, 2.73 mmol, 2,6 
equiv.), Na2CO3 1M (6 equiv.) and 
bis(triphenylphosphine)palladium(II) dichloride (10 mol%). After degassing during 5 min, 
the reaction mixture was stirred at 80 oC o/n before being cooled at rt, diluted in Et2O 
and filtered through a pad of celite. The filtrate was concentrated under reduced 
pressure and the crude product was purified by flash column chromatography (hexane 
100%) to afford compound II.34 as a white solid (158 mg, 84%). M.p. 75-76 oC; 1H NMR 
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(400 MHz, CDCl3) δ 7.76 (d, J = 8.6 Hz, 2H, H4, H5), 7.72 (s, 2H, H1,H8), 7.60 (d, J = 8.6 Hz, 
2H, H3, H6), 6.87 (dd, J = 17.6, 10.8 Hz, 2H, CH=CH2), 5.87 (d, J = 17.6 Hz, 2H, CH=CHtrans), 
5.34 (d, J = 10.8 Hz, 2H, CH=CHcis). 13C NMR (101 MHz, CDCl3) δ 137.0 (CH=CH2), 135.5 
(C2, C7), 133.8 (C9), 133.0 (C10), 128.1 (C4, C5), 126.6 (C3, C6), 123.4 (C1, C8), 114.4 
(CH=CH2). Analytical date were in agreement with those already published.556 
 
2.1.4. Synthesis of compounds II.41, II.43, II.44 and II.46 
 
Dimethyl 2,2'-((1,3-phenylenebis(propane-3,1-diyl))bis(sulfanediyl))diacetate (II.41) 
II.21 (214 mg, 1.35 mmol) was coupled with 
methyl thioglicolate (483 µL, 5.40 mmol) for 1 h 
under the conditions described in the general 
procedure C. The crude product was purified by 
flash column chromatography (hexane/EtOAc, 9:1) to afford II.41 as an oil (269 mg, 
54%). 1H NMR (400 MHz, CDCl3) δ 7.20 (t, J = 7.4 Hz, 1H, H5), 7.01 (d, J = 8.0 Hz, 3H, H2, 
H4, H6), 3.71 (s, 6H, CH3), 3.23 (s, 4H, SCH2C=O), 2.66 (dt, J = 17.6, 7.4 Hz, 8H, 
ArCH2CH2CH2S, ArCH2CH2CH2S), 1.96 – 1.86 (m, 4H, ArCH2CH2CH2S). 13C NMR (101 MHz, 
CDCl3) δ 171.1 (C=O), 141.5 (C1, C3), 128.8 (C5), 128.6 (C6), 126.2 (C2,C4), 52.5 (CH3), 34.7 
(ArCH2CH2CH2S), 33.5 (SCH2C=O), 32.2 (ArCH2CH2CH2S), 30.6 (ArCH2CH2CH2S).  
 
Dimethyl 2,2'-((naphthalene-2,7-diylbis(propane-3,1-diyl))bis(sulfanediyl))diacetate 
(II.43) 
II.29 (250 mg, 1.20 mmol) was coupled with 
methyl thiolate (429 µL, 4.80 mmol) for 1 h 
under the conditions described in the 
general procedure C. The crude product 
was purified by flash column chromatography (hexane/EtOAc, 9:1) to afford II.43 as a 
white solid (466 mg, 92%). 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.2 Hz, 2H, H4, H5), 
7.55 (s, 2H, H1, H8), 7.27 (d, J = 8.2 Hz, 2H, H3, H6), 3.70 (s, 6H, CH3), 3.24 (s, 4H, SCH2C=O), 
2.87 (t, J = 7.6 Hz, 4H, ArCH2CH2CH2S), 2.67 (t, J = 7.2 Hz, 4H, ArCH2CH2CH2S), 2.08 – 1.94 
(m, 4H, ArCH2CH2CH2S). 13C NMR (101 MHz, CDCl3) δ 171.1 (C=O), 139.0 (C2, C7), 133.8 
(C9), 130.8 (C10), 127.9 (C4, C5), 126.7 (C3, C6), 126.2 (C1, C8), 52.5 (CH3), 34.9 
(ArCH2CH2CH2S), 33.5 (SCH2C=O), 32.2 (ArCH2CH2CH2S), 30.5 (ArCH2CH2CH2S).  
 
Methyl 2-((3-(7-hydroxynaphthalen-2-yl)propyl)thio)acetate (II.44) 
 II.33 (53 mg, 0.29 mmol) was coupled with 
methyl thiolate (69 µL, 0.78 mmol) for 15 min 
under the conditions described in the general 
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procedure C. The crude product was purified by preparative TLC (hexane/EtOAc, 8:2) to 
afford II.44 as a light yellow solid (64 mg, 77%). M.p. 57-60 oC; 1H NMR (400 MHz, CDCl3) 
δ 8.10 (s, 1H, H1), 7.92 (d, J = 8.4 Hz, 1H, H3), 7.82 (d, J = 8.4 Hz, 2H, H4, H5), 7.72 (s, 1H, 
H8), 7.35 (d, J = 8.4 Hz, 1H, H6), 3.72 (s, 3H, CH3), 3.26 (s, 2H, SCH2C=O), 2.92 (t, J = 7.4 
Hz, 2H, ArCH2CH2CH2S), 2.71 (t, J = 7.2 Hz, 2H, ArCH2CH2CH2S), 2.10 – 2.01 (m, 2H, 
ArCH2CH2CH2S). 13C NMR (101 MHz, CDCl3) δ 171.1 (C=O), 139.5 (C7), 138.8 (C2), 134.0 
(C9), 131.4 (C10), 128.4 (C3), 127.9 (C4), 127.5 (C6), 127.1 (C8), 125.80 (C1), 125.3 (C5), 52.5 
(CH3), 34.9 (ArCH2CH2CH2S), 33.6 (SCH2C=O), 32.2 (ArCH2CH2CH2S), 30.5 (ArCH2CH2CH2S). 
 
Dimethyl 2,2'-((naphthalene-2,7-diylbis(ethane-2,1-diyl))bis(sulfanediyl))diacetate 
(II.46) 
II.34 (158 mg, 0.88 mmol) was coupled 
with methyl thiolate (315 µL, 3.52 mmol) 
for 3 h under the conditions described in 
the general procedure C. The crude 
product was purified by flash column chromatography (hexane/EtOAc, 8:2) to afford 
II.46 as a light yellow oil (177 mg, 51%). 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.4 Hz, 
2H, H4, H5), 7.60 (s, 2H, H1,H8), 7.30 (d, J = 8.4 Hz, 2H, H3, H6), 3.74 (s, 6H, CH3), 3.25 (s, 
4H, SCH2C=O), 3.09 – 3.03 (m, 4H, ArCH2CH2S), 3.01 – 2.95 (m, 4H, ArCH2CH2S). 13C NMR 
(101 MHz, CDCl3) δ 171.0 (C=O), 137.9 (C2, C7), 133.8 (C9), 131.2 (C10), 128.0 (C4, C5), 
126.8 (C3, C6), 126.6 (C1, C8), 52.5 (CH3), 35.9 (ArCH2CH2S), 34.1 (ArCH2CH2S), 33.7 
(SCH2C=O).  
 
2.1.5. Synthesis of compounds II.38, II.42, II.45 and II.47 
 
2,2'-((1,3-phenylenebis(propane-3,1-diyl))bis (sulfanediyl))diacetic acid (II.38) 
II.41 (269 mg, 0.73 mmol) was treated under 
the conditions described in the general 
procedure D to afford II.38 as an incolor oil (238 
mg, 96%). 1H NMR (400 MHz, CDCl3) δ 7.20 (t, J 
= 7.4 Hz, 1H, H5), 7.00 (d, J = 8.3 Hz, 3H, H2, H4, 
H6), 3.24 (s, 4H, SCH2C=O), 2.68 (q, J = 7.4 Hz, 8H, ArCH2CH2CH2S, ArCH2CH2CH2S), 1.96 – 
1.86 (m, 4H, ArCH2CH2CH2S). 13C NMR (101 MHz, CDCl3) δ 177.9 (C=O), 141.6 (C1, C3), 
128.6 (C2), 128.5 (C5), 126.4 (C4, C6), 34.7 (ArCH2CH2CH2S), 34.5 (SCH2C=O), 33.2 
(ArCH2CH2CH2S), 31.4 (ArCH2CH2CH2S). MS (ESI) m/z 341 [M-H]-. 
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2,2'-((naphthalene-2,7-diylbis(propane-3,1-diyl))bis (sulfanediyl))diacetic acid (II.42) 
 II.43 (563 mg, 1.34 mmol) was treated 
under the conditions described in the 
general procedure D to afford II.42 as a 
white solid (479 mg, 91%).  M.p. 132-135 
oC; 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.8 Hz, 2H, H4, H5), 7.63 (s, 2H, H1, H8), 7.24 
(d, J = 8.8 Hz, 2H, H3, H6), 3.21 (s, 4H, SCH2C=O), 2.91 (t, J = 6.4 Hz, 4H, ArCH2CH2CH2S), 
2.66 (t, J = 7.0 Hz, 4H, ArCH2CH2CH2S), 2.08 – 1.98 (m, 4H, ArCH2CH2CH2S). 13C NMR (101 
MHz, CDCl3) δ 177.8 (C=O), 138.5 (C2, C7), 133.7 (C9), 130.8 (C10), 127.9 (C4, C5), 126.9 (C3, 
C6), 126.7 (C1, C8), 34.2 (ArCH2CH2CH2S), 31.5 (SCH2C=O), 31.0 (ArCH2CH2CH2S), 29.8 
(ArCH2CH2CH2S). MS (ESI) m/z 391 [M-H]-. 
 
2-((3-(7-hydroxynaphthalen-2-yl)propyl)thio)acetic acid (II.45) 
II.44 (71 mg, 0.24 mmol) was treated under the 
conditions described in the general procedure 
D to afford II.45 as an off-white solid (57 mg, 
84%). M.p. 127-130 oC; 1H NMR (400 MHz, 
DMSO-d6) δ 8.28 (s, 1H, H1), 8.00 (d, J = 8.4 Hz, 1H, H4), 7.93 (d, J = 8.4 Hz, 1H, H3), 7.89 
(d, J = 8.4 Hz, 1H, H5), 7.82 (s, 1H, H8), 7.42 (d, J = 8.4 Hz, 1H, H6), 3.26 (s, 2H, SCH2C=O), 
2.85 (t, J = 7.4 Hz, 2H, ArCH2CH2CH2S), 2.64 (t, J = 7.2 Hz, 2H, ArCH2CH2CH2S), 2.01 – 1.87 
(m, 2H, ArCH2CH2CH2S). 13C NMR (101 MHz, DMSO-d6) δ 171.8 (C=O), 139.7 (C7), 137.5 
(C2), 133.6 (C9), 131.0 (C10), 128.4 (C4), 127.7 (C6, C5), 126.7 (C8), 125.2 (C1), 124.7 (C3), 
34.3 (ArCH2CH2CH2S), 33.3 (SCH2C=O), 31.4 (ArCH2CH2CH2S), 30.2 (ArCH2CH2CH2S). 
 
2,2'-((naphthalene-2,7-diylbis(ethane-2,1-diyl))bis (sulfanediyl))diacetic acid (II.47) 
II.46 (150 mg, 0.38 mmol) was treated 
under the conditions described in the 
general procedure D to afford II.47  as an 
incolor oil (75 mg, 54%). 1H NMR (400 
MHz, CDCl3) δ 7.72 (d, J = 8.3 Hz, 2H, H4, H5), 7.59 (s, 2H, H1,H8), 7.27 (d, J = 8.3 Hz, 2H, 
H3, H6), 3.23 (s, 4H, SCH2C=O), 3.02 (dd, J = 15.1, 6.6 Hz, 8H, ArCH2CH2S, ArCH2CH2S). 13C 
NMR (101 MHz, CDCl3) δ 175.2 (C=O), 137.7 (C2, C7), 133.7 (C9), 131.1 (C10), 128.0 (C4, 
C5), 126.8 (C3, C6), 126.7 (C1, C8), 35.7 (ArCH2CH2S), 34.1 (ArCH2CH2S), 33.7 (SCH2C=O). 
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2.1.6. Synthesis of compounds II.16a-b, II.42, II.17, II.18a-e and II.48 
 
2,2'-((1,3-phenylenebis(propane-3,1-diyl))bis(sulfanediyl))bis(N-(2-(dimethylamino) 
ethyl)acetamide) (II.16a)  
II.38 (75 mg, 0.22 mmol) was 
coupled with N,N-
dimethylethylenediamine (43 
µL,0.40 mmol) according to the 
general procedure E to afford II.16a as a salmon-coloured solid (75 mg, 78%). 1H NMR 
(400 MHz, CDCl3) δ 7.26 (bs, 2H, NH), 7.17 (t, J = 7.5 Hz, 1H, H5), 7.00 – 6.92 (m, 3H, H2, 
H4, H6), 3.32 (dd, J = 11.4, 5.8 Hz, 4H, NHCH2CH2NMe2), 3.20 (s, 4H, SCH2C=O), 2.65 (t, J 
= 7.4 Hz, 4H, ArCH2CH2CH2S), 2.53 (t, J = 7.4 Hz, 4H, ArCH2CH2CH2S), 2.39 (t, J = 5.8 Hz, 
4H, NHCH2CH2NMe2), 2.19 (s, 12H, CH3), 1.87 (quint, J = 7.4 Hz, 4H, ArCH2CH2CH2S). 13C 
NMR (101 MHz, CDCl3) δ 169.0 (C=O), 141.4 (C1, C3), 128.7 (C2), 128.6 (C5), 126.2 (C4, C6), 
57.8 (NHCH2CH2NMe2), 45.2 (CH3), 37.1 (NHCH2CH2NMe2), 36.1 (SCH2C=O), 34.7 
(ArCH2CH2CH2S), 32.4 (ArCH2CH2CH2S), 30.7 (ArCH2CH2CH2S). MS (ESI) m/z 483 [M+H]+. 
HRMS-ESI: m/z [M + H]+ calcd for C24H42N4O2S2: 483.2822, found: 483.2822. 
 
2,2'-((1,3-phenylenebis(propane-3,1-diyl))bis(sulfanediyl))bis(1-(4-methylpiperazin-1-
yl)ethanone) (II.16b) 
II.38 (75 mg, 0.22 mmol) was 
coupled with 1-methylpiperazine 
(44 µL,0.40 mmol) according to the 
general procedure E to afford II.16b 
as a coulorless oil (75 mg, 78%).  1H 
NMR (300 MHz, CDCl3) δ 7.19 (t, J = 7.8 Hz, 1H, H5), 7.03-6.97 (m, 3H, H2, H4, H6), 3.63 (t, 
J = 5.0 Hz, 4H, N(CH2CH2)NMe), 3.51 (t, J = 5.0 Hz, 4H, N(CH2CH2)NMe), 3.31 (s, 4H, 
SCH2C=O), 2.67 (dt, J = 14.6, 7.5 Hz, 8H, ArCH2CH2CH2S, ArCH2CH2CH2S), 2.44 (t, J = 5.0 
Hz,4H, N(CH2CH2)NMe), 2.37 (t, J = 5.0 Hz,4H, N(CH2CH2)NMe), 2.30 (s, 6H, CH3), 1.93 
(quint, J = 7.5 Hz, 4H, ArCH2CH2CH2S). 13C NMR (75 MHz, CDCl3) δ 167.9 (C=O), 141.6 (C1, 
C3), 128.8 (C2), 128.5 (C5), 126.2 (C4, C6), 55.1 (N(CH2CH2)NMe), 54.8 (N(CH2CH2)NMe), 
46.4 (N(CH2CH2)NMe), 46.1 (CH3), 41.8 (N(CH2CH2)NMe), 34.8 (ArCH2CH2CH2S), 33.4 
(SCH2C=O), 31.9 (ArCH2CH2CH2S), 30.9 (ArCH2CH2CH2S). MS (ESI) m/z 507 [M+H]+. Anal. 
Calcd for C26H43N4O2S2.0.25H2O: C, 61.07; H, 8.40; N, 10.96. Found: C, 61.02; H, 8.62; N, 
10.70.  
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2,2'-((naphthalene-2,7-diylbis(ethane-2,1-diyl))bis(sulfanediyl))bis(N-(2-
(dimethylamino)ethyl)acetamide) (II.17) 
 II.47 (75 mg, 0.22 mmol) 
was coupled with N,N-
dimethylethylenediamine 
(27 µL, 0.25 mmol) 
according to the general 
procedure E to afford II.17 as a brown oil (27 mg, 43%).1H NMR (400 MHz, CDCl3) δ 7.74 
(d, J = 9.1 Hz, 2H, H4, H5), 7.57 (s, 2H, H1, H8), 7.27 (d, J = 9.1 Hz, 2H, H3 and H6), 7.21 (bs, 
2H, NH), 3.34 (dd, J = 11.4, 5.8 Hz, 4H, NHCH2CH2NMe2), 3.25 (s, 4H, SCH2C=O), 3.04 (t, J 
= 7.6 Hz, 4H, ArCH2CH2S), 2.89 (t, J = 7.6 Hz, 4H, ArCH2CH2S), 2.41 (t, J = 5.8 Hz, 4H, 
NHCH2CH2NMe2), 2.22 (s, 12H, CH3). 13C NMR (101 MHz, CDCl3) δ 169.0 (C=O), 137.8 (C2, 
C7), 133.7 (C9), 131.1 (C10), 128.0 (C4, C5), 126.7 (C3, C6), 126.6 (C1, C8), 57.9 
(NHCH2CH2NMe2), 45.2 (CH3), 37.1 (NHCH2CH2NMe2), 36.3 (SCH2C=O), 35.9 (ArCH2CH2S), 
34.4 (ArCH2CH2S). MS (ESI) m/z 505 [M+H]+. HRMS-ESI: m/z [M + H]+ calcd for 
C26H41N4O2S2: 505.2665, found: 505.2662. 
 
2,2'-((Naphthalene-2,7-diylbis (propane-3,1-diyl))bis(sulfanediyl)) bis(N-(2-
(dimethylamino)ethyl)acetamide) (II.18a) 
 II.42 (75 mg, 0.19 
mmol) was coupled with 
N,N-
dimethylethylenediamine 
(38 µL, 0.35 mmol) 
according to the general procedure E to afford II.18a as a light yellow solid (62 mg, 67%). 
M.p. 93-95 oC. 1H NMR (400 MHz, CDCl3) δ 7.73(d, J = 8.4 Hz, 2H, H4, H5), 7.54 (s, 2H, H1, 
H8), 7.26 (d, J = 8.4 Hz, 4H, H3, H6, NH), 3.34 (dd, J = 11.2, 5.8 Hz, 4H, NHCH2CH2NMe2), 
3.24 (s, 4H, SCH2C=O), 2.87 (t, J = 7.4 Hz, 4H, ArCH2CH2CH2S), 2.59 (t, J = 7.4 Hz, 4H, 
ArCH2CH2CH2S), 2.40 (t, J = 5.8 Hz, 4H, NHCH2CH2NMe2), 2.21 (s, 12H, CH3), 2.07-1.95 (m, 
4H, ArCH2CH2CH2S). 13C NMR (101 MHz, CDCl3) δ 169.0 (C=O), 138.9 (C2, C7), 133.8 (C9), 
130.8 (C10), 127.9 (C4, C5), 126.7 (C3, C6), 126.2 (C1, C8), 57.9 (NHCH2CH2NMe2), 45.2 (CH3), 
37.2 (NHCH2CH2NMe2), 36.2 (SCH2C=O), 34.9 (ArCH2CH2CH2S), 32.4 (ArCH2CH2CH2S), 
30.6 (ArCH2CH2CH2S). MS (ESI) m/z 533 [M+H]+. Anal. Calcd for C28H44N4O2S2●0.25H2O: 
C, 62.65; H, 8.37; N, 10.44. Found: C, 62.27; H, 8.15; N, 10.20. 
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2,2'-((Naphthalene-2,7-diylbis (propane-3,1-diyl))bis(sulfanediyl)) bis(N-(2-
(diethylamino)ethyl)acetamide) (II.18b) 
 II.42 (100 mg, 0.25 
mmol) was coupled 
with N,N-
diethylethylenediamine 
(65 µL, 0.46 mmol) according to the general procedure E to afford II.18b as an orange 
oil (136 mg, 99%). 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 7.8 Hz, 2H, H4, H5), 7.53 (s, 2H, 
H1, H8), 7.44 (s, 2H, NH), 7.25 (d, J = 7.8 Hz, 2H, H3, H6), 3.31 (dd, J = 11.2, 5.6 Hz, 4H, 
NHCH2CH2NEt2), 3.23 (s, 4H, SCH2C=O), 2.85 (t, J = 7.4 Hz, 4H, ArCH2CH2CH2S), 2.69 – 
2.43 (m, 16H, ArCH2CH2CH2S, NHCH2CH2NEt2, NCH2CH3), 2.03 – 1.96 (m, 4H, 
ArCH2CH2CH2S), 1.00 (t, J = 7.0 Hz, 12H, NCH2CH3). 13C NMR (101 MHz, CDCl3) δ 168.9 
(C=O), 138.9 (C2, C7), 133.8 (C9), 130.8 (C10), 127.9 (C4, C5), 126.7 (C3, C6), 126.3 (C1, C8), 
51.4 (NHCH2CH2NEt2), 46.8 (NCH2CH3), 37.2 (NHCH2CH2NEt2), 36.3 (SCH2C=O), 35.0 
(ArCH2CH2CH2S), 32.5 (ArCH2CH2CH2S), 30.7 (ArCH2CH2CH2S), 11.9 (NCH2CH3). MS (ESI) 
m/z 589 [M+H]+  
 
2,2'-((Naphthalene-2,7-diylbis (propane-3,1-diyl))bis (sulfanediyl))bis(N-(3-
(diethylamino)propyl)acetamide) (II.18c) 
 II.42 (75 mg, 0.19 
mmol) was coupled 
with 3-
(diethylamino)propylamine (55 µL, 0.35 mmol) according to the general procedure E to 
afford II.18c as an orange oil (64 mg, 59%). 1H NMR (400 MHz, CDCl3) δ 7.94 (bs, 2H, NH), 
7.72 (d, J = 8.2 Hz, 2H, H4, H5), 7.53 (s, 2H, H1, H8), 7.25 (d, J = 8.2 Hz, 2H, H3, H6), 3.33 
(dd, J = 12.0, 6 Hz, 4H, NHCH2CH2CH2NEt2), 3.20 (s, 4H, SCH2C=O), 2.85 (t, J = 7.6 Hz, 4H, 
ArCH2CH2CH2S), 2.53 (m, 16H, ArCH2CH2CH2S, NHCH2CH2CH2NEt2, NCH2CH3), 1.98 (m, 
4H, ArCH2CH2CH2S), 1.63 (m, 4H, NHCH2CH2CH2NEt2), 1.02 (t, J = 7.1 Hz, 12H, NCH2CH3). 
13C NMR (101 MHz, CDCl3) δ 169.0 (C=O), 138.9 (C2, C7), 133.8 (C9), 130.8 (C10), 127.9 (C4, 
C5), 126.7 (C3, C6), 126.3 (C1, C8), 51.9 (NHCH2CH2CH2NEt2), 46.9 (NCH2CH3), 39.8 
(NHCH2CH2CH2NEt2), 36.3 (SCH2C=O), 35.0 (ArCH2CH2CH2S), 32.5 (ArCH2CH2CH2S), 30.6 
(ArCH2CH2CH2S), 26.0 (NHCH2CH2CH2NEt2), 11.5 (NCH2CH3). MS (ESI) m/z 617 [M+H]+ 
HRMS-ESI: m/z [M + H]+ calcd for C34H57N4O2S2: 617.3917, found: 617.3917. 
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2,2'-((naphthalene-2,7-diylbis(propane-3,1-diyl))bis(sulfanediyl))bis(1-(4-methyl 
piperazin-1-yl)ethanone) (II.18d) 
 II.42 (100 mg, 0.25 mmol) was 
coupled with 1-methylpiperazine 
(51 µL, 0.46 mmol) according to 
the general procedure E to afford 
II.18d as an white solid (120 mg, 
93%). 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.4 Hz, 2H, H4, H5), 7.57 (s, 2H, H1, H8), 7.29 
(d, J = 8.4 Hz, 2H, H3, H6), 3.64 (s, 4H, N(CH2CH2)NMe), 3.56 – 3.50 (m, 4H, 
N(CH2CH2)NMe), 3.34 (s, 4H, SCH2C=O), 2.89 (t, J = 7.6 Hz, 4H, ArCH2CH2CH2S), 2.70 (t, J 
= 7.2 Hz, 4H, ArCH2CH2CH2S), 2.48 – 2.41 (m, 4H, N(CH2CH2)NMe), 2.40 – 2.35 (m, 4H, 
N(CH2CH2)NMe), 2.31 (s, 6H, CH3), 2.10 – 2.01 (m, 4H, ArCH2CH2CH2S). 13C NMR (101 
MHz, CDCl3) δ 167.9 (C=O), 139.1 (C2, C7), 133.9 (C9), 130.8 (C10), 127.8 (C4, C5), 126.8 (C3, 
C6), 126.3 (C1, C8), 55.2 (N(CH2CH2)NMe), 54.8 (N(CH2CH2)NMe) 46.5 (N(CH2CH2)NMe), 
46.1 (NCH3), 41.86 (N(CH2CH2)NMe), 35.0 (ArCH2CH2CH2S), 33.5 (SCH2C=O), 31.9 
(ArCH2CH2CH2S), 30.73 (ArCH2CH2CH2S). MS (ESI) m/z 557 [M+H]+. HRMS-ESI: m/z [M + 
H]+ calcd for C30H44N4O2S2: 557.2977, found: 557.2978. 
 
2,2'-((Naphthalene-2,7-diylbis (propane-3,1-diyl))bis (sulfanediyl))bis(N-(2-
morpholinoethyl)acetamide) (II.18e)  
 II.42 (75 mg, 0.19 mmol) 
was coupled with 4-(2-
aminoethyl)morpholine 
(46 µL, 0.35 mmol) 
according to the general 
procedure E to afford II.18e as an orange oil (107 mg, 100%). 1H NMR (400 MHz, CDCl3) 
δ 7.70 (d, J = 8.4 Hz, 2H, H4, H5), 7.50 (s, 2H, H1, H8), 7.31 (s, 2H, NH), 7.22 (d, J = 8.4 Hz, 
2H, H3, H6), 3.61 (s, 8H, N(CH2CH2)2O), 3.32 (dd, J = 6, 11.2 Hz, 4H, NHCH2CH2NEt2O), 3.21 
(s, 4H, SCH2C=O), 2.83 (t, J = 7.4 Hz, 4H, ArCH2CH2CH2S), 2.55 (t, J = 7.2 Hz, 4H, 
ArCH2CH2CH2S), 2.41 (t, J = 6 Hz, 4H, NHCH2CH2NEt2O), 2.36 (s, 8H, N(CH2CH2)2O), 1.97 
(m, 4H, ArCH2CH2CH2S). 13C NMR (101 MHz, CDCl3) δ 168.8 (C=O), 138.7 (C2, C7), 133.7 
(C9), 130.7 (C10), 127.8 (C4, C5), 126.6 (C3, C6), 126.1 (C1, C8), 66.9 (N(CH2CH2)2O), 56.8 
(NHCH2CH2NEt2O), 53.2 (N(CH2CH2)2O), 36.1 (SCH2C=O), 35.9 (NHCH2CH2NEt2O), 34.8 
(ArCH2CH2CH2S), 32.3 (ArCH2CH2CH2S), 30.6 (2xArCH2CH2CH2S). MS (ESI) m/z 617 
[M+H]+. HRMS-ESI: m/z [M + H]+ calcd for C32H49N4O4S2: 617.3190, found: 617.3187. 
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N-(2-(dimethylamino)ethyl)-2-((3-(7-hydroxynaphthalen-2-yl)propyl)thio)acetamide 
(II.48) 
 II.45 (37 mg, 0.13 mmol) was coupled 
with N,N-dimethylethylenediamine (12 
µL, 0.12 mmol) according to the slightly 
modified general procedure E (where 
only 1.1 equiv. of TBTU, 1 equiv. of 
DIPEA and 1 equiv. of amine was used) to afford II.48 as an off-white solid (23 mg, 55%). 
M.p. > 320 oC; 1H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H, H1), 7.92 (d, J = 8.4 Hz, 1H, H4), 
7.82 (d, J = 8.4 Hz, 2H, H3, H5), 7.70 (s, 1H, H8), 7.33 (d, J = 8.4 Hz, 1H, H6), 7.26 (s, 1H, 
NH), 3.34 (dd, J = 11.3, 5.6 Hz, 2H, NHCH2CH2NMe2), 3.25 (s, 2H, SCH2C=O), 2.91 (t, J = 
7.4 Hz, 2H, ArCH2CH2CH2S), 2.61 (t, J = 7.2 Hz, 2H, ArCH2CH2CH2S), 2.40 (t, J = 5.9 Hz, 2H, 
NHCH2CH2NMe2), 2.23 (s, 6H, CH3), 2.08 – 1.99 (m, 2H, ArCH2CH2CH2S). 13C NMR (101 
MHz, CDCl3) δ 169.1 (C=O), 139.3 (C7), 138.8 (C2), 134.0 (C9), 131.4 (C10), 128.4 (C4), 128.0 
(C5), 127.5 (C6), 127.1 (C8), 125.8 (C1), 125.3 (C3), 57.9 (NHCH2CH2NMe2), 45.2 (CH3), 37.1 
(NHCH2CH2NMe2), 36.3 (SCH2C=O), 35.0 (ArCH2CH2CH2S), 32.5( ArCH2CH2CH2S), 30.6 
(ArCH2CH2CH2S). HRMS-ESI: m/z [M + K]+ calcd for C19H26N2O2SK: 384.1506, found: 
384.1516. 
 
2.1.7. Synthesis of compounds II.51, II.19 and II.20 
 
4,4'-(naphthalene-2,7-diyl)diphenol (II.51) 
 To a solution of 2,7-dibromonaphthalene II.35 
(100 mg, 0.35 mmol, 1 equiv.) in 1,4-dioxane 
(0.1 M) at rt were added phenylboronic acid 
II.52 (125 mg, 0.91 mmol, 2.6 equiv.), 1 M 
aqueous Na2CO3 (6 equiv.) and 
bis(triphenylphosphine)palladium(II) dichloride 
(10 mol%). After degassing during 5 min, the 
reaction mixture was stirred at 80 oC o/n before being cooled to rt, diluted with EtOAc 
and filtered through a pad of celite. The filtrate was concentrated under reduced 
pressure and the crude product was purified by preparative TLC (tolune/EtOH, 9:1) to 
afford compound II.51 (93 mg, 85%) as a off-white solid. M.p. 245-247 oC; 1H NMR (400 
MHz, MeOD) δ 8.03 (s, 2H, H1, H8), 7.87 (d, J = 8.4 Hz, 2H, H4, H5), 7.68 (d, J = 8.4 Hz, 2H, 
H3, H6), 7.61 (d, J = 8.4 Hz, 4H, H2’, H6’), 6.91 (d, J = 8.4 Hz, 2H, H3’, H5’). 13C NMR (101 
MHz, MeOD) δ 158.3 (C-OH), 140.1 (C2, C7), 135.7 (C9), 133.7 (C1’), 132.5 (C10), 129.3 (C2’, 
C6’), 129.0 (C4, C5), 125.9 (C3, C6), 125.7 (C1, C8), 116.7 (C3’, C5’). MS (ESI) m/z 352 [M+K]+. 
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2,2'-((naphthalene-2,7-diylbis(4,1-phenylene)) bis(oxy))bis(N,N-diethylethanamine) 
(II.19) 
To a suspension of alcohol 
II.51 (43 mg, 0.14 mmol, 1 
equiv.) in dry acetone 
(0.075 M) was added K2CO3 
(3 equiv.) and 2-chloro-N,N-
diethylethylamine 
hydrochloride (142 mg, 0.84 mmol, 6 equiv.) was added. The reaction mixture was 
stirred at reflux o/n. Reaction solvent was evaporated, EtOAc was added to the reaction 
mixture and the organic phase was washed with water. The aqueous phased was 
basified with NaOH 1N and extracted again with EtOAc. The combined organic phases 
were washed with water, brine and dried with anhydrous Na2SO4. The solvent was 
removed under reduced pressure and the crude product was purified by alumina 
preparative TLC (EtOAc/MeOH, 9:1) to afford compound II.19 as yellow-pale solid (16 
mg, 22%). M.p. 88-89 oC; 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 2H, H1, H8), 7.88 (d, J = 8.4 
Hz, 2H, H4, H5), 7.71 – 7.62 (m, 6H, H3, H6. H2’, H6’), 7.03 (d, J = 8.4 Hz, 4H, H3’, H5’), 4.13 
(t, J = 6.4 Hz, 4H, OCH2CH2N(Et)2), 2.93 (t, J = 6.4 Hz, 4H, OCH2CH2N(Et)2 ), 2.68 (q, J = 7.2 
Hz, 8H, CH2CH3), 1.11 (t, J = 7.2 Hz, 12H, CH2CH3). 13C NMR (101 MHz, CDCl3) δ 158.7 
(COCH2CH3N), 138.7 (C2, C7), 134.2 (C9), 133.7 (C1’), 131.3 (C10), 128.5 (C2’, C6’), 128.2 (C4, 
C5), 125.4 (C3, C6), 125.3 (C1, C8), 115.07 (C3’, C5’), 66.7 (OCH2CH2N), 51.9 (OCH2CH2N), 
48.0 (NCH2CH3), 11.9 (NCH2CH3). MS (ESI) m/z 511 [M+H]+. HRMS-ESI: m/z [M + K]+ calcd 
for C34H43N2O2: 511.3319, found: 511,3316. 
 
2,7-bis(4-(quinolin-3-yloxy)phenyl)naphthalene (II.20) 
Pyridine (5 equiv.) was 
added to a solution of 
II.51 (70 mg, 0.22 
mmol, 1 equiv.), 3-
quinolineboronic acid 
pinacol ester (172 mg, 
0.66 mmol, 3 equiv.), 
copper(II) acetate (1.0 equiv.), and powdered 4 A molecular sieves in dry DCM (0.1 M). 
The reaction mixture was then stirred at room temperature during 24 hours at room 
temperature. After completion, was diluted in DCM and filtered through a pad of celite. 
The solvent was removed under reduced pressure and the crude product was purified 
by preparative TLC (hexane/EtOAc, 7:3) to afford II.20 (15 mg, 12%) as a white solid.  1H 
NMR (300 MHz, CDCl3) δ 8.88 (d, J = 2.7 Hz, 2H, Hb), 8.13 (m, 4H, H1, H4, H5, H8), 7.97 (d, 
 
158       
J = 8.6 Hz, 2H, Hg), 7.74 (m, 8H, H2’, H6’, Hd, Hf), 7.67 – 7.62 (m, 4H, H3, H6, Hh), 7.55 (dd, 
J = 11.6, 4.6 Hz, 2H, He), 7.25 – 7.20 (d, J = 8.7 Hz, 4H, H3’, H5’). 
 
2.2. Synthesis of compounds described in Chapter III 
 
2.2.1. General methods 
 
General procedure F for the nucleophilic aromatic substitution. To a solution of ethyl 
6-bromo-4-chloroquinoline-3-carboxylate (1 equiv.) in dry 1,4-dioxane (0.2 M) at rt was 
added the amine (1.1 to 3.1 equiv.). The resulting solution was stirred at 110 oC in a 
sealed tube under nitrogen atmosphere for 12 h. After completion of the reaction, the 
reaction mixture was cooled to rt and 1 N aqueous NaOH was added to neutralise the 
solution, followed by dilution with water (pH ~ 8) and extraction with EtOAc.  The 
combined organic phases were washed with water, brine and dried with anhydrous 
Na2SO4. The solvent was removed under reduced pressure to afford the desired 
compounds. 
 
General procedure G for ester reduction. To a solution of ester (1 equiv.) in dry THF 
(0.1 M) at 0 oC was added LiAlH4 (1.2 to 3 equiv.). The reaction mixture was stirred at rt 
during 1 h. After completion of the reaction, the reaction was quenched with 5% 
aqueous KHSO4. The aqueous mixture was extracted with EtOAc and the combined 
organic phases were washed with water, brine and dried with anhydrous Na2SO4. The 
solvent was removed under reduced pressure. The crude product was purified by flash 
column chromatography. 
 
General procedure H for alcohol oxidation and Horner-Wadsworth-Emmons 
reaction. To a solution of alcohol (1 equiv.) in dry DMF (0.1 M) at room temperature was 
added IBX (1.5 equiv.) and TFA (1.5 equiv.). The reaction mixture was then stirred, at 
room temperature under N2 atmosphere, during 3 h before being diluted with EtOAc. 
The organic phase was washed with 5% aqueous NaHCO3, water, brine and dried with 
anhydrous Na2SO4. The solvent was evaporated under reduced pressure and the crude 
aldehyde was used in the next step without further purification. To a solution of 
aldehyde in dry ethanol (0.2 M), at room temperature in a sealed tube, was added K2CO3 
(3 equiv.) and triethyl phosphonoacetate (1.2 equiv.). The reaction mixture was stirred 
at 100 oC o/n under nitrogen atmosfere before being cooled to room temperature and 
all volatiles were removed under reduced pressure. The crude mixture was dissolved in 
EtOAc and the organic phase was consecutively washed with 5% aqueous KHSO4, water, 
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brine and dried with anhydrous Na2SO4. The solvent was removed under reduced 
pressure and the crude Z-alkene was used in the next step without further purification. 
To a solution of the Z-alkene in dry ethanol (0.2 M), at room temperature in a sealed 
tube, was added K2CO3 (3 equiv.). The reaction mixture was stirred at 120 oC o/n under 
nitrogen atmosfere before being cooled to room temperature and all volatiles were 
removed under reduced pressure. The crude mixture was dissolved in EtOAc and the 
organic phase was consecutively washed with 5% aqueous KHSO4, water, brine and 
dried with anhydrous Na2SO4. The solvent was removed under reduced pressure and 
the crude product was purified to afford the desired compounds. 
 
General procedure I for Buchwald-Hartwig reaction. To a solution of bromide (1 
equiv.) in dioxane (0.1 M) at rt were added amine (1.6 equiv.), K2CO3 (10 equiv.), 
palladium(II) acetate (10 mol%) and xantphos (0.2 equiv.). After degassing during 5 min, 
the reaction mixture was stirred at 120 oC o/n before being cooled at rt, diluted in EtOAc 
and filtered through a pad of celite. The filtrate was concentrated under reduced 
pressure and the crude product was purified to afford the desired compounds. 
 
General procedure J for N-methylation. To a suspension of III.24 or III.25 (1 equiv.) in 
dry toluene (0.5 M), ethyl trifluoromethanesulfonate (6 equiv.) was added dropwise 
under N2 atmosphere. The reaction mixture was stirred at rt during 48 h. MeOH was 
added to the reaction mixture and the solvent was removed under reduced pressure. 
Then, Et2O was added to the crude product and the precipitate was filtered using a 
Büchner funnel to afford the desired compounds. 
2.2.2. Synthesis of compound III.9 
 
Diethyl {[(4-bromophenyl)amino]methylene}malonate (III.7) 
4-bromoaniline III.5 (3.00 g, 17.4 mmol, 1 equiv.) and 
diethyl(2-ethoxymethylene)malonate III.6 (4.30 mL, 
21.0 mmol, 1.2 equiv.) reacted in a sealed tube at 115 
oC during 1.5 h. After cooling to room temperature, 
EtOAc was added to the reaction. The precipitate was 
filtered using a Büchner funnel and dried to afford III.7 
(5.89 g, 99%) as a white solid. M.p. 100-102 oC; 1H NMR 
(300 MHz, CDCl3) δ 11.03 (d, J = 13.0 Hz, 1H, NH), 8.48 (d, J = 13.0 Hz, 1H, 
NCHCH(CO2Et)2), 7.49 (d, J = 8.8 Hz, 2H, H2, H6), 7.5 (d, J = 8.8 Hz, 2H, H3, H5), 4.42-4.22 
(m, 4H, CH2), 1.45-1.26 (m, 6H, CH3). Analytical date were in agreement with those 
already published.557 
Ethyl 6-bromo-4-hydroxyquinoline-3-carboxylate (III.8)  
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III.7 (5.33 g, 15.6 mmol, 1 equiv.) was added to diphenyl 
ether (31 mL). The mixture was refluxed for 2 h and then 
allowed to cool to room temperature. Hexane was added 
to th reaction mixture, and the precipite was filtered under 
vacuum and dried to afford III.8 (3.70 g, 80%) as a white 
solid. M.p. > 320 oC; 1H NMR (400 MHz, DMSO-d6) δ 8.59 (s, 
1H, H2), 8.23 (d, J = 2.1 Hz, 1H, H5), 7.61 (d, J = 8.2 Hz, 1H, H8), 7.01 (dd, J = 8.2, 2.1 Hz, 
1H, H7), 4.23 (q, J = 7.1 Hz, 2H, CH2), 1.28 (t, J = 7.1 Hz, 3H, CH3). Analytical date were in 
agreement with those already published.187 
 
Ethyl 6-bromo-4-chloroquinoline-3-carboxylate (III.9) 
POCl3 (3.6 mL) was added dropwise to III.8 (1.50 g, 5.07 
mmol, 1 equiv.) under an nitrogen atmosphere at 0 oC. The 
reaction mixture reacted in a sealed tube at 115 oC during 2 
h. Then it was cooled to room temperature and carefully 
poured onto ice. Under agitation, NH3 25% was added until 
pH = 7. The aqueos phase was extracted with DCM. The organic phase was washed with 
brine and dried with anhydrous Na2SO4. The solvent was removed under reduced 
pressure to afford III.9 (1.59 g, 100%) as a light yellow solid. 1H NMR (500 MHz, CDCl3) δ 
9.21 (s, 1H, H2), 8.47 (d, 1.5 Hz, 1H, H5), 8.02 (d, 9.0 Hz, 1H, H8), 7.95 (dd, 1.5 Hz, 9.0 Hz, 
1H, H7), 4.40 (q, 7.0 Hz, 2H, CH2), 1.60 (t, 7.0 Hz, 3H, CH3). 
 
2.2.3. Synthesis of compound III.11 
 
1-(4-nitro-2-(trifluoromethyl)phenyl)piperazine (III.14)  
Piperazine III.13 (494 mg, 5.74 mmol, 2 equiv.) was 
added to a mixture of 2-fluoro-5-nitrobenzotrifluoride 
III.12 (394 µL, 2.87 mmol, 1 equiv.) and potassium 
carbonate (1.5 equiv.) in DMSO (1 M). The reaction 
mixture was stirred o/n at 90 oC. After completion of the 
reaction, the mixture was diluted with EtOAc and the organic phase was washed with 
water and brine and dried with anhydrous Na2SO4. The solvent was removed under 
reduced pressure to afford compound III.14 (757 mg, 96%) as orange oil. 1H NMR (400 
MHz, CDCl3) δ 8.51 (d, J = 2.0 Hz, 1H, H3’), 8.33 (dd, J = 8.8, 2.0 Hz, 1H, H5’), 7.29 (d, J = 
8.8 Hz, 1H, H6’), 3.13 (d, J = 3.0 Hz, 4H, CH2), 3.07 (d, J = 3.0 Hz, 4H, CH2). 13C NMR (101 
MHz, CDCl3) δ 157.3 (C1’), 142.2 (C4’), 128.0 (CH5’), 124.7 (C3’), 124.6 (CF3),  122.5 (C6’), 
121.9 (C2’), 53.8 (CH2), 45.9 (CH2). 
tert-butyl 4-(4-nitro-2-(trifluoromethyl)phenyl)piperazine-1-carboxylate (III.15) 
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To a solution of III.14 (700 mg, 2.54 mmol, 1 equiv.) and 
DMAP (0.1 equiv) in dry THF (0.2 M), was added Boc2O 
(876 µL, 3.82 mmol, 1.5 equiv.) under a nitrogen 
atmosphere. The reaction mixture was stirred o/n at rt. 
After evaporation of the solvent, EtOAc was added and 
the organic phase was washed with 1N aqueous HCl, brine and dried with anhydrous 
Na2SO4. The solvent was removed under reduced pressure to afford compound III.15 
(897 mg, 94%) as an orange solid. M.p. 100-102 oC ;1H NMR (400 MHz, CDCl3) δ 8.52 (s, 
1H, H3’), 8.35 (d, J = 8.8 Hz, 1H, H5’), 7.29 (d, J = 8.8 Hz, 1H, H6’), 3.60 (s, 4H, CH2), 3.05 (s, 
4H, 2xCH2), 1.48 (s, 9H, Boc). Analytical date were in agreement with those already 
published.558 
 
tert-butyl 4-(4-amino-2-(trifluoromethyl)phenyl)piperazine-1-carboxylate (III.11) 
 A solution of III.15 (850 mg, 2.26 mmol, 1 equiv.) in 
MeOH/EtOAc (1:1, 0.1 M) was treated with 15% Pd/C 
(10% w/w). The reaction was stirred o/n under an H2 at 
atmospheric pressure and rt. After completion of the 
reaction, the mixture was filtered through a celite bed. 
The solvent was removed under reduced pressure to afford compound III.10 (762 mg, 
97%).  as a light yellow solid. M.p. 140-142 oC; 1H NMR (400 MHz, CDCl3) δ 7.13 (d, J = 
8.4 Hz, 1H, H6), 6.91 (s, 1H, H3’), 6.79 (d, J = 8.4 Hz, 1H, H5’), 3.76 (s, 2H, NH2), 3.51 (s, 4H, 
CH2), 2.76 (s, 4H, CH2), 1.48 (s, 9H, Boc). Analytical date were in agreement with those 
already published.558 
 
2.2.4. Synthesis of compounds III.16, III.17 and III.18 
 
Ethyl 6-bromo-4-((4-(4-(tert-butoxycarbonyl)piperazin-1-yl)-3-
(trifluoromethyl)phenyl)amino)quinoline-3-carboxylate (III.16) 
 III.9 (1.27 g, 4.04 mmol) was coupled with III.11 
(1.47 g, 4.25 mmol, 1.1 equiv.) under the conditions 
described in general procedure F to afford III.16 as 
a light yellow solid (1.63 g, 65%). M.p. 162-164 oC; 
1H NMR (400 MHz, CDCl3) δ 10.50 (s, 1H, NH), 9.27 
(s, 1H, H2), 7.88 (d, J = 8.6 Hz, 1H, H8), 7.71 (d, J = 
8.6 Hz, 1H, H7), 7.62 (s, 1H, H5), 7.35 (s, 1H, H2’), 7.28 
(d, J = 8.8 Hz, 1H, H5’), 7.13 (d, J = 8.8 Hz, 1H, H6’), 
4.45 (q, J = 6.9 Hz, 2H, CH3), 3.56 (s, 4H, CH2Ppz), 2.86 
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(s, 4H, CH2Ppz), 1.47 (m, 12H, CH2CH3, Boc). Analytical date were in agreement with those 
already published.559 
 
Ethyl 6-bromo-4-((4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)amino)quinoline-3-
carboxylate (III.19)  
III.19 was obtained as minor product of the previous 
reaction. The aqueous phase was acidified until pH 
~ 6 and further extracted with EtOAc. The solvent 
was removed under reduced pressure to afford 
III.19 as a yellow solid (359 mg, 17%). M.p. 240-242 
oC;  1H NMR (300 MHz, CDCl3) δ 10.48 (s, 1H, Quin-
NH-Ph), 9.26 (s, 1H, H2), 7.88 (d, J = 8.9 Hz, 1H, H8), 
7.71 (dd, J = 8.9, 2.1 Hz, 1H, H7), 7.61 (d, J = 2.1 Hz, 
1H, H5), 7.35-7.25 (m, 2H, H2’, H5’), 7.14 (dd, J = 8.4, 2.3 Hz, 1H, H6’), 4.44 (q, J = 7.1 Hz, 
2H, CH2CH3), 3.21 (s, 4H, CH2Ppz), 3.09 (s, 4H, CH2Ppz), 1.45 (t, J = 7.1 Hz, 3H, CH3).13C NMR 
(75 MHz, CDCl3) δ 168.2 (C=O), 151.7 (C2), 151.0 (C4),149.6 (C8a), 148.3 (C4’), 139.7 (C1’), 
134.8 (C7), 132.0 (C8), 129.0 (C3’), 128.7 (C5), 126.2 (C6’), 125.6 (C2’), 121.6 (CF3), 121.1 
(C5’), 120.4 (C4a), 118.7 (C6), 107.9 (C3), 61.8 (CH2CH3), 52.4 (CPpz), 45.1 (CPpz), 14.4 (CH3). 
MS (ESI) m/z 523 [M+H]+.  
 
Ethyl 6-bromo-4-(methylamino)quinoline-3-carboxylate (III.17) 
III.9 (1.59 g, 5.05 mmol) was coupled with a methylamine 
solution 2.0 M in methanol (4.10 mL, 10.36 mmol, 2.1 
equiv.) under the conditions described in general 
procedure F to afford III.17 as a light yellow solid (1.54 g, 
99%). Mp 113-116 oC; 1H NMR (300 MHz, CDCl3) δ 9.45 (s, 
1H, NH), 9.04 (s, 1H, H2), 8.43 (d, J = 1.9 Hz, 1H, H5), 7.78 (d, 
J = 8.9 Hz, 1H, H8), 7.69 (dd, J = 8.9, 1.9 Hz, 1H, H7), 4.36 (q, J = 7.1 Hz, 2H, CH2CH3), 3.47 
(d, J = 5.6 Hz, 3H, NHCH3), 1.40 (t, J = 7.1 Hz, 3H, CH2CH3). 13C NMR (75 MHz, CDCl3) δ 
168.9 (C=O), 156.4 (C4), 152.0 (C2), 150.0 (C8a), 134.2 (C7), 131.7 (C8), 128.5 (C5), 120.6 
(C4a), 117.2 (C6), 102.9 (C3), 60.9 (CH2CH3), 35.5 (NHCH3), 14.4 (OCH2CH3). MS (ESI) m/z 
309 and 310 [M+H]+. 
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Ethyl 6-bromo-4-((2-(dimethylamino)ethyl)amino)quinoline-3-carboxylate (II.18) 
 III.9 (1.59 g, 5.05 mmol) was coupled with N,N-
dimethylethylenediamine (1.93 mL, 17.69 mmol, 3.5 
equiv.) under the conditions described in general 
procedure F to afford III.18  as light yellow solid (1.75 g, 
95%). M.p. 119-122 oC; 1H NMR (300 MHz, CDCl3) δ 9.42 
(s, 1H, NH), 9.06 (s, 1H, H2), 8.37 (d, J = 1.7 Hz, 1H, H5), 7.79 
(d, J = 8.9 Hz, 1H, H8), 7.70 (dd, J = 8.9, 1.7 Hz, 1H, H7), 4.38 
(q, J = 7.1 Hz, 2H, CH2CH3), 3.84 (dd, J = 10.9, 5.8 Hz, 2H, NCH2CH2NMe2), 2.61 (t, J = 6.0 
Hz, 2H NCH2CH2NMe2), 2.35 (s, 6H, N(CH3)2), 1.41 (t, J = 7.1 Hz, 3H, CH2CH3). 13C NMR 
(75 MHz, CDCl3) δ 168.3 (C=O), 155.7 (C4), 152.2 (C2), 149.9 (C8a), 134.2 (C7), 131.6 (C8), 
128.5 (C5), 121.0 (C4a), 117.2 (C6), 103.6 (C3), 60.9 (CH2CH3), 59.4 (NCH2CH2NMe2), 46.6 
(NCH2CH2NMe2), 45.5 (N(CH3)2), 14.5 (CH2CH3). MS (ESI) m/z 366 and 368 [M+H]+. 
 
2.2.5. Synthesis of compounds III.20, III.21 and III.22 
 
Tert-butyl 4-(4-((6-bromo-3-(hydroxymethyl)quinolin-4-yl)amino)-2-
(trifluoromethyl)phenyl)piperazine-1-carboxylate (III.20)  
 III.16 (1.63 g, 2.62 mmol) was treated with LiAlH4 
(298 mg, 7.85 mmol, 3 equiv.) under the conditions 
described in the general procedure G. The crude 
product was purified by flash column 
chromatography (hexane/EtOAc, 7:3) to afford 
III.20 as a yellow solid (941 mg, 62%). M.p. 202-204 
oC. 1H NMR (300 MHz, CDCl3) δ 8.58 (s, 1H, H2), 7.89 
(d, J = 9.0 Hz, 1H, H8), 7.80 (d, J = 2.1 Hz, 1H, H5), 
7.69 (dd, J = 9.0, 2.1 Hz, 1H, H7), 7.49 (s, 1H, NH), 
7.16 (d, J = 8.6 Hz, 1H, H5’), 7.12 (d, J = 2.6 Hz, 1H, H2’), 6.81 (dd, J = 8.6, 2.6 Hz, 1H, H6’), 
4.81 (s, 2H, CH2OH), 3.53 (s, 4H, CH2Ppz), 2.85 – 2.73 (m, 4H, CH2Ppz), 1.47 (s, 9H, Boc).   
 
(6-bromo-4-(methylamino)quinolin-3-yl)methanol (III.21) 
III.17 (1.53 g, 4.94 mmol) was treated with LiAlH4 (281 mg, 
7.40 mmol, 1.5 equiv.) under the conditions described in the 
general procedure G. The crude product was purified by flash 
column chromatography (EtOAc/MeOH, 95:5) to afford III.21 
as a yellow solid (975 mg, 74%). M.p. 182-184 oC. 1H NMR 
(300 MHz, CDCl3) δ 8.41 (s, 1H, H2), 8.38 (d, J = 2.1 Hz, 1H, H5), 7.76 (d, J = 8.9 Hz, 1H, H8), 
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7.68 (dd, J = 8.9, 2.1 Hz, 1H, H7), 6.32 (br s, 1H, NH), 4.82 (s, 2H, CH2OH), 3.41 (d, J = 5.4 
Hz, 3H, CH3). 
 
(6-bromo-4-((2-(dimethylamino)ethyl)amino)quinolin-3-yl)methanol (III.22) 
III.18 (1.74 g, 4.76 mmol) was treated with LiAlH4 (217 mg, 
5.71 mmol, 1.2 equiv.) under the conditions described in 
the general procedure G to afford the compound III.22 as a 
light yellow solid (1.49 g, 96%). M. p.: 103-105 oC.1H NMR 
(300 MHz, CDCl3) δ 8.49 (s, 1H, H2), 8.17 (d, J = 2.2 Hz, 1H, 
H5), 7.85 (d, J = 9.0 Hz, 1H, H8), 7.68 (dd, J = 9.0, 2.2 Hz, 1H 
H7), 5.08 (s, 1H, NH), 4.80 (d, J = 3.4 Hz, 2H, CH2OH), 3.69 
(dd, J = 11.1, 5.5 Hz, 2H, NCH2CH2NMe2), 2.50 (t, J = 5.5 Hz, 
2H, NCH2CH2NMe2), 2.17 (s, 6H, N(CH3)2). 13C NMR (75 MHz, CDCl3) δ 152.1 (C2), 151.4 
(C4), 148.1 (C8a), 132.5 (C7), 131.5 (C8), 126.0 (C5), 122.7 (C4a), 119.4 (C3), 118.5 (C6), 60.92 
(CH2OH), 59.42 (NCH2CH2NMe2), 45.73 (NCH2CH2NMe2), 44.85 (N(CH3)2).  
 
2.2.6. Synthesis of compounds III.23, III.24 and III.25 
 
Tert-butyl 4-(4-(9-bromo-2-oxobenzo[h][1,6]naphthyridin-1(2H)-yl)-2-
(trifluoromethyl)phenyl)piperazine-1-carboxylate (III.23) 
To a solution of III.20 (385 mg, 0.66 mmol) in dry DMF 
(0.1 M) at rt was added IBX (241 mg, 0.86 mmol, 1.3 
equiv.). The reaction mixture was then stirred, at rt 
under nitrogen atmosphere, during 3 h before being 
diluted with EtOAc. The organic phase was washed 
with 5% aqueous NaHCO3, water, brine and dried with 
anhydrous Na2SO4. The solvent was evaporated under 
reduced pressure and the crude aldehyde was used in 
the next step without further purification. To a 
solution of aldehyde in dry ethanol (0.1 M), at rt in a sealed tube, was added K2CO3 (3 
equiv.) and triethyl phosphonoacetate (1.2 equiv.). The reaction mixture was stirred at 
100 oC o/n before being cooled to rt and all volatiles were removed under reduced 
pressure. The crude mixture was dissolved in EtOAc and the organic phase was 
consecutively washed with 5% aqueous KHSO4, water, brine and dried with anhydrous 
Na2SO4. The solvent was removed under reduced pressure to afford compound III.23 as 
a light yellow solid (349 mg, 87% over 2 steps). M.p. 223-235 oC; 1H NMR (300 MHz, 
CDCl3) δ 8.98 (s, 1H, H14), 8.02 – 7.94 (m, 2H, H4, H11), 7.69 (dd, J = 8.9, 2.1 Hz, 1H, H10), 
7.61 (d, J = 8.5 Hz, 1H, H5’), 7.58 (d, J = 2.4 Hz, 1H, H2’), 7.53 (dd, J = 8.5, 2.4 Hz, 1H, H6’), 
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6.97 (d, J = 9.5 Hz, 1H, H3), 6.67 (d, J = 2.1 Hz, 1H, H8), 3.64 (s, 4H, CH2Ppz), 3.11 – 2.97 (m, 
4H, CH2Ppz), 1.50 (s, 9H, Boc).  
 
9-bromo-1-methylbenzo[h][1,6]naphthyridin-2(1H)-one (III.24) 
III.21 reacted under the conditions described in the general 
procedure H to afford the compound III.24 as a brown solid. M.p. 
180-183 oC; 1H NMR (300 MHz, CDCl3) δ 8.88 (s, 1H, H14), 8.68 (d, 
J = 2.0 Hz, 1H, H8), 8.01 (d, J = 8.9 Hz, 1H, H11), 7.90 – 7.78 (m, 2 
H, H4, H10), 6.87 (d, J = 9.3 Hz, 1H, H3), 4.09 (s, 3H, CH3). 13C NMR 
(75 MHz, CDCl3) δ 164.1 (C=O), 150.7 (C14), 148.1 (C12), 143.2 (C6), 
137.9 (C4), 133.5 (C11), 132.3 (C10), 127.5 (C8), 122.2 (C3), 119.9 (C9), 119.8 (C7), 114.0 (C5), 
38.3 (NCH3). 
 
9-bromo-1-(2-(dimethylamino)ethyl)benzo[h][1,6]naphthyridin-2(1H)-one (III.25) 
III.22 reacted under the conditions described in the general 
procedure H to afford the compound III.25 as a off-white solid.  
1H NMR (300 MHz, CDCl3) δ 8.88 (s, 1H, H14), 8.68 (d, J = 2.0 Hz, 
1H, H8), 8.01 (d, J = 8.9 Hz, 1H, H11), 7.90 – 7.78 (m, 2 H, H4, H10), 
6.86 (d, J = 9.3 Hz, 1H, H3), 4.63 (t, 2H, CH2CH2NMe2), 3.06 (t, 2H, 
CH2CH2NMe2), 2.39 (s, 6H, N(CH3)2). 
 
2.2.7. Synthesis of the target compounds 
 
9-bromo-1-(4-(4-methylpiperazin-1-yl)-3-trifluoromethyl)phenyl) 
benzo[h][1,6]naphthyridin-2(1H)-one (III.2a) 
To a solution of III.23 (340 mg, 0.56 mmol, 1 equiv.) in dry 
DCM (0.2 M) was slowly added TFA (10 equiv.) at 0 oC. The 
resulting mixture was stirred at 0 oC during 10 minutes at rt 
during 3 h. The solvent was evaporated, methanol was 
added followed by evaporation, and then ether was added 
and evaporated to afford the corresponding TFA salt which 
was used in the next step without further purification. To a 
solution of the TFA salt (1 equiv.) in dry methanol (3 ml) and 
paraformaldehyde (4 equiv.) was added formic acid (4 equiv.). The reaction mixture was 
refluxed for 24 h. After cooling to rt, the reaction mixture was partitioned between ether 
and water. The aqueous phase was basified with Na2CO2 2N until pH=12 andthen 
extracted with ether. The combined organic phases were washed with brine, dried with 
anhydrous Na2SO4 and the solvent removed under reduced pressure to afford III.2a as a 
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light brown solid (158 mg, 52%). M.p. 177-180 oC; 1H NMR (300 MHz, CDCl3) δ 8.98 (s, 
1H, H14), 8.01 – 7.93 (m, 2H, H4, H11), 7.71 – 7.63 (m, 2H, H10, H5’), 7.56 (d, J = 2.4 Hz, 1H, 
H2’), 7.51 (dd, J = 8.4, 2.4 Hz, 1H, H6’), 6.97 (d, J = 9.5 Hz, 1H, H3), 6.69 (d, J = 2.0 Hz, 1H, 
H8), 3.14 (dt, J = 11.6, 6.0 Hz, 4H, CH2Ppz), 2.67 (s, 4H, CH2Ppz), 2.41 (s, 3H, CH3). 13C NMR 
(75 MHz, CDCl3) δ 163.2 (C=O), 154.2 (C4’), 150.9 (C14), 148.3 (C12), 141.7 (C6), 139.5 (C4), 
135.8 (C1’), 133.3 (C10), 133.2 (C6’), 132.5 (C11), 129.3 (C3’), 128.0 (C8), 127.8 (C2’), 126.3 
(C5’), 122.9 (C3), 121.5 (CF3), 120.2 (C7), 118.7 (C9), 113.8 (C5), 53.5 (CPpz), 55.4 (CPpz), 46.1 
(CH3). MS (ESI) m/z 517 [M+H]+. 
 
9-((2-(dimethylamino)ethyl)amino)-1-(4-(4-methylpiperazin-1-yl)-3-
(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (III.2b)  
 III.2a (33 mg, 0.06 mmol, 1 equiv.) was coupled with N,N-
dimethylethylenediamine (11 µL, 0.10 mmol, 1.5 equiv.), 
according to the slightly modified general procedure I 
(where toluene (0.2 M) was used as solvent and the 
reaction proceeded at  100 oC). The crude product was 
purified by preparative TLC (EtOAc/MeOH , 95:5) to 
afford III.2b as a brown solid (12 mg, 35%). 1H NMR (300 
MHz, CDCl3) δ 8.69 (s, 1H, H14), 7.91 (d, J = 9.4 Hz, 1H, H4), 
7.85 (d, J = 9.0 Hz, 1H, H11), 7.69 (d, J = 2.0 Hz, 1H, H2’), 
7.52 – 7.48 (m, 2H, H5’, H6’), 7.01 (dd, J = 9.0, 2.4 Hz, 1H, H10), 6.86 (d, J = 9.4 Hz, 1H, H3), 
5.94 (d, J = 2.4 Hz, 1H, H8), 4.53 (s, 1H, NH), 3.07 (ddd, J = 15.7, 11.1, 6.0 Hz, 4H, CH2Ppz), 
2.62 (br s, 4H, CH2Ppz), 2.49 – 2.30 (m, 7H, CH2CH2, NCH3), 2.16 (s, 6H, N(CH3)2). 
 
9-((2-(dimethylamino)ethyl)amino)-1-methylbenzo[h][1,6]naphthyridin-2(1H)-one 
(III.3a)  
III.24 (50 mg, 0.17 mmol) was coupled with  N,N-
dimethylethylenediamine (30 µL, 0.28 mmol), according 
to general procedure I. The crude product was purified by 
preparative TLC (DCM/MeOH, 9:1) to afford III.3a  as a 
dark yellow solid (29 mg, 57%). M.p. 155-157 oC; 1H NMR 
(300 MHz, CDCl3) δ 8.62 (s, 1H, H14), 7.94 (d, J = 9.0 Hz, 
1H, H11), 7.80 (d, J = 9.3 Hz, 1H, H4), 7.38 (d, J = 2.2 Hz, 1H, 
H8), 7.19 (dd, J = 9.0, 2.4 Hz, 1H, H10), 6.80 (d, J = 9.3 Hz, 1H, H3), 4.90 (s, 1H, NH), 4.10 
(s, 3H, NCH3), 3.27 (s, 2H, NHCH2CH2NMe2), 2.75 – 2.62 (m, 2H, NHCH2CH2NMe2), 2.32 
(s, 6H, N(CH3)2). 13C NMR (75 MHz, CDCl3) δ 164.9 (C=O), 146.1 (C14), 146.0 (C9), 143.7 
(C12), 142.8 (C6), 138.3 (C4), 131.5 (C11), 121.2 (C3), 120.8 (C10), 120.3 (C7), 114.3 (C5), 
102.3 (C8), 57.7 (NHCH2CH2NMe2), 45.2 (N(CH3)2)., 41.0 (NHCH2CH2NMe2), 38.40 (NCH3). 
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2-(9-bromo-2-oxobenzo[h][1,6]naphthyridin-1(2H)-yl)-N,N,N-trimethylethanaminium 
trifluoromethanesulfonate (III.3b) 
III.25 (100 mg, 0.29 mmol) reacted with methyl 
trifluoromethanesulfonate (196 µL, 1.73 mmol), 
according to general procedure J. The filtrate was 
evaporated and purified by preparative TLC 
(DCM/MeOH/TEA, 85:15:0.1) to afford III.3b as a 
yellow solid (8 mg, 5%).  
 
 
1-(2-(dimethylamino)ethyl)-9-((2-
(dimethylamino)ethyl)amino)benzo[h][1,6]naphthyridin-2(1H)-one (III.3c) 
III.25 (145 mg, 0.17 mmol) was coupled with N,N-
dimethylethylenediamine (73 µL, 0.67 mmol), according 
to general procedure I. The crude product was purified by 
flash column chromatography (DCM/MeOH, 95:5) to 
afford III.3c as a yellow solid (107 mg, 73%). 1H NMR (300 
MHz, CDCl3) δ 8.59 (s, 1H, H14), 7.93 (d, J = 9.0 Hz, 1H, H11), 
7.77 (d, J = 9.3 Hz, 1H, H4), 7.60 (s, 1H, H8), 7.20 (dd, J = 7.0, 1.8 Hz, 1H, H10), 6.77 (d, J = 
9.3 Hz, 1H, H3), 4.97 (s, 1H, NH), 4.70 (t, 2H, NCH2CH2NMe2), 3.50 – 3.33 (m, 2H, 
NHCH2CH2NMe2), 3.04 (t, 2H, NCH2CH2NMe2), 2.73 – 2.59 (m, 3H, NHCH2CH2NMe2), 2.33 
(d, J = 12.4 Hz, 12H, NCH3). 13C NMR (75 MHz, CDCl3) δ 164.7 (C=O),  146.9 (C12), 146.3 
(C14), 143.8 (C6), 138.8 (C9), 131.7 (C11), 121.3 (C3), 120.7 (C10), 119.9 (C7), 114.3 (C5), 
102.4 (C8), 57.9 (NHCH2CH2NMe2), 57.4 (NCH2CH2NMe2), 47.6 (NCH2CH2NMe2), 45.9 
(NCH2CH2N(CH3)2), 45.2 (NHCH2CH2N(CH3)2), 40.9 (NHCH2CH2NMe2). 
 
9-bromo-1,6-dimethyl-2-oxo-1,2-dihydrobenzo[h][1,6]naphthyridin-6-ium 
trifluoromethanesulfonate (III.4)  
III.24 (85 mg, 0.29 mmol) reacted with methyl 
trifluoromethanesulfonate (200 µL, 1.76 mmol), 
according to general procedure J to afford III.4  as an off-
white solid (89 mg, 67%). M.p. 164-167 oC; 1H NMR (300 
MHz, MeOD) δ 9.53 (s, 1H, H14), 9.11 (d, J = 1.6 Hz, 1H, 
H8), 8.40 – 8.31 (m, 2H, H10, H11), 8.17 (d, J = 9.6 Hz, 1H, 
H4), 7.01 (d, J = 9.6 Hz, 1H, H3), 4.54 (s, 3H, N+CH3), 4.14 
(s, 3H, NCH3). 13C NMR (75 MHz, MeOD) δ 164.8 (C=O), 151.2 (C14), 150.8 (C6), 139.2 
(C12), 139.1 (C4), 138.7 (C11), 131.3 (C8), 124.4 (C3), 123.3 (C9), 122.1 (C7), 121.9 (C10), 
114.7 (C5), 45.4 (N+CH3), 39.5 (NCH3). 
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2.3. Synthesis of compounds described in Chapter III 
 
2.3.1. General methods 
 
General procedure K for trityl deprotection. TFA (11 equiv.) and TES (3 equiv.) were 
added to a solution of trityl protected Fmoc-cysteine or dipeptide in DCM and the 
mixture was stirred at rt for 3 h under nitrogen atmosphere. The solvent was evaporated 
under reduced pressure and the crude residue was washed with toluene and after each 
washing it was evaporated to dryness. The solid residue was washed with pentane and 
the precipitate was filtered to afford the desired compounds. 
 
General procedure L for dipeptide synthesis. N-protected-amino acid (1.2 equiv.) and 
acid-protected amino acid (1.0 equiv.) were dissolved in DMF. Then TBTU (1.2 equiv.), 
HOBt (1.2 equiv.), and DIPEA (1.2 equiv.) were added. The reaction mixture was stirred 
at rt o/n. After completion of the reaction, water as added to the reaction mixture and 
the product was extracted with EtOAc. The organic phase was washed with 5 % aqueous 
KHSO4, saturated aqueous NaHCO3, water, brine, dried with anhydrous Na2SO4 The 
solvent was removed under reduced pressure and the crude product was purified to 
afford the desired compounds. 
 
General Procedure M for Boc-Protection of Nucleobases. To a solution of nucleobase 
(1.0 equiv.) and DMAP (0.1 equiv.)  in dry THF (0.2 M) was added Boc2O (4.0 equiv.) and 
the reaction mixture was stirred overnight at rt, under a nitrogen atmosphere. After the 
reaction reach completation, the solvent was evaporated and the crude product was 
redissolved in AcOEt. The organic phase was washed subsequently with 5% aqueous 
KHSO4, saturated aqueous NaHCO3, water and brine, dried with anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude product was purified by flash column 
chromatography. 
 
General Procedure N for selective N-Boc deprotection. To a solution of tris-N-Boc-
nucleobase (1 equiv.) dissolved in MeOH (0.1 M) was added saturated aqueous NaHCO3 
(half of MeOH volume). The turbid solution was stirred at 50 °C for 1 h, at which point 
clean conversion to bis-Boc protected nuclabase was observed by TLC. After evaporation 
of MeOH, water was added to the reaction mixture (pH=4) and the pH of the mixture 
was adjusted to ca. 7. The aqueous phase was then extracted with DCM and the 
combined organic phases were washed with water and brine, dried with anhydrous 
Na2SO4,  and concentrated under reduced pressure to afford the desired compounds. 
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General Procedure O for N-allylation of nucleobases. To a suspension of K2CO3 (3 
equiv.) in dry DMF was added nucleobase (1 equiv.) at 0 oC under nitrogen atmosphere. 
After 15 min, allyl bromide (1.2 equiv.) was added dropwise and stirring was continued 
at rt o/n. After reaction completation, water was added and the product was extracted 
with EtOAc. The organic layer was washed with 5% aqueous KHSO4, water and brine, 
dried with anhydrous Na2SO4 and concentrated under reduced pressure. The crude 
product was purified by flash column chromatography. 
  
General procedure P for thermaly-induced thiol-ene reaction. The DCE was degassed 
under nitrogen atmosphere in a sonicator bath for 15 min prior to use.  DCE was added 
to a thiol (1 equiv.), an alkene (3 equiv.), AIBN (0.5 equiv.) and the mixture was brought 
to reflux. The solution was allowed to cool to rt and the solvent was removed under 
reduced pressure.  
 
General procedure Q for photochemically-induced thiol-ene reactions. The DCE was 
degassed under nitrogen atmosphere in a sonicator bath for 15 min prior to use.  DCE 
was added to a thiol (1 equiv.), an alkene (3 equiv.) and 0.1 equivalents of DPAP.  The 
mixture was irradiated at rt under magnetic stirring. Then, the solvent was removed 
under reduced pressure. 
 
2.3.2. Synthesis of compounds IV.6 and IV.7 
 
N-(9-Fluorenylmethoxycarbonyl)-L-cysteine (IV.6) 
 N-(9-Fluorenylmethoxycarbonyl)-S-trityl-L-cysteine IV.8 (100 mg, 
0.17 mmol) was treated under the conditions described in the 
general procedure K to afford the compound III.6 as a white solid 
(53 mg, 87%). M.p. 112-115 oC; 1H NMR (400 MHz, CDCl3) δ 7.77 
(d, J = 7.5 Hz, 2H, Harom), 7.61 (d, J = 7.3 Hz, 2H, Harom), 7.41 (t, J = 
7.4 Hz, 2H, Harom), 7.33 (t, J = 8.3 Hz, 2H, Harom), 5.67 (d, J = 7.6 Hz, 1H, NH), 4.72 (s, 1H, 
H), 4.46 (d, J = 6.0 Hz, 2H, CH2Fmoc), 4.24 (t, J = 6.6 Hz, 1H, CHFmoc), 3.13 – 2.95 (m, 2H, 
CH2SH), 1.46 (t, J = 8.8 Hz, 1H, SH). Analytical date were in agreement with those already 
published.560 
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(R)-ethyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
(tritylthio)propanamido)acetate (III.10a) 
 N-(9-Fluorenylmethoxycarbonyl)-S-trityl-L-cysteine 
IV.8 (1.00 g, 1.71 mmol)  and glycine ethyl ester 
hydrochloride (199 mg, 1.42 mmol) reacted under the 
conditions descrived in general procedure L. The crude 
product was purified by flash column chromatography 
(hexane/EtOAc, 3:7) to afford III.10a as white solid (790 
mg, 83%).  M.p. 77-81 oC; 1H NMR (400 MHz, CDCl3) δ 7.75 (t, J = 7.8 Hz, 2H, HaromFmoc), 
7.57 (d, J = 6.8 Hz, 2H, HaromFmoc), 7.43-7.36 (m, 8H, HaromFmoc, HaromTrt), 7.29 – 7.19 (m, 
11H, HaromFmoc, HaromTrt), 6.32 (s, 1H, NHgly), 4.97 (d, J = 5.2 Hz, 1H, NHcys), 4.39 (d, J = 6.8 
Hz, 2H, CH2Fmoc), 4.21-4.10 (m, 4H, HFmoc, CH2CH3), 3.99-3.86 (m, 2H, CH2gly), 3.79 (d, J = 
6.4 Hz, 1H, Hα), 2.67 (t, J = 5.2 Hz, 2H, CH2SH), 1.25 (t, J = 6.8 Hz, 3H, CH3). Analytical date 
were in agreement with those already published.561 
 
(R)-benzyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
(tritylthio)propanamido)acetate (II.10b) 
 N-(9-Fluorenylmethoxycarbonyl)-S-trityl-L-
cysteine IV.8 (697 mg, 1.19 mmol) and glycine 
benzyl ester hydrochloride (200 mg, 0.99 mmol) 
reacted under the conditions descrived in general 
procedure L. The crude product was purified by 
flash column chromatography (hexane/EtOAc, 3:7) 
to afford II.10b as white solid (671 mg, 92%).  M.p. 74-77 oC; 1H NMR (400 MHz, CDCl3) 
δ 7.66 (t, J = 7.0 Hz, 2H, Harom), 7.49 (d, J = 6.8 Hz, 2H, Harom), 7.39 – 7.06 (m, 24H, Harom), 
6.30 (s, 1H, NHgly), 5.06 (s, 2H, CH2Bn), 4.92 (d, J = 6.8 Hz, 1H, NHcys), 4.31 (d, J = 6.8 Hz, 
2H, CH2Fmoc), 4.11 (t, J = 6.8 Hz, 1H, HFmoc), 3.89 (qd, J = 18.4, 4.6 Hz, 2H, CH2gly), 3.72 (d, 
J = 5.6 Hz, 1H, H), 2.59 (s, 2H, CH2SH). 13C NMR (101 MHz, CDCl3) δ 170.4 (C=O), 169.2 
(C=O), 156.1 (C=O), 144.4 (CquartTrt), 143.8 (CquatFmoc), 143.8 (CquartTrt), 141.4 (CquatFmoc), 
135.1 (CquatBn), 129.7 (Carom), 128.7 (Carom), 128.5 (Carom), 128.2 (Carom), 128.0 (Carom), 127.9 
(Carom), 127.4 (Carom), 127.2 (Carom), 127.1 (Carom), 125.2 (Carom), 120.1 (Carom), 67.4 
(CH2Fmoc, CH2Bn),  53.9 (CH), 47.2 (CHFmoc), 41.5 (CH2gly), 33.7 (CH2SH). MS (ESI) 755.34 
[M+Na]+.  
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(R)-ethyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
mercaptopropanamido)acetate (IV.7a) 
 IV.10a (200 mg, 0.30 mmol) was treated under the 
conditions described in the general procedure K to 
afford the compound III.7a  as a white solid (111 mg, 
87%). M.p. 133-136 oC; 1H NMR (400 MHz, DMSO-d6) δ 
8.46 (t, J = 5.4 Hz, 1H, NHgly), 7.90 (d, J = 7.2 Hz, 2H, 
HaromFmoc), 7.74 (dd, J = 7.0, 4.2 Hz, 2H, HaromFmoc), 7.62 (d, J = 8.0 Hz, 1H, NHcys), 7.42 (t, J 
= 7.2 Hz, 2H, HaromFmoc), 7.33 (t, J = 7.4 Hz, 2H, HaromFmoc), 4.34 – 4.21 (m, 3H, CHFmoc, 
CH2Fmoc), 4.17-4.12 (m, 1H, H), 4.08 (q, J = 7.0 Hz, 2H, CH2CH3), 3.90 – 3.77 (m, 2H, 
CH2gly), 2.88-2.80 (m, 1H, CH2SH), 2.71 – 2.62 (m, 1H, CH2SH), 2.33 (t, J = 8.2 Hz, 1H, 
CH2SH), 1.18 (t, J = 7.0 Hz, 3H, CH3). 13C NMR (101 MHz, DMSO-d6) δ 170.7 (C=O), 169.7 
(C=O), 156.0 (C=O), 143.8 (CquatFmoc), 140.7 (CquatFmoc), 127.7 (CHarom), 127.1 (CHarom), 
125.4 (CHarom), 120.1 (CHarom), 65.8 (CH2Fmoc), 60.5 (CH2CH3), 57.2 (CH), 46.6 (CHFmoc), 
40.8 (CH2gly), 26.2 (CH2SH), 14.1 (CH3). MS (ESI) 451 [M+Na]+. Anal. Calcd 
C22H24N2O5S.0,1H2O for: C, 61.40; H, 5.68; N, 6.51; S, 7.45. Found: C, 61.77; H, 5.83; N, 
6.40; S, 7.06. 
 
(R)-benzyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
mercaptopropanamido)acetate (IV.7b) 
IV.10b (200 mg, 0.27 mmol) was treated under 
the conditions described in the general procedure 
K to afford the compound III.7a as a white solid 
(107 mg, 80%). M.p. 128-130 oC; 1H NMR (400 
MHz, DMSO-d6) δ 8.51 (t, J= 5.8 Hz, NHgly), 7.90 (d, 
J = 7.6 Hz, 2H, HaromFmoc), 7.74 (dd, J = 6.6, 5 Hz, 2H, HaromFmoc), 7.64 (d, J = 8.0 Hz, 1H, 
NHcys), 7.42 (t, J = 7.4 Hz, 2H, HaromFmoc), 7.33 (m, 7H, HaromFmoc, HaromBn), 5.11 (s, 2H, CH2Bn), 
4.34 – 4.29 (m, 1H, CHFmoc), 4.27-4.21 (m, 2H, CH2Fmoc), 4.17-4.12 (m, 1H, H), 4.00 – 3.82 
(m, 2H, CH2gly), 2.79 (s, 1H, CH2SH), 2.67 (s, 1H, CH2SH), 2.32 (s, 1H, SH). 13C NMR (101 
MHz, DMSO-d6) δ 170.7 (C=O), 169.6 (C=O), 156.0 (C=O), 143.8 (CquatFmoc), 140.7 
(CquatFmoc), 135.8 (CquatBn), 128.4 (Carom), 128.1 (Carom), 128.0 (Carom), 127.7 (Carom), 127.1 
(Carom), 125.4 (Carom), 120.1 (Carom), 65.9 (CH2Fmoc, CH2Bn), 57.2 (CH), 46.7 (CHFmoc), 40.9 
(CH2gly), 26.2 (CH2SH). MS (ESI) 513 [M+Na]+. Anal. Calcd for C27H26N2O5S: C, 66.10; H, 
5.34; N, 5.71; S, 6.54. Found: C, 66.35; H, 5.70; N, 5.50; S, 6.51. 
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2.3.3. Synthesis of compounds IV.13, IV.14 and IV.19 
 
Tris-N-Boc-cytosine (IV.13) 
 Cytosine IV.11 (1.00 g, 9.00 mmol) reacted with Boc2O (8.27 mL, 36.00 
mmol)  under the conditions described in the general procedure M. The 
crude product was purified by flash column chromatography 
(hexane/EtOAc, 25:75) to afford IV.13 as a pale yellow oil (3.33 g, 90%). 
1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 7.9 Hz, 1 H, H6), 7.07 (d, J = 7.8 
Hz, 1 H, H5), 1.60 (s, 9 H, N1-Boc), 1.56 (s, 18 H, Boc of exocyclic amine). 
Analytical date were in agreement with those already published.541 
 
Tris-N-Boc-adenine (IV.14) 
 Adenine IV.12 (1.00 g, 7.40 mmol) was treated with Boc2O (6.80 mL, 
29.60 mmol) under the conditions described in the general procedure 
M. The crude product was purified by flash column chromatography 
(hexane/EtOAc, 7:3) to afford IV.14 as a white foam (3.01 g, 93%).  M.p. 
53–54 °C; 1H NMR (400 MHz, CDCl3) δ 9.02 (s, 1H, H2), 8.51 (s, 1H, H8), 
1.71 (s, 9H, N9-Boc), 1.43 (s, 18H, Boc of exocyclic amine). Analytical 
date were in agreement with those already published.537,538 
 
Tris-N-Boc-2-amino-6-chloropurine (IV.19) 
 2-amino-6-chloropurine IV.17 (500 mg, 2.94 mmol) was treated 
with Boc2O (2.71 mL, 11.79 mmol) under the conditions described 
in the general procedure M. The crude product was purified by 
flash chromatography (elution first with hexane/EtOAc (9:1) to 
remove unreacted Boc2O and then with EtOAc, 100%) to afford 
IV.19 as a white foam (948 mg, 68%). M.p. 50–51 oC; 1H NMR (400 
MHz, CDCl3) δ 8.58 (s, 1H, H8), 1.69 (s, 9H, C(CH)3 of N9-Boc), 1.46 (s, 18H, Boc of exocyclic 
amine). Analytical date were in agreement with those already published.537,538 
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2.3.4. Synthesis of compounds IV.15, IV.16 and IV.18 
 
Bis-N-Boc-cytosine (IV.15) 
 IV.13 (3.33 g, 8.09 mmol) was treated under the conditions described in 
the general procedure N to afford the compound III.15 as a white solid 
(2.11 g, 83%). M.p. > 320 oC; 1H RMN (400 MHz, CDCl3) δ 7.68 (d, J = 7.1 
Hz, 1 H, H6), 7.26 (s, 1 H, NH), 7.12 (d, J = 7.1 Hz, 1 H, H5), 1.56 (s, 18 H, 
Boc). Analytical date were in agreement with those already published.541 
 
Bis-N-Boc-adenine (IV.16) 
 IV.14 (3.01 g, 6.91 mmol) was treated under the conditions described 
in the general procedure N to afford the compound IV.16 as a white 
solid (1.73 g, 75%). M.p. 147-149 oC; 1H RMN (400 MHz, CDCl3) δ 8.81 
(s, 1 H, H2) 8.35 (s, 1 H, H8), 1.55 (s, 18 H, s, 18H, Boc). Analytical date 
were in agreement with those already published.537,538 
 
Bis-N-Boc-2-amino-6-chloropurine (IV.18) 
IV.19 (948 mg, 2.02 mmol) was treated under the conditions 
described in the general procedure N to afford the compound 
IV.18 as a waxy solid (709 mg, 96%). 1H NMR (400 MHz, CDCl3) δ 
8.36 (s, 1H, H8), 1.51 (s, 18H, Boc). Analytical date were in 
agreement with those already published.537,538 
 
2.3.5. Synthesis of compound IV.24 
 
Bis-tert-butyl (9-(2-chloroethyl)-9H-purin-6-yl)carbamate (IV.24) 
To a suspension of IV.16 (200 mg, 0.60 mmol, 1 equiv.) in dry DMF 
(0.2 M) at rt was added K2CO3 (3 equiv.) and 1-bromo-2-
chloroethane (60 µL, 0.72 mmol, 1.2 equiv.). The reaction mixture 
was stirred at rt under nitrogen atmosphere o/n. The reaction was 
diluted with ethyl acetate and washed with 1N HCl, water, brine 
and dried with anhydrous Na2SO4. The solvent was removed 
under reduced pressure. The crude product was purified by flash column 
chromatography (hexane/EtOAc,3:7) to afford IV.24 as a white solid (169 mg, 71%). 1H 
NMR (400 MHz, CDCl3) δ 8.83 (s, 1H, H2), 8.16 (s, 1H, H8), 4.61 (t, J = 5.5 Hz, 2H, NCH2), 
3.93 (t, J = 5.5 Hz, 2H, CH2Cl), 1.40 (s, 18H, Boc). 
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2.3.6. Synthesis of compounds IV.31, IV.32 and IV.33 
 
N1-allyl-bis-Boc-cytosine (IV.31) 
 IV.15 (330 mg, 1.06 mmol) reacted with allyl bromide (110 µL, 1.27 
mmol) under the conditions described in general procedure O.  The 
crude product was purified by flash column chromatography 
(hexane/EtOAc, 2:8) to afford IV.31 as a white solid (254 mg, 68%). 
M.p. 78-70 0C; 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 7.3 Hz, 1H, H6), 
7.02 (d, J = 7.3 Hz, 1H, H5), 5.98-5.88 (m, 1H, CH=CH2), 5.30 (d, J = 10.2 
Hz, 1H, CH=CHcis), 5.26 (d, J = 17.1 Hz, 1H, CH=CHtrans), 4.48 (d, J = 6.0 
Hz, 2H, NCH2), 1.56 (s, 18H, Boc). 13C NMR (CDCl3) δ 162.4 (C4), 155.1 
(C=O), 149.7 (C=OBoc), 147.3 (C6), 131.8 (CH=CH2), 119.7 (CH=CH2), 96.6 (C5), 85.1 
(CquatBoc), 52.3 (NCH2), 27.8 (CH3). MS (ESI) m/z 374 [M+Na]+. HRMS-ESI:  m/z [M + Na]+ 
calcd for C17H25N3NaO5: 374.1686, found: 374.1678. 
 
N9-allyl-bis-Boc-adenine (IV.32) 
 IV.16 (200 mg, 0.60 mmol) reacted with allyl bromide (62 µL, 0.72 
mmol) under the conditions described in general procedure O.  The 
crude product was purified by flash column chromatography 
(hexane/EtOAc, 2:8) to afford IV.32 as a white solid (129 mg, 58%). 
M.p. 74-77 0C; 1H NMR (400 MHz, CDCl3) δ 8.85 (s, 1H, H2), 8.07 (s, 1H, 
H8), 6.10-5.99 (m, 1H, CH=CH2), 5.33 (dd, J = 10.2, 0.4 Hz, 1H, CH=CHcis), 
5.21 (d, J = 17.2, 0.4 Hz, 1H, CH=CHtrans), 4.89 (d, J = 5.6 Hz, 2H, NCH2), 
1.43 (s, 18H, Boc). 13C NMR (101 MHz, CDCl3) δ 153.3 (C4), 152.3 (C2), 
150.5 (C6), 150.4 (C=OBoc), 144.7 (C8), 131.3 (CH=CH2), 128.8 (C5), 119.7 (CH=CH2), 83.8 
(CquatBoc), 46.2 (NCH2), 27.9 (CH3). MS (ESI) m/z 398 [M+Na]+. Anal. Calcd for C22H33N5O4: 
C, 57.59; H, 6.71; N, 18.65. Found: C, 57.96; H, 6.85; N, 18.37. 
 
N7-allyl-bis-Boc-adenine (IV.34) 
 IV.34 was obtained as a minor product of the previous 
reaction.White solid (81 mg, 36%). 1H NMR (400 MHz, CDCl3) δ 
9.04 (s, 1H, H2), 8.24 (s, 1H, H8), 6.01 – 5.92 (m, 1H, CH=CH2), 5.33 
(d, J = 10.3 Hz, 1H, CH=CHcis), 5.20 (d, J = 17.1 Hz, 1H, CH=CHtrans), 
4.82 (d, J = 5.6 Hz, 2H, NCH2), 1.38 (s, 18H, Boc). 13C NMR (101 
MHz, CDCl3) δ 163.7 (C4), 157.1 (C6), 152.9 (C2), 150.1 (C=OBoc), 148.8 (C8), 144.2 (C5), 
131.1 (CH=CH2), 120.1 (CH=CH2), 84.6 (CquatBoc), 49.3 (NCH2), 28.0 (CH3). 
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N1-allylthymine (IV.33) 
Thymine IV.30 (1.00g, 7.93 mmol) reacted with allyl bromide (822 µL, 
9.52 mmol)  under the conditions described in general procedure O. The 
crude product was purified by flash column chromatography 
(hexane/EtOAc, 7:3) to afford IV.33 as a white solid (792 mg, 60%).  M.p. 
95-97 oC; 1H NMR (CDCl3) δ 9.01 (br s, 1H, NH), 6.97 (s, 1H, CH=C(CH3)), 
5.91 – 5.81 (m, 1H, CH=CH2), 5.30 (d, J = 10.2 Hz, 1H, CH=CHcis), 5.26 (d, 
J = 17.8 Hz, 1H, CH=CHtrans), 4.33 (d, J = 5.8 Hz, 2H, NCH2), 1.92 (s, 3H, 
CH3). 13C NMR (CDCl3) δ 164.3 (C4=O), 150.9 (C2=O), 139.8 (C6), 131.8 (CH=CH2), 119.4 
(CH=CH2), 111.1 (C-5), 49.9 (NCH2), 12.5 (CCH3). MS (ESI) m/z 190 [M+Na]+. Analytical 
date were in agreement with those already published.532,533 
 
N1,N3-diallylthymine (IV.35) 
IV.35 was obtained as a minor product of the previous reaction. 
Incolor oil (322 mg, 20%).  1H NMR (400 MHz, CDCl3) δ 6.96 (s, 1H, H6), 
5.88 (ddd, J = 16.6, 10.6, 5.7 Hz, 2H, CH=CH2), 5.34 – 5.13 (m, 4H, 
CH=CH2), 4.58 (d, J = 5.7 Hz, 2H, N3CH2), 4.35 (d, J = 5.7 Hz, 2H, N1CH2), 
1.93 (s, 3H, CH3). 13C NMR (101 MHz, CDCl3) δ 163.6 (C4=O), 151.3 
(C2=O), 137.9 (C6), 132.1 (N1CH2CH=CH2), 131.9 (N3CH2CH=CH2), 119.2 
(N1CH2CH=CH2), 118.0 (N3CH2CH=CH2), 110.3 (C5), 50.9 (N1CH2), 43.6 
(N3CH2), 13.2 (CH3). Analytical date were in agreement with those already published.562 
 
2.3.7. Synthesis of compound IV.36 
 
N9-allyl-N2,N2’-bis-Boc-2-amino-6-chloropurine (IV.36) 
IV.18 (50 mg, 0.14 mmol) reacted with allyl bromide (14 µL, 0.16 
mmol) under the conditions described in general procedures O. 
The crude product was purified by preparative TLC 
(hexane/EtOAc, 2:8) to afford IV.36 as white solid (28 mg, 51%). 
1H NMR (CDCl3) δ 8.15 (s, 1H, H8), 6.10 – 5.96 (m, 1H, CH=CH2), 
5.37 (d, J = 10.2 Hz, 1H, CH=CHcis), 5.24 (d, J = 17.0 Hz, 1H, 
CH=CHtrans), 4.88 (d, J = 5.8 Hz, 2H, NCH2), 1.44 (s, 18H, Boc). 13C 
NMR (CDCl3) δ 152.7 (C4), 152.1 (C6), 151.4 (C=OBoc), 150.7 (C2), 145.9 (C8), 131.0 
(CH=CH2), 130.1 (C5), 120.2 (CH=CH2), 83.8 (CquatBoc), 46.5 (NCH2), 28.0 (CH3). MS (ESI) 
m/z 432 [M+Na]+. 
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N7-allyl-N2,N2’-bis-Boc-2-amino-6-chloropurine (IV.38) 
IV.38 was obtained as minor product of the previous reaction. 
White soild (15 mg, 27%). 1H NMR (400 MHz, CDCl3) δ 8.26 (s, 
1H, H8), 6.09 (ddd, J = 22.2, 10.4, 5.6 Hz, 1H, CH=CH2), 5.39 (d, 
J = 10.4 Hz, 1H, CH=CHcis), 5.17 – 5.08 (m, 3H, CH=CHtrans and 
NCH2), 1.44 (s, 18H, Boc). 
 
N2-mono-Boc-2-amino-6-chloropurine (IV.37) 
To a suspension of NaH 60 % dispersion in mineral oil  (1.1 equiv.) 
in dry THF was added IV.18 (50 mg, 0.14 mmol, 1 equiv.) at 0 oC 
under nitrogen atmosphere. After 15 minutes, allyl bromide (13 
µL, 0.15 mmol, 1.1 equiv.) was added dropwise. The reaction 
mixture was stirred at rt o/n. After reaction completation, it was 
quenched with water. After THF evaporation, the pH of the 
mixture was adjusted to ca. 7 and  extracted with DCM. The combined organic phases 
were washed with water and brine, dried with anhydrous Na2SO4,  and concentrated 
under reduced pressure. The crude product was purified by preparative TLC 
(hexane/EtOAc, 2:8) to afford IV.37 as a white solid (12 mg, 22%). M.p. decompose at 
200 °C; 1H NMR (400 MHz, CDCl3) δ 8.44 (s, 1H, H8), 7.81 (br s, 1H, NH), 1.57 (s, 9H, Boc). 
Analytical date were in agreement with those already published.538 
 
2.3.8. Synthesis of compound IV.45 
 
N9-allyl-2-amino-6-chloropurine (IV.44)  
2-amino-6-chloropurine IV.17 (400 mg, 2.36 mmol) reacted with 
allyl bromide (245 µL, 2.83 mmol) under the conditions described 
in general procedure O. The crude product was purified by flash 
column chromatography (hexane/EtOAc, 1:1) to afford IV.44  as a 
white solid (334 mg, 68%). M.p. 149-151 °C; 1H NMR (400 MHz, 
CDCl3) δ 7.77 (s, 1H, H8), 6.07 – 5.93 (m, 1H, CH=CH2), 5.32 (d, J = 
10.1 Hz, 1H, CH=CHcis), 5.20 (d, J = 17.1 Hz, 1H, CH=CHtrans), 5.12 (s, 
2H, NH2), 4.70 (d, J = 4.5 Hz, 2H, NCH2). MS (ESI) m/z 210 [M+H]+. Analytical date were 
in agreement with those already published.386 
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N-9-allylguanine (IV.45) 
 To solution of IV.44 (334 mg, 1.59 mmol) in 1 N aqueous HCI (9.0 
mL) was warmed to a gentle reflux for 2 h. After cooling to rt, the 
pH of the mixture was adjusted to ca. 7 with solid NaOH, and then 
cooled in an ice bath for 0.5 h. The precipitate was collected by 
filtration and dried in vacuo to afford IV.45 as a white solid (238 
mg, 71%). 1H NMR (400 MHz, DMSO-d6) δ 10.56 (s, 1H, NH), 7.64 
(s, 1H, H8), 6.45 (s, 2H, NH2), 6.20 – 5.85 (m, 1H, CH=CH2), 5.17 (d, 
J = 9.8 Hz, 1H, CH=CHcis), 4.96 (d, J = 16.9 Hz, 1H, CH=CHtrans), 4.58 (s, 2H, NCH2). Analytical 
date were in agreement with those already published.386 
 
2.3.9. Synthesis of compound IV.40 
 
N9-allyl-N2,N2’-bis-Boc-guanine (IV.40) 
 IV.45 (400 mg, 2.09 mmol) was treated with Boc2O (1.92 mL, 
8.37 mmol, 4 equiv.) under the conditions described in the 
general procedure M. The crude product was purified by flash 
chromatography [elution started with hexane/EtOAc (15:85) 
and polarity increased gradually until EtOAc/MeOH (95:5)] to 
afford IV.40 as a white solid (371 mg, 45%). M.p. 149-152 0C; 
1H NMR (400 MHz, CDCl3) δ 11.32 (s, 1H, NH), 7.64 (s, 1H, C8), 
5.96 (ddd, J = 16.5, 10.5, 5.0 Hz, 1H, CH=CH2), 5.28 (dd, J = 10.5, 0.6 Hz, 1H, CH=CHcis), 
5.14 (dd, J = 16.5, 0.6 Hz, 1H CH=CHtrans), 4.61 (dd, J = 5.0, 1.4 Hz, 2H, NCH2), 1.56 (s, 18H, 
Boc). 13C NMR (101 MHz, CDCl3) δ 155.9 (C=O), 149.2 (C=OBoc), 148.2 (C4), 146.3 (C2), 
138.9 (C8), 131.7 (CH=CH2), 121.3 (C5), 119.1 (CH=CH2), 86.3 (CquatBoc), 46.0 (NCH2), 27.8 
(Boc). MS (ESI) m/z 414 [M+Na]+.  
 
N9-allyl-N2-mono-Boc-guanine (IV.46) 
 IV.46 was obtained as a minor product of the previous reaction. 
White solid (253 mg, 42%). M.p. 167-170 0C. 1H NMR (400 MHz, 
CDCl3) δ 11.35 (s, 1H, NH), 7.63 (s, 1H, NHexo), 7.61 (s, 1H, H8),  5.95 
(m, 1H, CH=CH2), 5.27 (d, J = 10.4 Hz, 1H, CH=CHcis), 5.12 (d, J = 17.2 
Hz, 1H, CH=CHtrans), 4.61 (d, J = 5.6 Hz, 2H, NCH2), 1.51 (s, 9H, Boc). 
13C NMR (101 MHz, CDCl3) δ 155.8 (C=O), 152.5 (C=OBoc), 148.7 (C4), 
147.1 (C2), 138.6 (C8), 131.9 (CH=CH2), 120.7 (C5), 118.9 (CH=CH2), 
84.6 (CquatBoc), 45.9 (NCH2), 28.1 (Boc). MS (ESI) m/z 314 [M+Na]+. Anal. Calcd for 
C17H25N5O3.0.4H2O: C, 55,26; H, 6.45; N, 17.91. Found: C, 54.64; H, 6.41; N, 17,20. 
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N9-allyl-N2,N2’,O6-tris-Boc-guanine (IV.47) 
 IV.47 was obtained as a minor product of the reaction to obtain 
II.40. White solid (73 mg, 7%).1H NMR (400 MHz, CDCl3) δ 7.80 (s, 
1H, H8), 5.99 (ddd, J = 19.8, 10.0, 5.4 Hz, 1H, CH=CH2), 5.29 (d, J = 
10.0 Hz, 1H, CH=CHcis), 5.09 (d, J = 19.8 Hz, 1H, CH=CHtrans), 4.76 
(dt, J = 5.4, 1.4 Hz, 2H, NCH2), 1.60 (s, 8H, Boc), 1.43 (s, 18H, Boc 
of exocyclic amine). MS (ESI) m/z 514 [M+Na]+. 
 
2.3.10. Synthesis of compound IV.48 
 
N9-allyl-O6-benzylguanine (IV.48)  
To a suspension of IV.45 (40 mg, 0.21 mmol, 1 equiv.) in dry DMF 
(0.2 M), NaH 80 % dispersion in mineral oil (1.1 equiv.) was added 
under nitrogen atmosphere. After 15 min, benzyl bromide (27 µL, 
0.23 mmol, 1.1 equiv.) was added dropwise. The reaction mixture 
was stirred at rt o/n. After reaction completation, it was quenched 
with water. The aqueous phase was extracted with EtOAc. The 
combined organic phases were washed with 5% aqueous KHSO4, 
water and brine, dried with anhydrous Na2SO4, and concentrated 
under reduced pressure. The crude product was purified by 
preparative TLC (eluent EtOAc/MeOH, 94:6) to afford IV.48   as an 
incolor oil (9.5 mg, 16%). 1H NMR (400 MHz, CDCl3) δ 7.61 (s, 1H, H8), 7.51 (d, J = 7.0 Hz, 
2H, Hbenzyl), 7.39 – 7.27 (m, 3H, Hbenzyl), 6.07 – 5.93 (m, 1H, CH=CH2), 5.56 (s, 2H, OCH2), 
5.28 (d, J = 10.2 Hz, 1H, CH=CHcis), 5.15 (d, J = 17.0 Hz, 1H, CH=CHtrans), 4.93 (s, 2H, NH2), 
4.67 (d, J = 4.9 Hz, 2H, NCH2). MS (ESI) m/z 304 [M+Na]+. Analytical date were in 
agreement with those already published.563  
 
N9-allyl-N2-benzylguanine (IV.49)  
IV.49 was obtained as a major product of the previous  
reaction. Colorless oil (15 mg, 26%). 1H NMR (400 MHz, 
CDCl3) δ 7.59 (s, 1H, H8), 7.40-7.32 (m, 3H, Hbenzyl), 7.29 (d, J 
= 8.3 Hz, 2H, Hbenzyl), 5.99 (ddd, J = 16.5, 10.2, 4.7 Hz, 1H, 
CH=CH2), 5.36 (s, 2H, NCH2Cbenzyl), 5.30 (d, J = 10.2 Hz, 1H, 
CH=CHcis), 5.19 (d, J = 16.5 Hz, 1H CH=CHtrans), 5.09 (d, J = 
17.3 Hz, 2H, NH), 4.61 (d, J = 4.7 Hz, 2H, NCH2CH=CH2). MS 
(ESI) m/z 304 [M+Na]+. 
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2.3.11. Synthesis of the target compounds 
 
N-acetyl-S-octyl-L-cysteine (IV.50a) 
 N-acetyl-L-cysteine IV.21 (50 mg, 0.31 mmol) reacted with octene 
(144 µL, 0.93 mmol) under the conditions described in both 
general procedure P for 1.5 h (52 mg, 62%) and general procedure 
Q for 1 h (84 mg, 100%)  to afford compound IV.50a as a colorless 
oil. 1H NMR (400 MHz, CDCl3) δ 6.45 (d, J = 6.9 Hz, 1H, NH), 4.76 
(dd, J = 12.1, 5.5 Hz, 1H, H), 3.03 (d, J = 5.1 Hz, 2H, CCH2S), 2.54 
(t, J = 7.4 Hz, 2H, SCH2CH2(CH2)5CH3), 2.09 (s, 3H, NC(O)CH3), 1.57 
(dt, J = 14.9, 7.3 Hz, 2H, SCH2CH2(CH2)5CH3), 1.40 – 1.21 (m, 10H, SCH2CH2(CH2)5CH3), 
0.88 (t, J = 6.8 Hz, 3H, SCH2CH2(CH2)5CH3). 
 
(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((3-hydroxypropyl)thio) 
propanoic acid (IV.50c) 
 IV.6 (50 mg, 0.15 mmol) reacted with allyl alcohol (30 µL, 0.45 
mmol) under the conditions described in general procedure P for 
3.5 h to afford compound IV.50c as an colorless oil (58 mg, 100%). 
1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.4 Hz, 2H, HaromFmoc), 7.59 
(d, J = 7.3 Hz, 2H, HaromFmoc), 7.38 (t, J = 7.2 Hz, 2H, HaromFmoc), 7.33 
– 7.26 (t, J = 7.9 Hz  2H, HaromFmoc), 6.01 (d, J = 7.6 Hz, 1H, NH), 
4.63 (s, 1H, H), 4.38 (d, J = 6.8 Hz, 2H, CH2Fmoc), 4.21 (t, J = 6.8 Hz, 
1H, CHFmoc), 3.69 (t, J = 5.2 Hz, 2H, SCH2CH2CH2OH), 3.02 (dd, J = 12.7, 4.7 Hz, CCH2S), 
2.65 (d, J = 6.1 Hz, 2H, SCH2CH2CH2OH), 1.79 (t, J = 6.1 Hz, 2H, SCH2CH2CH2OH). MS (ESI) 
m/z 424 [M+Na]+. 
 
(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((3-(5-methyl-2,4-dioxo-3,4-
dihydropyrimidin-1(2H)-yl)propyl)thio)propanoic acid (IV.50d) 
 IV.6 (50 mg, 0.15 mmol) reacted with IV.33 (73 mg, 0.45 
mmol) under the conditions described in both general 
procedure P for 3 h (42 mg, 57%) and general procedure Q for 
2 h (65 mg, 87%) to afford compound IV.50d as a white solid. 
1H NMR (400 MHz, CDCl3) δ 9.93 (s, 1H, NHthymine), 7.75 (d, J = 
7.5 Hz, 2H, HaromFmoc), 7.61 (t, J = 7.4 Hz, 2H, HaromFmoc), 7.38 (t, 
J = 7.4 Hz, 2H, HaromFmoc ), 7.28 (q, J = 7.4 Hz, 2H, HaromFmoc), 6.97 
(s, 1H, CHthymine), 5.99 (br s, 1H, NHcys), 4.63 (s, 1H, H), 4.39 (d, 
J = 7.1 Hz, 2H, CH2Fmoc), 4.21 (t, J = 7.1 Hz, 1H, CHFmoc), 3.84 (dd, 
J = 13.7, 6.5 Hz, 1H, NCH2CH2CH2SCH2), 3.67 (dd, J = 13.4, 6.8 
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Hz, 1H, NCH2CH2CH2SCH2), 3.10 – 3.04 (m, 2H, NCH2CH2CH2SCH2), 2.59 (t, J = 6.4 Hz, 2H, 
NCH2CH2CH2SCH2), 1.98 – 1.83 (m, 5H, CH3thymine, NCH2CH2CH2SCH2). MS (ESI) m/z 508 
[M−H]−. 
 
(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((2-(4-(bis(tert-
butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl)ethyl)thio)propanoic acid (IV.50e) 
IV.6 (50 mg, 0.15 mmol) reacted with IV.31 (153 mg, 0.45 
mmol) under the conditions described in general procedure Q 
for 2 h to afford compound IV.50e as a white solid (79 mg, 
78%). 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 7.2 Hz, 2H, 
HaromFmoc), 7.62 (s, 2H, HaromFmoc), 7.45 – 7.29 (m, 5H, Hcytosine, 
HaromFmoc), 7.11 (d, J = 6.3 Hz, 1H, Hcytosine), 5.94 (br s, 1H, NHcys), 
4.65 (s, 1H, H), 4.35 (d, J = 19.9 Hz, 2H, CH2Fmoc), 4.24 (m, 1H, 
CHFmoc), 4.07 (d, J = 7.0 Hz, 1H, NCH2CH2CH2SCH2), 3.88 (m, 1H, 
NCH2CH2CH2SCH2), 3.20 – 2.96 (m, 2H, NCH2CH2CH2SCH2), 2.61 
(m, 2H, NCH2CH2CH2SCH2), 2.04 (m, 2H, NCH2CH2CH2SCH2), 
1.54 (s, 18H, Boc). MS (ESI) m/z 694 [M−H]−. 
 
(R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((3-(2-((tert-
butoxycarbonyl)amino)-6-oxo-1H-purin-9(6H)-yl)propyl)thio) propanoic acid (IV.50g) 
IV.6 (50 mg, 0.15 mmol) reacted with IV.46 (127 mg, 
0.45 mmol) under the conditions described in 
general procedure Q for 3 h to afford compound 
IV.50g as a white solid (28 mg, 30%). 1H NMR (400 
MHz, CDCl3) δ 11.50 (s, 1H, NHguanine), 8.56 (s, 1H, 
NHguanine), 7.78 (s, 1H, H8guanine), 7.70 (t, J = 6.6 Hz, 2H, 
HaromFmoc), 7.57 (d, J = 7.4 Hz, 3H, HaromFmoc), 7.36 (t, J 
= 7.4 Hz, 3H, HaromFmoc), 6.17 (d, J = 7.5 Hz, 1H, NHcys), 
4.66 (d, J = 6.5 Hz, 1H, H), 4.46 (dd, J = 10.5, 7.0 Hz, 
1H, NCH2CH2CH2SCH2), 4.38 (dd, J = 10.6, 6.7 Hz, 1H, 
NCH2CH2CH2SCH2), 4.20 (t, J = 6.7 Hz, 1H, CHFmoc), 4.07 (t, J = 6.7 Hz, 2H, CH2Fmoc), 3.16 
(dd, J = 14.6, 5.1 Hz, 1H, NCH2CH2CH2SCH2), 3.03 (dd, J = 14.0, 4.4 Hz, 1H, 
NCH2CH2CH2SCH2), 2.56 (t, J = 6.3 Hz, 2H, NCH2CH2CH2SCH2), 1.57 – 1.42 (m, 2H, 
NCH2CH2CH2SCH2). 
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 (R)-ethyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((3-
hydroxypropyl)thio)propanamido)acetate (IV.51a) 
 IV.7a (50 mg, 0.12 mmol) reacted with allyl alcohol (24 
µL, 0.36 mmol) under the conditions described in 
general procedure P for 20 h to afford compound IV.5a 
as an colorless oil (12 mg, 21%). 1H NMR (400 MHz, 
CDCl3) δ 7.76 (d, J = 7.5 Hz, 2H, HaromFmoc), 7.59 (d, J = 
7.5 Hz, 2H, HaromFmoc), 7.40 (t, J = 7.5 Hz, 2H, HaromFmoc), 
7.31 (td, J = 7.5, 0.9 Hz, 2H, HaromFmoc), 7.05 (br s, 1H, 
NHgly), 5.89 (br s, 1H, NHcys), 4.43 (s, 3H, CH2Fmoc, H), 4.21 (dd, J = 14.4, 7.2 Hz, 3H, CHFmoc, 
OCH2CH3), 4.03 (s, 2H, CH2gly), 3.72 (t, J = 5.8 Hz, 2H, SCH2CH2CH2OH), 3.00 (d, J = 8.2 Hz, 
1H, CCH2S), 2.86 (d, J = 8.2 Hz, 1H, CCH2S), 2.72 (s, 2H, SCH2CH2CH2OH), 1.84 (dt, J = 12.0, 
6.1 Hz, 2H, SCH2CH2CH2OH), 1.26 (t, J = 7.2, 3H, CH3). 
 
(R)-ethyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((2-(5-methyl-2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)ethyl)thio) propanamido)acetate (IV.51c) 
 IV.7a (50 mg, 0.12 mmol) reacted with IV.33 (58 mg, 
0.36 mmol) under the conditions described in general 
procedure Q for 3 h to afford IV.51c as a white solid 
(35 mg, 51%). M.p. 89-91 oC; 1H NMR (400 MHz, CDCl3) 
δ 9.14 (br s, 1H, NHthymine), 7.68 (d, J = 7.5 Hz, 2H, 
HaromFmoc), 7.53 (d, J = 7.2 Hz, 2H, HaromFmoc), 7.32 (t, J = 
7.4 Hz, 2H, HaromFmoc), 7.22 (dd, J = 14.2, 6.9 Hz, 3H, 
HaromFmoc, NHgly), 6.93 (s, 1H, H6thymine), 5.97 (d, J = 7.4 
Hz, 1H, NHcys), 4.34 (d, J = 6.4 Hz, 3H, CH2Fmoc, H), 4.13 
(dd, J = 14.8, 7.4 Hz, 3H, CHFmoc, OCH2CH3), 3.98 (d, J = 
5.9 Hz, 2H, CH2gly), 3.81 (dt, J = 12.6, 6.8 Hz, 1H, NCH2CH2CH2SCH2), 3.64 (dt, J = 12.6, 6.8 
Hz, 1H, NCH2CH2CH2SCH2), 2.91 (dd, J = 12.9, 6.9 Hz, 1H, NCH2CH2CH2SCH2), 2.80 (dd, J = 
12.9, 6.9 Hz, 1H, NCH2CH2CH2SCH2), 2.56 (s, 2H, NCH2CH2CH2SCH2), 2.02 – 1.76 (m, 5H, 
CH3thymine, NCH2CH2CH2SCH2), 1.20 (t, J = 7.1 Hz, 3H, CH2CH3). 13C NMR (101 MHz, CDCl3) 
δ 170.7 (C=Odip), 169.8 (C=Odip), 164.3 (C4=Othymine), 156.2 (C=Odip), 151.0 (C2=Othymine), 
143.8 (CquatFmoc), 141.4 (CquatFmoc), 140.5 (C6thymine), 127.9 (CaromFmoc), 127.2 (CaromFmoc), 
125.2 (CaromFmoc), 120.1 (CHaromFmoc), 111.2 (C5thymine), 67.3 (CH2Fmoc), 61.8 (OCH2CH3), 54.3 
(C), 47.3 (NCH2CH2CH2SCH2), 47.2 (CHFmoc), 41.6 (CH2gly), 34.4 (NCH2CH2CH2SCH2), 29.2 
(NCH2CH2CH2SCH2), 28.4 (NCH2CH2CH2SCH2), 14.3 (CH2CH3), 12.4 (CH3thymine).  
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(R)-ethyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((3-(6-(bis(tert-
butoxycarbonyl)amino)-9H-purin-9-yl)propyl)thio) propanamido)acetate (IV.51e) 
 IV.7a (50 mg, 0.12 mmol)  reacted with IV.32 (131 mg, 
0.36 mmol) under the conditions described in general 
procedure Q for 3 h to afford IV.51e (45 mg, 48%). 1H 
NMR (400 MHz, CDCl3) δ 8.86 (s, 1H, H2thymine), 8.14 (s, 
1H, H8thymine), 7.76 (d, J = 7.2 Hz, 2H, HaromFmoc), 7.59 (d, 
J = 7.2 Hz, 2H, HaromFmoc), 7.39 (t, J = 7,4 Hz, 1H, 
HaromFmoc), 7.31 (t, J = 7,4 Hz, 1H, HaromFmoc), 7.04 (s, 1H, 
NHgly), 5.80 (s, 1H, NHcys), 4.49-4.33 (m, 5H, CH2Fmoc, 
H , NCH2CH2CH2SCH2), 4.21 (dd, J = 14.5, 7.2 Hz, 3H, 
CHFmoc, OCH2CH3), 4.04 (s, 2H, CH2gly), 2.98 (s, 1H, 
NCH2CH2CH2SCH2), 2.86 (s, 1H, NCH2CH2CH2SCH2), 2.61 (s, 2H, CH2CH2CH2SCH2), 2.24 (s, 
2H, NCH2CH2CH2SCH2), 1.45 (s, 18H, Boc), 1.27 (t, J = 7.2 Hz, 3H, CH3). 13C NMR (101 MHz, 
CDCl3) δ 170.4 (C=O), 169.5 (C=O), 160.5 (C2adenine), 153.5 (C4adenine), 152.2 (C8adenine), 
150.7 (C=OBoc), 150.5 (C6adenine), 143.7 (CquatFmoc), 141.5 (CquatFmoc), 128.9 (C5adenine),  127.9 
(CaromFmoc), 127.2 (CaromFmoc), 125.2 (CaromFmoc), 120.2 (CaromFmoc), 84.0 (Cquat t-BuBoc), 67.3 
(CH2Fmoc), 61.9 (OCH2CH3), 54.3 (C-H), 47.2 (CHFmoc), 42.8 (NCH2CH2CH2SCH2), 41.6 
(CH2gly), 34.2 (NCH2CH2CH2SCH2), 29.2 (NCH2CH2CH2SCH2), 29.1 (NCH2CH2CH2SCH2), 28.0 
(C(CH3)3)., 14.3 (OCH2CH3). MS (ESI) m/z 826.48 [M+Na]+.  
 
(R)-benzyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((3-(5-methyl-2,4-
dioxo-3,4-dihydropyrimidin-1(2H)-yl)propyl) 
thio)propanamido)acetate (IV.51f) 
 IV.7b (50 mg, 0.11 mmol) reacted with IV.33 (52 
mg, 0.33 mmol) under the conditions described in 
general procedure Q for 3 h to afford IV.51f (34 mg, 
49%).1H NMR (400 MHz, CDCl3) δ 8.54 (s, 1H, 
NHtymine), 7.76 (d, J = 7.6 Hz, 2H, HaromFmoc), 7.60 (d, 
J = 7.2 Hz, 2H, HaromFmoc), 7.44 – 7.24 (m, 9H, 
HaromFmoc, HaromBn), 7.19 (s, 1H, NHgly), 6.99 (s, 1H, 
CHtymine), 5.89 (s, 1H, NHcys), 5.19 (s, 2H, CH2Bn), 4.42 
(d, J = 5.6 Hz, 3H, CH2Fmoc, H), 4.22 (t, J = 6.6 Hz, 1H, 
CHFmoc), 4.09 (q, ,2H, CH2gly), 3.88 (s, 1H, 
NCH2CH2CH2SCH2), 3.71-3.65 (m, 1H, NCH2CH2CH2SCH2), 2.96 (s, 1H, NCH2CH2CH2SCH2), 
2.85 (s, 1H, NCH2CH2CH2SCH2), 2.62 (s, 2H, CH2CH2CH2SCH2), 1.97 (s, 2H, 
NCH2CH2CH2SCH2), 1.89 (s, 3H, CH3tymine). 13C NMR (101 MHz, CDCl3) δ 170.6 (C=Odip), 
169.6 (C=Odip), 164.0 (C4=Othymine), 156.2 (C=Odip) , 151.1 (C2=Othymine), 143.8 (CquatFmoc), 
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141.5 (CquatFmoc), 140.4 (C6thymine), 135.1 (CquatBn), 128.8 (Carom), 128.8 (Carom), 128.6 (Carom), 
127.9 (Carom), 127.2 (Carom), 125.2 (Carom), 120.2 (Carom), 111.2 (C5thymine), 67.6 (CH2Bn), 67.3 
(CH2Fmoc), 54.3 (Cα), 47.3 (NCH2CH2CH2SCH2), 47.2 (CHFmoc), 41.7 (CH2gly), 34.4 
(NCH2CH2CH2SCH2), 29.3 (NCH2CH2CH2SCH2), 28.4 (NCH2CH2CH2SCH2), 12.5 (CH3tymine). 
MS (ESI) m/z 679 [M+Na]+.  
 
(R)-benzyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((3-(4-(bis(tert-
butoxycarbonyl)amino)-2-oxopyrimidin-1(2H)-yl) propyl)thio)propanamido)acetate 
(IV.51g) 
 IV.7b (50 mg, 0.11 mmol)  reacted with IV.31 (112 
mg, 0.33 mmol) under the conditions described in 
general procedure Q for 3 h to afford IV.51g (55 
mg, 62%). 1H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 
7.6 Hz, 2H, HaromFmoc), 7.60 (d, J = 6.8 Hz, 2H, 
HaromFmoc), 7.54 (d, J = 7.2 Hz, 1H, Hcytosine), 7.41 – 
7.29 (m, 10 H, HaromFmoc, HaromBn, NHgly), 7.02 (d, J = 
7.2 Hz, 1H, Hcytosine), 5.85 (s, 1H, NHcys), 5.16 (s, 2H, 
CH2Bn), 4.41 (d, J = 5.8 Hz, 3H, CH2Fmoc, H), 4.22 (t, J 
= 5.8 Hz, 1H, CHFmoc), 4.15-4.00 (m, 3H, CH2gly, 
NCH2CH2CH2SCH2), 3.89 – 3.82 (m, 1H, NCH2CH2CH2SCH2), 2.91 (d, J = 12.8 Hz, 
NCH2CH2CH2SCH2), 2.61 (s, 2H, NCH2CH2CH2SCH2), 2.05 (s, 2H, NCH2CH2CH2SCH2), 1.54 
(s, 18H, Boc). 13C NMR (101 MHz, CDCl3) δ 170.8 (C=Odip), 169.4 (C=Odip), 162.5 (C4cytosine), 
155.1 (C=Odip), 155.3 (C=Ocytosine), 149.7 (C=OBoc), 148.2 (CHcytosine), 143.8 (CquatFmoc), 
141.4 (CquatFmoc), 135.3 (CquatBn), 128.7 (Carom), 128.6 (Carom), 128.5 (Carom), 127.9 (Carom), 
127.2 (Carom), 125.3 (Carom), 120.1 (Carom), 96.6 (CHcytosine), 85.1 (CquatBoc), 67.3(CH2Fmoc), 
67.3 (CH2Bn), 54.20 (CH), 49.66 (NCH2CH2CH2SCH2), 47.21 (CHFmoc), 41.61 (CH2gly), 34.47 
(NCH2CH2CH2SCH2), 29.13 (NCH2CH2CH2SCH2), 27.93 (NCH2CH2CH2SCH2), 27.80 (CH3). 
Mp: 64-67 oC. MS (ESI) m/z 864 [M+Na]+. HRMS: (M-H)+ (C44H52N5O10S) cacld 842.3429, 
found 842.3414. 
 
 
 
 
 
 
 
 
 
184       
(R)-benzyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((3-(6-(bis(tert-
butoxycarbonyl)amino)-9H-purin-9-yl)propyl)thio) propanamido)acetate (IV.51h) 
 IV.7b (50 mg, 0.11 mmol)  reacted with IV.32 (115 
mg, 0.33 mmol) under the conditions described in 
general procedure Q for 3 h to afford IV.51h (50 
mg, 57%). 1H NMR (400 MHz, CDCl3) δ 8.85 (s, 1H, 
H2), 8.11 (s, 1H, H8), 7.75 (d, J = 7.6 Hz, 2H, 
HaromFmoc), 7.58 (d, J = 7.2 Hz, 2H, HaromFmoc), 7.40-
7.28 (m, 9H, HaromFmoc, HaromBn), 7.06 (s, 1H, NHgly), 
5.79 (s, 1H, NHcys), 5.17 (s, 2H, CH2Bn), 4.48 – 4.25 
(m, 5H, CH2Fmoc, CH, NCH2CH2CH2SCH2), 4.21 (t, J = 
6.6 Hz, 1H, CHFmoc), 4.09 (s, 2H, CH2gly), 2.91 (dd, J 
= 57.2, 12.4 Hz, 2H, NCH2CH2CH2SCH2), 2.58 (s, 2H, 
CH2CH2CH2SCH2), 2.21 (s, 2H, NCH2CH2CH2SCH2), 1.42 (d, J = 24.4 Hz, 18H, Boc). 13C NMR 
(101 MHz, CDCl3) δ 170.5 (C=Odip), 169.4 (C=Odip), 156.1 (C=Odip), 153.5 (C4adenine), 152.2 
(C2adenine), 150.7 (C6adenine), 150.5 (C=OBoc), 145.1 (C8adenine), 143.7 (CquatFmoc), 141.4 
(CquatFmoc), 135.11 (CquatBn), 129.0 (C5adenine), 128.8 (Carom), 128.8 (Carom), 128.6 (Carom), 
127.9 (Carom), 127.2 (Carom), 125.2 (Carom), 120.2 (Carom), 84.0 (CquatBoc), 67.5 (CH2Fmoc), 67.3 
(CH2Bn), 54.2 (CH), 47.2 (CHFmoc), 42.7 (NCH2CH2CH2SCH2), 41.6 (CH2gly), 34.2 
(NCH2CH2CH2SCH2), 29.8 (NCH2CH2CH2SCH2), 29.1 (NCH2CH2CH2SCH2), 27.9 (CH3). Mp: 
62-65 oC. MS (ESI) m/z 888 [M+Na]+. HRMS: (M-H)+ (C45H52N7O9S) cacld 866.3542 found 
866.3524.  
 
(R)-benzyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((3-(2-((tert-
butoxycarbonyl)amino)-6-oxo-1H-purin-9(6H)-yl)propyl)thio)propanamido)acetate 
(IV.51i) 
 IV.7b (50 mg, 0.11 mmol)  reacted with IV.51i (89 
mg, 0.33 mmol) under the conditions described in 
general procedure Q for 3 h to afford IV.51i (31 mg, 
44%). 1H NMR (400 MHz, CDCl3) δ 11.53 (s, 1H, 
NH1guanina), 9.01 (s, 1H, NHexoguanina), 7.67 (t, J = 7.4 
Hz, 2H, HaromFmoc), 7.57 (s, 1H, CH8guanine), 7.5 (d, J = 
6.8 Hz, 2H, HaromFmoc), 7.37-7.21 (m, 10H, HaromFmoc, 
HaromBn, NHgly), 6.49 (s, 1H, NHcys), 5.15 (s, 2H, 
CH2Bn), 4.54 – 4.33 (m, 3H, CH2Fmoc, H ), 4.20-4.11 
(m, 4H, HFmoc, CH2gly, NCH2CH2CH2SCH2), 3.90 (s, 1H, 
NCH2CH2CH2SCH2), 3.10 (d, J = 10.4 Hz, 1H, 
NCH2CH2CH2SCH2), 2.85 (dd, J = 13.6, 8.4 Hz, 1H, NCH2CH2CH2SCH2), 2.65–2.50 (m, 2H, 
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NCH2CH2CH2SCH2), 2.18 – 1.92 (m, 2H, NCH2CH2CH2SCH2), 1.48 (s, 9H, Boc). 13C NMR 
(101 MHz, CDCl3) δ 169.36 (C=Odip), 165.6 (C=Odip), 156.6 (C=Odip) 155.9 (C=O6guanine), 
153.3 (C=OBoc), 147.8 (C4), 143.7 (CquatFmoc), 143.6 (C2), 141.4 (CquatFmoc), 135.1 (CquatBn), 
128.8 (Carom), 128.5 (Carom), 128.5 (Carom), 127.9 (Carom), 127.1 (Carom), 124.9 (Carom), 120.1 
(Carom), 84.0 (CquatBoc), 67.5 (CH2Fmoc),  67.1 (CH2Bn), 54.6 (CH), 47.2 (CHFmoc), 42.4 
(NCH2CH2CH2SCH2), 41.6 (CH2gly), 33.4 (NCH2CH2CH2SCH2), 28.9 (NCH2CH2CH2SCH2), 28.3 
(NCH2CH2CH2SCH2), 28.1 (CH3).  
 
(R)-ethyl 2-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-
(allylthio)propanamido)acetate (IV.52) 
IV.7b (50 mg, 0.11 mmol) reacted with allyl bromide 
(30µL, 0.33 mmol) under the conditions described in 
general procedure P for 3 h to afford compound IV.52   as 
an colorless oil (12 mg, 21%). 1H NMR (400 MHz, CDCl3) δ 
7.77 (d, J = 7.4 Hz, 2H, HaromFmoc), 7.60 (d, J = 7.4 Hz, 2H, 
HaromFmoc), 7.41 (t, J = 7.4 Hz, 2H, HaromFmoc), 7.32 (t, J = 7.4 
Hz, 2H, HaromFmoc), 6.82 (br s, 1H, NHgly), 5.78 (dt, J = 18.2, 8.0 Hz, 1H, CH=CH2), 5.68 ( br 
s, 1H, NHcys), 5.18 (d, J = 16.7 Hz, 1H, CH=CHtrans), 5.13 (d, J = 10.0 Hz, 1H, , CH=CHcis) 4.48 
– 4.32 (m, 3H, CH2Fmoc , H), 4.22 (dd, J = 14.5, 7.1 Hz, 3H, CHFmoc, OCH2CH3), 4.04 (s, 2H,  
CH2gly), 3.18 (s, 2H, SCH2CH=CH2), 2.92 (d, J = 12.3 Hz, 1H, CCH2S), 2.82 (dd, J = 12.3, 6.3 
Hz, 1H, CCH2S), 1.26 – 1.17 (t, J = 7.1 Hz 3H, CH3). MS (ESI) 491.18 [M+Na]+. 
 
3. FRET-melting assay procedure 
 
The ability of the test compounds to stabilise G-quadruplex DNA (F21T and KRAS21R) 
and a self-complementary hairpin DNA (T-Loop) sequences was investigated by using a 
fluorescence resonance energy transfer (FRET) assay with ligand concentrations ranging 
from 0.1 to 5 M. The labelled oligonucleotides contained the donor fluorophore 6-
carboxyfluorescein (FAM) and the acceptor fluorophore 6-
carboxytetramethylrhodamine (TAMRA). Sequences were as follows: F21T (5’-[FAM]-
GGG TTA GGG TAG GGT TAG GG-[TAMRA]-3’), KRas21R (5’-[FAM]-AGG GCG GTG TGG 
GAA GAG GGA-[TAMRA]-3’), T-loop (5’-[FAM]-TAT AGC TAT ATT TTT TTA TAG CTA TA-
[TAMRA]-3’). Each oligonucleotide was initially diluted to 100 m in nuclease-free water 
(not DEPC-treated). Stock solutions of 20 m and subsequent dilutions were obtained 
in FRET buffer (60 m KCl, potassium cacodylate, pH 7.4). The FRET probe sequences 
were diluted from stock to the correct concentration (0.4 m) and then annealed by 
heating at 85 0C for 10 min, followed by slow cooling to rt in the heating block. 
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Test compounds were prepared as 10 m DMSO stock solutions and diluted to 1 m 
using 1 m nuclease-free water (not DEPC-treated). The rest of the dilutions were 
performed using FRET buffer. Annealed DNA (50 L) and test compound solution (50 L) 
were distributed across 96-well RT-PCR plates. Relevant controls were also performed 
to check for interference with the assay. Fluorescence readings were made with 
excitation at  450–495 nm and detection at  515–545 nm, taken at intervals of 1 oC in 
the range 30–95 0C, with a constant temperature being maintained for 30 s prior to each 
reading to ensure a stable value. Experiments were performed in triplicate. Final analysis 
of the data was carried out with GraphPad Prism v.5.0. The advanced curve-fitting 
function in GraphPad Prism was used for calculation of Tm values. 
 
4. In cellula assays 
 
4.1. Cell Culture  
 
Human colorectal adenocarcinoma cell lines (HT-29 and CaCo-2), lung cancer (NCI-
H460) and breast cancer (MCF- 7) cell lines and, human normal skin fribroblasts (CRL-
1502) cells were acquired from ATCC. Cell lines were cultivated in RPMI-1640 media 
supplemented with L-glutamine, 10% fetal bovine serum (FBS) and antibiotic 
antimycotic solution and were grown in an incubator with a 5% CO2 humidified 
atmosphere and at 37 oC.  
 
4.2. Antiproliferative assay  
 
Each cell line was plated in 96-well plates with a density of approximately 5x103 (NCI-
H460), 1x104 (HT-29) and 1,5x104 (MCF-7) cells/well. Plates were incubated overnight 
and treated the next day with the samples to be tested. Stock solutions of the 
compounds were prepared and diluted with the cell culture media containing 0.5% FBS. 
This same media composition was used for the performance of the assays. Cisplatin 
stock solution was prepared at 10 mM concentration in phosphate buffer saline (PBS). 
After 48 h incubation with the compounds, media was removed, cells were washed with 
PBS and treated for 3 h with fresh media containing 50 µg/mL neutral red. After this 
period, cells were washed with PBS and the amount of neutral red retained by the cells 
extracted with an organic solution (19.96 mL distilled water, 20 mL ethanol and 400 µL 
glacial acetic acid). Plate was gently shake and read at 540 nm in a plate reader. Viability 
was determined by the ratio of absorbance of treated cells and non-treated cells 
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(control). For each experimental situation, 3 repliques were done and the average points 
were used to construct a fitting toxicity curve in GraphPad. From each fitting curve, an 
IC50 was determined and associated error is the standard deviation of the different IC50s 
produced from independent experiments. Assays performed by Dr. Raquel Frade. 
 
4.3. Toxicity assay  
 
CaCo-2 or CRL-1502 cells were plated in 96-well plates and grown until formation of a 
monolayer. Monolayers were posteriorly incubated with the compounds for 24 h 
previously to viability assessment. Viability was determined using the neutral red dye as 
previously described. Assays performed by Dr. Raquel Frade. 
 
4.4. Apoptosis evaluation 
 
Apoptosis was quantified using the Guava Nexin Reagent kit (Merck Millipore). The 
Nexin assay uses two distinct dyes, Annexin V to detect phosphatidylserine (PS) on the 
external membrane of apoptotic cells, and the cell impermeant dye, 7-AAD, as an 
indicator of membrane structural integrity. For this purpose, HT-29 cells were plated in 
24-well plates at 5x104 cells/well. Twenty-four hours after plating, cells were exposed 
either to DMSO (vehicle control) or to the compounds in test at the IC50 and 2-fold IC50 
concentration for additional 48 h. After that, the culture medium was collected and cells 
detached with Accutase. Cells were the collected to the same tube and centrifuged at 
500 g for 5 min at 4 oC. The cell pellet was resuspended in PBS supplemented with 2% 
FBS. Subsequently, 50 µL of cell suspension were mixed with 50 µL of Guava Nexin 
reagent and incubated for 20 min, at room temperature in the absence of light. 
Following the staining procedure, sample acquisition and data analysis of at least 5000 
events per sample were performed using the Guava easyCyteTM Flow Cytometer 
(Merck Millipore) and Nexin software module. Assays performed by Dr. Joana Amaral. 
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